The Weekly Term Sheet (2026-W18)
W18 at a glance
Window total: ~US$25.0B in committed cash and equity consideration, plus US$8.6B in assumed debt (Sun Pharma / Organon), plus up to ~US$10.4B in disclosed contingent biobucks (max-case milestones and CVRs, undiscounted). The committed-versus-contingent split matters because most aggregate deal-value figures published in trade press conflate cash-at-close with milestone-and-royalty headlines.
| Bucket | W18 amount | Notes |
|---|---|---|
| M&A committed equity / cash consideration | ~US$21.3B | New cash to selling shareholders at close |
| Assumed debt (Sun Pharma / Organon) | US$8.6B | Balance-sheet assumption, not new cash to shareholders; gross debt as of 31 Dec 2025 |
| Capital-markets equity priced / printed | ~US$2.47B | IPOs, follow-ons, PIPEs (committed at pricing) |
| PRV cash monetisations | US$0.375B | Rocket US$180M + SPARC US$195M (cash at close) |
| Disclosed licensing / option upfronts and near-term cash | ~US$0.74B | Protagonist near-term cash US$475M (rusfertide opt-out, license restructuring not M&A); Pinetree US$25M option closing; Cue US$15M upfront + US$30M concurrent PIPE (counted in capital markets); Huahui upfront US$20M; EvolveImmune US$18M paid milestone; Merck US$150M Koselugo amendment payment received; Nxera US$22.5M Neurocrine Q1 milestone (Teva US$700M Emalex upfront sits in the M&A bucket above) |
| Disclosed contingent biobucks (max scenarios, undiscounted) | up to ~US$10.4B | See breakdown below |
Contingent biobucks breakdown (max-case, undiscounted; subject to clinical, regulatory and commercial milestones):
| Deal | Contingent component | Amount |
|---|---|---|
| Lilly / Profluent | Development + commercial milestones + tiered royalties | up to US$2.25B + royalties |
| Lilly / Ajax | Clinical + regulatory milestones (split with undisclosed upfront in US$2.3B aggregate) | est. ~US$2.0B contingent |
| Huahui / BeOne HH160 | Development / regulatory + sales milestones | US$1.87B + tiered royalties |
| AbbVie / Kestrel | Future exercise payments + dev / reg milestones | up to US$1.45B aggregate |
| Protagonist / Takeda rusfertide opt-out | Further milestones (incremental to US$475M near-term cash) | up to US$975M + 14–29% tiered royalties |
| OSR Holdings / BCM Europe AG VXM01 | Milestones (no upfront disclosed) | up to US$815M + tiered royalties |
| Cue / Ascendant Health Ascendant-221 | Dev / reg / commercial milestones (incremental to US$15M upfront) | up to US$676.5M + tiered royalties |
| Teva / Emalex ecopipam | Commercial milestones | up to US$200M + tiered royalties on global net sales |
| ARCHIMED / Esperion CVR | Two-tranche sales-based CVR | up to US$100M aggregate |
| Ligand / XOMA TREMFYA CVR | 75% of net TREMFYA litigation proceeds | magnitude undisclosed (excluded from total) |
| Disclosed contingent biobucks total (excluding TREMFYA CVR) | ~US$10.34B + tiered royalties on multiple assets |
The structural standout of the week is Protagonist's April 28 opt-out under the Takeda rusfertide collaboration, which converts a 50:50 US profit share into a worldwide tiered royalty: US$475M near-term cash, up to US$975M further milestones, and 14–29% tiered royalties (29% at ≥US$1.5B annual net sales; 21% weighted average at US$1.5B). This is the highest disclosed top-tier royalty band in 2026 dealmaking.
Nine M&A transactions set the M&A core (committed equity / cash; not contingent):
| Transaction | Committed equity / cash | Contingent component |
|---|---|---|
| Sun Pharma / Organon | US$3.99B equity + US$8.6B assumed debt = US$11.75B EV | Vtama (tapinarof) up to US$950M commercial milestones + tiered royalties to former Dermavant shareholders (inherited tail) |
| Gilead / Arcellx (close) | ~US$7.8B implied equity (cash-paid at close) | None new (closing event) |
| BioMarin / Amicus (close) | ~US$4.8B equity (cash-paid at close) | DMX-200 inherited up to US$560M + low-teens to low-twenties royalty |
| Chiesi / KalVista | US$1.9B cash at US$27.00/share (36% premium to 30-day VWAP) | None disclosed at deal level |
| Teva / Emalex | US$700M cash upfront | up to US$200M commercial milestones + tiered royalties on global net sales |
| ARCHIMED / Esperion | ~US$1.0B equity at US$3.16/share (58% premium to Apr 30 close) | up to US$100M two-tranche CVR (bempedoic-acid + bumetanide) |
| Ligand / XOMA | US$739M cash at US$39.00/share (~14% premium to 30-day VWAP) | 75% pass-through CVR on TREMFYA litigation net proceeds (magnitude undisclosed) |
| Lilly / Ajax | est. ~US$0.3B upfront in US$2.3B aggregate; component split undisclosed | est. ~US$2.0B clinical + regulatory milestones |
| LEO Pharma / Replay | US$50M upfront | Further consideration not disclosed |
| M&A committed equity total | ~US$21.3B |
Two listed-royalty-fund positions enter live structural review. The Chiesi / KalVista April 29 acquisition (US$1.9B equity at US$27.00/share, 36% premium to 30-day VWAP) triggers a change-of-control review on DRI Healthcare Trust's US$127M synthetic royalty on worldwide Ekterly net sales, with put-option and buyback provisions potentially exercisable. The ARCHIMED / Esperion May 1 take-private (US$3.16/share + up to US$100M two-tranche CVR) is acquired with a four-counterparty inherited royalty + debt stack intact: OMERS Life Sciences (Aug 2024; 15–25% royalty on Daiichi Sankyo Europe bempedoic-acid net sales until 1.7x of US$304.7M invested capital), Athyrium Capital Management (Apr 2026; 12–33% royalty on Otsuka Japan bempedoic-acid net sales until 2.0x of US$50M invested capital), HealthCare Royalty Partners (Dec 2024 senior secured term loan), and Pharmakon Advisors (Dec 2024 senior secured term loan + Convertible Note + take-private debt commitment).
Other major licensing and option events.
- Lilly / Profluent (Apr 28): AI-designed recombinases licensing, up to US$2.25B in milestones plus tiered royalties.
- AbbVie / Kestrel (Apr 28): warrant-plus-option pan-KRAS, up to US$1.45B aggregate.
- Huahui / BeOne Medicines HH160 (Apr 30): Asia-originated PD-1 / CTLA-4 / VEGF-A trispecific antibody licensing, up to US$1.99B in milestones plus tiered royalties on global net sales.
- OSR Holdings / BCM Europe AG (Apr 29): oral VEGFR-2 immunotherapy global license, up to US$815M in milestones with a 29.7% equity-pledge collateral structure (related-party).
- Cue Biopharma / Ascendant Health Ascendant-221 (Apr 30): anti-IgE license, US$15M upfront + up to US$676.5M milestones + tiered royalties (ex-Greater China rights), alongside a US$30M concurrent Cue PIPE.
- Pfizer ANDA settlements (Apr 28): Vyndamax US generic launch fixed at June 1, 2031 (Hikma, Dexcel, Cipla).
- Two-PRV cash-sale layer: Rocket US$180M plus Sun Pharma Advanced Research Company (SPARC) US$195M for the Sezaby Rare Pediatric Disease Voucher, anchoring the post-CNPV PRV market at US$180–200M.
Two royalty-collateral regulatory events. The Axsome AUVELITY (AXS-05) FDA approval on April 30 in Alzheimer's-disease agitation crystallises the Antecip Bioventures II 3.0% net-sales royalty layer on a second commercial indication, a related-party royalty structure between Axsome and a CEO-controlled vehicle. AstraZeneca's April 27 Saphnelo Pen FDA approval in SLE expands the population on which BMS receives a mid-teens US royalty under the legacy Medarex agreement. LEO Pharma / Replay (April 30; US$50M upfront) brings an HSV-vector gene therapy platform with a University of Pittsburgh upstream license (Glorioso lab) into LEO's rare-dermatology portfolio.
Capital-markets activity reopened sharply alongside the deal sequence. Approximately US$2.47B of in-window equity financing priced or printed:
- Oruka Therapeutics US$700.4M upsized public offering (Apr 28; JBRs Leerink, TD Cowen, Goldman Sachs, Stifel, Guggenheim; LifeSci passive). Pricing release
- Veradermics US$384.4M upsized public offering plus concurrent private placement (Apr 29; JBRs Jefferies, Leerink, Citigroup, Cantor; LifeSci passive; Needham lead manager). Veradermics free writing prospectus / SEC filing
- Avalyn Pharma US$345M IPO (Apr 29 priced; Apr 30 trading debut; May 1 closing with full overallotment exercised; 19,166,667 shares at US$18.00; JBRs Morgan Stanley, Jefferies, Evercore ISI, Guggenheim; ticker AVLN). Pricing release
- Hemab Therapeutics US$301.5M IPO (Apr 30 priced; May 1 trading debut; 16.75M shares at US$18.00 upsized 27%; ticker COAG; JBRs Goldman Sachs, Jefferies, Evercore ISI; Wedbush PacGrow lead). Pricing release
- Seaport Therapeutics US$254.9M IPO (Apr 30 priced; May 1 trading debut; 14.16M shares at US$18.00; PureTech Health spinout positioned as Karuna successor). Pricing release
- Sagimet Biosciences US$175M follow-on (Apr 27; JBRs Leerink, TD Cowen, Guggenheim, Oppenheimer). Pricing release
- Intellia Therapeutics US$194.6M public offering (Apr 29 priced with full greenshoe; 19.26M shares at US$10.75; JBRs Jefferies, Goldman Sachs, Citigroup). Pricing release
- Climb Bio US$110M PIPE (Apr 28; lead placement agents Leerink and Piper Sandler). SEC 8-K
Private capital and Asia licensing alongside the public-market activity. Fathom US$47M Series A. Coultreon Biopharma (formerly Onco3R) US$125M oversubscribed Series A led by Sofinnova with Forbion and Novo Holdings as co-leads, advancing a Galapagos-originated oral SIK3 inhibitor (COL-5671). Vivacta Biotechnology (Shanghai) >US$50M Series A and A+ for the GT801 in vivo CAR-T program (CD19; T-LNP / mRNA platform), co-led by Loyal Valley Capital and Decheng Capital, the same in vivo CAR-T category Lilly is consolidating via the Kelonia acquisition. mbiomics €30M Series A total / €12M third close. Lighthouse Pharmaceuticals US$12M Series A for LHP588 (P. gingivalis-targeted small molecule, Phase 2 Alzheimer's disease). AB Science €3.2M private placement.
Asia and ex-US licensing. Huahui Health / BeOne Medicines HH160 (April 30): US$20M upfront + US$100M option exercise + up to US$374M development and regulatory milestones + up to US$1.5B sales-based milestones + tiered royalties on net sales for a preclinical PD-1 / CTLA-4 / VEGF-A trispecific antibody, BeOne's largest early-stage global-rights deal to date. OSR Holdings (NASDAQ: OSRH) / BCM Europe AG (April 29): definitive global exclusive license for VXM01 oral VEGFR-2 immunotherapy with up to US$815M in milestones, US$30M IP buyback from Vaximm subsidiary, and a related-party pledge under which BCME pledges its entire ~29.7% OSRH equity stake as collateral for milestone obligations. Pinetree / AstraZeneca PTX-299 option exercise (April 29): US$25M closing payment for the EGFR-degrader program, on top of the original July 2024 up to US$45M upfront / near-term + total deal value over US$500M + tiered global royalties.
Royalty-license disputes in motion. Two remain live: XOMA / J&J TREMFYA via the Ligand CVR (75% pass-through), and GSK / TESARO vs AnaptysBio Jemperli (reversion trial July 14–17, 2026; Sagard US$300M deployed).
Late-stage clinical readouts. Eight late-stage readouts including the Pfizer ELREXFIO (elranatamab) MagnetisMM-5 Phase 3 readout in earlier-line RRMM (April 29) and the first-ever in vivo CRISPR Phase 3 (Intellia HAELO), Zealand–Boehringer survodutide Phase 3 (16.6% weight loss; Zealand high single-digit to low double-digit royalty plus EUR 315M outstanding milestones), and PTC / Novartis votoplam PIVOT-HD (52% slowing of HD progression).
Q1 2026 earnings cluster: nine royalty-line disclosures.
- GSK Q1 2026 (Apr 29): reaffirmed FY2026 royalty income guidance of £800M to £850M.
- AstraZeneca Q1 2026 (Apr 29): Alliance Revenue of US$825M (+26% CER): Enhertu US$508M (Daiichi profit-share), Tezspire US$154M (Amgen), Beyfortus US$91M (Sanofi), Datroway US$42M (Daiichi), Other royalty US$29M.
- Merck & Co. Q1 2026 (Apr 30): Koselugo alliance revenue from AstraZeneca of US$161M (vs US$44M Q1 2025), including a US$150M payment under the 2025 Koselugo amendment; cleanest amendment-trigger disclosure of the window.
- Bristol Myers Squibb Q1 2026 (Apr 30): non-GAAP EPS step-down to US$1.58 from US$1.80, attributed to the conclusion of the legacy AstraZeneca diabetes royalty stream at end-2025.
- Regeneron Q1 2026 (Apr 29): Sanofi collaboration revenue of US$1.6B, Dupixent at US$4.9B (+33%); the Sanofi development balance will be fully repaid by end-Q2, with REGN beginning to receive its full Dupixent profit share from Q3 2026.
- Biogen Q1 2026 (Apr 29): Leqembi at US$168M (+74%); a US$0.80 EPS IPR&D charge from the Apr 20 TJ Biopharma felzartamab China license.
- AbbVie Q1 2026 (Apr 29): US$744M IPR&D + milestones expense, materially above expectations, driven by RemeGen, Capstan, and Kestrel; FY2026 EPS guidance updated to US$13.96 to US$14.16.
- Genmab Q1 2026 (Apr 30 / J&J synchronised release): DARZALEX worldwide net trade sales of US$3,964M (US$2,208M US + US$1,756M ROW) under the J&J ~20% royalty layer; largest single-antibody royalty stream in the W18 cluster.
- Sanofi Q1 2026 (Apr 23 release; W18 follow-on commentary): €40M financial income from unwinding the Beyfortus US royalty liability under the Sobi / Sanofi structure.
- Nxera Pharma Q1 2026 (May 1; TSE: 4565): three royalty / milestone-relevant items: US$22.5M from Neurocrine (NBI-1117570 schizophrenia Phase 2 first-patient-dosed), undisclosed Lilly metabolic-disease milestone, and Holling Bio-Pharma Taiwan TFDA approval of QUVIVIQ.
Structural legal event. The US Supreme Court oral argument in Hikma v. Amarin (No. 24-889) on skinny-label induced-infringement pleading on April 29 remains the most consequential structural legal event of W18 for the royalty-fund audience; ruling expected before the July 2026 recess.
Deal value breakdown
| Deal | Type | Committed value | Date |
|---|---|---|---|
| Sun Pharma / Organon | M&A (definitive agreement) | $11.75B EV ($3.99B equity + $8.6B debt assumption – $574M cash) | Sun 26 Apr |
| Rocket Pharmaceuticals PRV sale | Asset purchase agreement (PRV monetization) | $180M cash at closing (undisclosed buyer) | Sun 26 Apr |
| BioMarin / Amicus | M&A (closing) | ~$4.8B equity + ~$3.7B non-convertible debt financing | Mon 27 Apr |
| Ligand / XOMA Royalty | M&A + CVR | ~$739M equity + 1 non-transferable CVR per share (75% of net TREMFYA litigation proceeds) | Mon 27 Apr |
| Lilly / Ajax Therapeutics | M&A (definitive agreement) | Up to $2.3B aggregate cash (upfront + clinical/regulatory milestones; component split undisclosed) | Mon 27 Apr |
| Sagimet Biosciences | Public follow-on (priced) | $175M gross at $6.00/share (29.17M shares) | Mon 27 Apr |
| Fathom Therapeutics | Series A (private) | $47M oversubscribed | Mon 27 Apr |
| IMG Pharma / Matsumoto | M&A (Japan OTC bolt-up) | Terms not disclosed | Mon 27 Apr |
| Hemab Therapeutics (COAG) | IPO (priced Apr 30 evening; trading May 1) | 16.75M shares at $18.00 (upsized 27%) = $301.5M gross; +2,512,500 share underwriter option; JBRs Goldman Sachs, Jefferies, Evercore ISI; Wedbush PacGrow lead; lead Novo Nordisk Foundation; closing on/about May 4 | Thu 30 Apr |
| Seaport Therapeutics | IPO (priced Apr 30 evening; trading May 1) | ~14.16M shares at $18.00 = $254.9M gross; PureTech Health spinout (Karuna successor); first neuro-focused biotech IPO of 2026 | Thu 30 Apr |
| Gilead / Arcellx | M&A (closing of Feb 23 announcement) | ~$7.8B implied equity (closing event; not new W18 announcement) | Mon 27 Apr |
| Protagonist / Takeda (rusfertide US opt-out) | License restructuring (US profit-share to global royalty conversion) | $200M cash on opt-out election + up to $1.25B further milestones + tiered 14–29% royalties on worldwide net sales (29% at ≥$1.5B; 21% weighted-avg at $1.5B; 1% to third-party upstream) | Tue 28 Apr |
| Lilly / Profluent | Multi-program licensing collaboration (AI-designed recombinases) | Undisclosed upfront + R&D funding + up to $2.25B development and commercial milestones + tiered royalties | Tue 28 Apr |
| AbbVie / Kestrel Therapeutics | Warrant + exclusive acquisition option | Undisclosed upfront + R&D funding + future exercise payments + milestones; up to $1.45B aggregate | Tue 28 Apr |
| Pfizer / Hikma, Dexcel, Cipla (Vyndamax ANDA settlements) | Patent litigation settlement (ANDA Hatch-Waxman) | Generic launch fixed at June 1, 2031 (multi-billion-dollar US franchise lift) | Tue 28 Apr |
| Avalo / AlmataBio (milestone restructuring) | Restructuring of contingent consideration | $2.25M for 90-day option to settle $15M Phase 3 milestone for additional $5.125M (max $7.375M vs $15M baseline) | Tue 28 Apr |
| EvolveImmune / AbbVie | Preclinical milestone (under Oct 2024 EVOLVE option-to-license) | $18M milestone payment | Tue 28 Apr |
| Coultreon Biopharma (formerly Onco3R) | Series A (private) | $125M oversubscribed; Sofinnova led, Forbion + Novo Holdings co-leads; Galapagos-originated SIK3 inhibitor | Tue 28 Apr |
| Arcera Life Sciences / Fosun Pharma | Non-binding strategic collaboration MoU | No financial terms disclosed; framework only | Tue 28 Apr |
| Chiesi Group / KalVista Pharmaceuticals | M&A (definitive agreement; cash tender) | $1.9B equity at $27.00/share (36% premium to 30-day VWAP; 40% to Tuesday close); expected close Q3 2026 | Wed 29 Apr |
| Teva Pharmaceuticals / Emalex Biosciences | M&A (definitive agreement) | $700M cash upfront + up to $200M commercial milestones + tiered royalties on global net sales of ecopipam = up to $900M total; expected close Q3 2026 | Wed 29 Apr |
| AstraZeneca plc Q1 2026 results | Earnings release (royalty-material) | Alliance Revenue $825M (+26% CER): Enhertu $508M (Daiichi profit-share), Tezspire $154M (Amgen), Beyfortus $91M (Sanofi), Datroway $42M (Daiichi), Other royalty $29M | Wed 29 Apr |
| GSK plc Q1 2026 results | Earnings release (royalty-material) | FY2026 royalty income guidance of £800M–£850M reaffirmed | Wed 29 Apr |
| SCOTUS oral argument: Hikma v. Amarin (No. 24-889) | Structural legal event | First skinny-label induced-infringement case at SCOTUS since Caraco (2012); ruling expected before July 2026 recess | Wed 29 Apr |
| Pfizer / ELREXFIO (elranatamab) Phase 3 MagnetisMM-5 | Late-stage clinical readout | Topline win in 2L+ RRMM monotherapy vs DPd standard-of-care; PFS primary endpoint met at interim analysis; OS immature; n=497; expands the labelled population for an internally-discovered Pfizer asset (PF-06863135); $74M global sales 2025 vs J&J Tecvayli $670M | Wed 29 Apr |
| Oruka Therapeutics | Upsized public follow-on (priced) | $700.4M gross at $72.50/share (9.66M shares); 30-day +1.45M share underwriter option; JBRs Leerink, TD Cowen, Goldman Sachs, Stifel, Guggenheim; LifeSci passive | Tue 28 Apr |
| Veradermics | Upsized public follow-on (priced) + concurrent private placement | $384.4M gross at $100.00/share (3,843,790 shares); +576,568 share underwriter option; JBRs Jefferies, Leerink, Citigroup, Cantor; LifeSci passive; Needham lead manager | Wed 29 Apr |
| Avalyn Pharma | IPO (priced Apr 29; closed May 1 with full greenshoe) | $345M aggregate gross at $18.00/share (19,166,667 shares total: 16.67M base + full 2.5M overallotment exercised); JBRs Morgan Stanley, Jefferies, Evercore ISI, Guggenheim; ticker AVLN; trading debut Apr 30; closed May 1 | Wed 29 Apr |
| Intellia Therapeutics | Underwritten public offering (priced) | $180M gross firm + 2.51M-share greenshoe fully exercised April 29 = $194.6M estimated net (19.26M shares total at $10.75); JBRs Jefferies, Goldman Sachs, Citigroup; closing April 30 | Wed 29 Apr |
| Climb Bio | Private placement (PIPE) | $110M; lead placement agents Leerink + Piper Sandler; investors Adage, ADAR1, Affinity, Ally Bridge, Cormorant, Driehaus, Great Point, RA Capital, Redmile, Sirenia, Woodline | Tue 28 Apr |
| Huahui Health / BeOne Medicines HH160 | Global exclusive option, license and collaboration | $20M upfront + $100M option exercise payment + up to $374M development/regulatory milestones + up to $1.5B sales milestones + tiered royalties on net sales (up to ~$1.99B aggregate before royalties); preclinical PD-1 / CTLA-4 / VEGF-A trispecific antibody | Thu 30 Apr |
| Pinetree Therapeutics / AstraZeneca PTX-299 | Option exercise (under July 2024 option and global license agreement) | $25M option closing payment; AZ assumes global development and commercialization of EGFR-degrader; underlying agreement: up to $45M upfront/near-term + total deal value >$500M + tiered global net-sales royalties | Wed 29 Apr |
| OSR Holdings / BCM Europe AG (BCME) for VXM01 | Definitive global exclusive license + IP buyback + put option (related-party) | Up to $815M milestones payable directly to OSRH; OSRH acquires VXM01 IP from Vaximm subsidiary for $30M; OSRH gets 100% of downstream royalties after BCME recovers investment + preferred return; OSRH put option to BCME for $15M of common stock at $10.00/share, exercisable 6 months post-effective; BCME pledges 100% of its ~29.7% OSRH equity stake as collateral for milestone obligations; clinical-stage oral immunotherapy targeting VEGFR-2 (Phase 3-ready) for glioblastoma and pancreatic cancer | Wed 29 Apr |
| Vivacta Biotechnology (Shanghai) | Series A and A+ (combined) | >$50M; co-led by Loyal Valley Capital and Decheng Capital; OrbiMed, Hankang, Eisai Innovation, C&D, Qiming, Beijing Shunxi, Apricot Capital; lead asset GT801 anti-CD19 in vivo CAR-T (T-LNP / mRNA platform; spin-off of Grit Biotherapeutics) | Wed 29 Apr |
| mbiomics | Series A third closing | €30M Series A total / €12M third close; existing investors MIG Fonds, Bayern Kapital | Tue 28 Apr |
| Lighthouse Pharmaceuticals | Series A | $12M; Double Point Ventures led; lead asset LHP588 (P. gingivalis-targeted small molecule, Phase 2 Alzheimer's disease) | Tue 28 Apr |
| AB Science | Private placement with warrants | €3.2M gross + up to ~€2.2M further on warrant exercise; Maxim Group LLC sole placement agent | Wed 29 Apr |
| LakeShore Biopharma amended take-private | M&A (amended merger agreement) | ~$2.7M implied equity (reduced consideration vs original Nov 2025 agreement); Oceanpine + multiple rollover investors | Wed 29 Apr |
| Shionogi / Torii Pharmaceutical | Internal absorption merger (intra-group) | No external consideration disclosed; merger agreement signed Apr 27; planned effective date Apr 1, 2027 | Mon 27 Apr |
| LEO Pharma / Replay | M&A (definitive agreement) | $50M cash upfront; preclinical HSV gene therapy platform (synHSV) for dystrophic epidermolysis bullosa; further consideration not disclosed; LEO Pharma is privately held (Lundbeck Foundation) | Thu 30 Apr |
| Cue Biopharma / Ascendant Health (Ascendant-221) | Exclusive license + concurrent PIPE | $15M upfront + up to $676.5M development, regulatory and commercial milestones + tiered royalties on net sales (up to ~$691.5M aggregate before royalties); ex-Greater China rights to Phase 2 anti-IgE mAb in chronic spontaneous urticaria; concurrent $30M Cue Biopharma PIPE | Thu 30 Apr |
| Axsome Therapeutics AUVELITY (dextromethorphan/bupropion) Alzheimer's-agitation FDA approval | Regulatory approval (sNDA, label expansion) | Second indication for an internally-marketed CNS asset; Antecip Bioventures II (Tabuteau-owned) holds 3.0% royalty on net sales of products containing AXS-05 licensed technology, subject to up to 50% reduction for required third-party payments; first non-antipsychotic approved for AD agitation | Thu 30 Apr |
| Kissei / Orient EuroPharma (OEP) for REZLIDHIA (olutasidenib) in Taiwan | Sub-license (under Sept 2024 Rigel / Kissei head license) | Sub-license terms not disclosed; Rigel retains mid-twenty to lower-thirty percent tiered transfer-price economics on Kissei territory net sales under head license; Forma / Novo Nordisk receives a portion of Rigel's sublicensing revenue under the Aug 2022 worldwide in-license agreement | Fri 1 May |
| Restore Vision RV-001 Phase 1/2 interim (Apr 30 / May 1) | Early-stage clinical readout | First-in-human optogenetic gene therapy interim (jRCT2033240611, n=6 total, 2 cohorts of 3); low-dose cohort: 100% (3/3) progressed from no light perception to light perception within one month; high-dose cohort: 33% (1/3) progressed within one month, with one patient reporting chart-based visual acuity measurable by the Berkeley Rudimentary Vision Test (BRVT); dose-dependent trends across visual acuity, full-field stimulus testing, and functional mobility; no DLTs or drug-related SAEs in either cohort; Keio University spin-out; no public third-party royalty layer disclosed | Fri 1 May |
| Contineum Therapeutics PIPE-791 Phase 1b chronic pain readout | Early-stage clinical readout | Once-daily 10mg oral LPA1 antagonist; n=43 (23 COAP + 20 CLBP); 4-week crossover (NCT06810245); primary endpoint (safety/tolerability) met with no SAEs and mild-to-moderate AEs (headache n=3, fatigue n=2); TP1 efficacy: COAP -1.60 PI-NRS (95% CI -2.49, -0.72) vs placebo -1.27; CLBP -1.33 vs placebo -0.55 (cleaner drug/placebo separation in CLBP); PIPE-791 wholly owned (no upstream royalty); separately, Contineum's M1 program PIPE-307 is licensed to Janssen Pharmaceutica NV for $50M upfront + $25M equity (June 2023) + >$1B in milestones + low-to-high teens royalty | Thu 30 Apr |
| Iterative Health | Series C | $77M; expansion of multispecialty clinical research network (GI / endoscopy AI; not royalty-relevant) | Thu 30 Apr |
| Ascendo Biotechnology | Series A | Size and syndicate composition not fully disclosed; ASD141 monoclonal antibody for advanced solid tumors (Phase 1; "innate immune checkpoint" mechanism) | Thu 30 Apr |
| Sun Pharma Advanced Research Company (SPARC) PRV sale | Asset purchase agreement (PRV monetization) | $195M cash at closing for the Sezaby (phenobarbital sodium injection) Rare Pediatric Disease Voucher; buyer undisclosed; Stifel sole financial advisor; second PRV transaction in W18 alongside Rocket ($180M) | Thu 30 Apr |
| DRI Healthcare Trust (TSX: DHT.UN) statement on KalVista / Chiesi | Listed-royalty-fund disclosure (change-of-control review) | DRI publicly confirmed it holds a worldwide royalty on net sales of all formulations of Ekterly (sebetralstat) and is evaluating put-option / buyback provisions triggered by the Chiesi acquisition; first listed-royalty-fund position in 2026 with a directly-impacting in-window M&A change-of-control event | Wed 29 Apr |
| ARCHIMED / Esperion Therapeutics (ESPR) | M&A (definitive agreement; PE take-private) | $3.16/share cash + 1 non-tradeable CVR per share (up to $100M aggregate: up to $40M on CY 2027 US bempedoic-acid net sales >$300M with linear interpolation through $350M; $60M digital trigger on US ENBUMYST / bumetanide annual net sales ≥$160M through Dec 31, 2030) = up to ~$1.1B fully diluted equity value; 58% premium to Apr 30 close; Pharmakon-financed take-private debt; first PE-led commercial-stage US-listed biopharma take-private of 2026; OMERS Europe royalty (15–25% to 1.7x cap), Athyrium Japan royalty (12–33% to 2.0x cap), HCRx co-lender stack inherited intact; expected close Q3 2026 | Fri 1 May |
| Merck & Co. (MRK) Q1 2026 results | Earnings release (royalty-material) | Koselugo alliance revenue from AstraZeneca $161M Q1 2026 (vs $44M Q1 2025), including a $150M payment received under the 2025 Koselugo collaboration amendment; Cidara acquisition closed Q1 ($3.62/share charge); Terns Pharmaceuticals acquisition pending close Q2 | Thu 30 Apr |
| Bristol Myers Squibb (BMY) Q1 2026 results | Earnings release (royalty-material) | Non-GAAP EPS $1.58 (vs $1.80 prior-year), explicitly attributed to the conclusion of legacy AstraZeneca diabetes royalty income at end-2025; clean royalty-stream-cessation data point | Thu 30 Apr |
| Regeneron (REGN) Q1 2026 results | Earnings release (royalty-material) | Sanofi collaboration revenue $1.6B Q1 2026; Dupixent $4.9B (+33%); Sanofi development balance to be fully repaid by end-Q2 2026; Regeneron begins receiving full Dupixent profit share from Q3 2026 onward | Wed 29 Apr |
| Biogen (BIIB) Q1 2026 results | Earnings release (royalty-material) | Leqembi $168M (+74%); $0.80 EPS IPR&D charge from TJ Biopharma felzartamab China license (signed Apr 20, pre-window); pending Apellis acquisition would absorb Syfovre / Empaveli royalty obligations on close | Wed 29 Apr |
| Sanofi (SNY) Q1 2026 results | Earnings release (royalty-material) | €40M financial income from unwinding of the Beyfortus US royalty liability under the Sobi / Sanofi structure; CEO commentary signaled BD/M&A activity will increase financial expenses in 2026; results released Apr 23 (W17), in-window investor calls and follow-up disclosures into W18 | Thu 23 Apr |
| AbbVie (ABBV) Q1 2026 results | Earnings release (royalty-material) | $744M IPR&D + milestones expense, above company expectations, driven by RemeGen RC148 PD-1 × VEGF bispecific close, Capstan close, and Kestrel option warrant; FY2026 EPS guidance updated to $13.96–$14.16 to incorporate | Wed 29 Apr |
| Genmab (GMAB) Q1 2026 royalty disclosure | Earnings release (royalty-material) | DARZALEX worldwide net trade sales $3,964M Q1 2026 ($2,208M US; $1,756M ROW); Genmab earns up to ~20% royalty under exclusive J&J license; largest single-antibody royalty stream tracked in window | Thu 30 Apr |
| Nxera Pharma (TSE: 4565) Q1 2026 results | Earnings release (royalty-material) | $22.5M milestone from Neurocrine Biosciences on NBI-1117570 (M4-preferring muscarinic agonist) Phase 2 schizophrenia first-patient-dosed (recognised in full Q1 FY2026 revenue); undisclosed development milestone from Eli Lilly under multi-target metabolic disease collaboration; Holling Bio-Pharma (Taiwan) TFDA approval of QUVIVIQ (daridorexant) triggers APAC sublicensing milestone | Fri 1 May |
| Taiho Pharmaceutical / Cullinan Therapeutics (CGEM) zipalertinib NDA acceptance | Regulatory event (NDA acceptance) | FDA accepted NDA for zipalertinib in EGFR exon 20 insertion mutation NSCLC; Cullinan retains 50/50 US economics and all milestone-trigger clocks now started under the original Taiho collaboration | Thu 30 Apr |
| CHMP April 2026 plenary outcomes (published Apr 24) | Regulatory event (EMA CHMP opinions; date-flag) | Beyond Santhera AGAMREE (already covered): positive opinions for Sanofi Cenrifki (tolebrutinib) in non-relapsing secondary progressive MS, Novartis Itvisma (onasemnogene abeparvovec) SMA broader-age formulation, Arrowhead Redemplo (plozasiran) for FCS (worldwide rights retained, EU MA expected Q2 2026), Intas ranibizumab biosimilar Rexatilux, Viatris palbociclib generic; indication extensions for AbbVie Aquipta and Skyrizi, BMS Opdivo (1L AVD cHL), AbbVie Venclyxto. Negative actions: Soleno (SLNO) withdrew EU MAA for Viokat (diazoxide choline) in Prader-Willi; Novartis withdrew Pluvicto pre-chemo asymptomatic mCRPC extension (label data only); CHMP refused Opdualag PD-L1 ≥1% melanoma extension. Plenary ran Apr 20–23, outcomes published Apr 24; trade-press analyst coverage carried into W18 | Fri 24 Apr |
Royalty-fund and structural read-throughs
| # | Event | Counterparties | Structure |
|---|---|---|---|
| i | Listed-royalty consolidation | Ligand (LGND) / XOMA Royalty (XOMA) | All-cash $39.00/share + CVR; ~$739M cash equity; 75% of net TREMFYA litigation proceeds passed through to selling stockholders |
| ii | Vtama upstream royalty assumed | Sun Pharma / Organon (inherited from Roivant–Dermavant 2024) | Up to $950M commercial milestones + tiered royalties on net sales to former Dermavant shareholders |
| iii | DMX-200 upstream royalty assumed | BioMarin / Amicus (inherited from Dimerix 2025) | $30M paid; up to $560M milestones; low-teens to low-twenties tiered royalty on US net sales |
| iv | Samsung Bioepis biosimilars partnership | Sun Pharma / Organon (inherited) | Profit-share / commercial economics on Hadlima, Renflexis, Brenzys/Eticovo, Aybintio, Ontruzant |
| v | Janssen TREMFYA litigation | XOMA → CVR holders (post-close) | XOMA contractual breach claim seeking royalty on Tremfya net sales (royalty rate magnitude undisclosed; XOMA management has indicated similar phage-display structures historically settle in low single digits) |
| vi | Mezagitamab + Takeda externalised assets | XOMA (now Ligand) | Low-to-mid single-digit royalty + up to $853M milestones across nine Takeda-externalised programmes |
| vii | Vabysmo capped pass-through | Healthcare Royalty (royalty-backed loan to XOMA) | $113M royalty-backed debt facility; expected full repayment ~end of 2030 on current Vabysmo trajectory |
| viii | Ziihera (zanidatamab) sBLA Priority Review | Jazz Pharmaceuticals → Zymeworks (license, Oct 2022 / Dec 2022 opt-in) → Royalty Pharma (royalty-backed note, March 2, 2026) | Jazz pays Zymeworks tiered 10–20% royalty on worldwide net sales + up to $525M regulatory milestones + up to $862.5M commercial milestones (total potential payments up to $1.76B); BeOne pays Zymeworks separate royalties on Asia/Pacific net sales; Royalty Pharma holds $250M non-recourse note repaid from 30% of Zymeworks' worldwide tiered royalties on Ziihera. PDUFA target action date August 25, 2026 in 1L HER2+ GEA |
| ix | AJ1-11095 (Type II JAK2 inhibitor) upstream royalty assumed | Lilly / Ajax → Schrödinger (founding co-development collaboration, 2019; expanded 2025) | Schrödinger eligible for milestone payments and single-digit royalties on net sales of products from the Ajax collaboration; equity stake in Ajax retained through close |
| x | ORKA-001 (IL-23p19 mAb) upstream royalty disclosed at Phase 2a readout | Oruka Therapeutics → Paragon Therapeutics (license agreements, 2024) | Worldwide royalty-bearing exclusive license to ORKA-001 (excl. IBD) and ORKA-002; up to ~$22M milestones per program; low single-digit percentage royalty on net sales; royalty term to later of last-to-expire patent or 12 years from first sale; WuXi Biologics cell-line technology used for manufacture |
| xi | Lonvo-z (NTLA-2002) HAELO Phase 3 + rolling BLA | Intellia Therapeutics (wholly owned) → Caribou Biosciences (foundational CRISPR/Cas9 sublicense from UC Berkeley + University of Vienna + Charpentier patent estate) | Wholly owned by Intellia at the program level (Regeneron's 25% co-development / co-promotion right applies to nex-z / ATTR, not to lonvo-z); upstream Caribou / UC sublicense terms not separately re-disclosed at the lonvo-z program level. RMAT designation supports rolling BLA; expected U.S. launch 1H 2027 if approved |
| xii | GSK / TESARO vs AnaptysBio Jemperli royalty-license dispute | GSK / TESARO ↔ AnaptysBio (March 2014 license, amended Oct 2020) ↔ Sagard Healthcare Royalty Partners (Oct 2021 + May 2024 monetizations) | Tiered royalty 8 / 12 / 20 / 25% (see dedicated section) + 1% on Zejula; royalty term to 2035 US / 2036 EU. Sagard holds capped non-recourse interest across all sales tiers (US$300M deployed; US$600M / US$675M cap). AnaptysBio seeks full reversion of Jemperli rights; trial set July 14–17, 2026 |
| xiii | Zovegalisib (RLY-2608) Phase 3 plan; PI3Kα + atirmociclib + AI triplet | Relay Therapeutics → D. E. Shaw Research (DESRES Agreement, 2020); Relay ↔ Pfizer (clinical trial supply, June 2024) | Relay retains worldwide rights to zovegalisib; DESRES low single-digit royalty upstream (PI3Kα is a Category 1 Target; royalty obligation survives August 2025 research-term expiration). Pfizer-Relay is a pure clinical-supply collaboration: no upfront, no milestones, no royalty either direction; Pfizer retains worldwide rights to atirmociclib (internally discovered, no upstream) |
| xiv | Rusfertide US opt-out: 50:50 profit share converted to global royalty | Protagonist Therapeutics ↔ Takeda (Jan 2024 worldwide license, $300M upfront previously paid) | Protagonist elects opt-out: $200M cash on election + $200M on FDA approval (PV) + $75M further approval milestone = $475M near-term, plus up to $975M additional milestones (including $25M per ex-US approval), plus tiered 14–29% royalties on worldwide net sales (replacing US profit share). Per Protagonist 8-K disclosure: 29% rate at ≥$1.5B annual net sales; 21% weighted-average rate at $1.5B; 1% royalty payable to third-party upstream. PDUFA target action date Q3 2026. Highest disclosed top-tier royalty band in 2026 dealmaking |
| xv | AI-designed recombinases licensing | Lilly ↔ Profluent Bio (announced April 28) | Multi-program collaboration with exclusive license options; undisclosed upfront + committed R&D funding + up to $2.25B development and commercial milestones + tiered royalties on net sales; preclinical/discovery; no equity component |
| xvi | Pan-KRAS warrant-plus-acquisition-option | AbbVie ↔ Kestrel Therapeutics (announced April 28; first patient dosed KST-6051 same day) | Hybrid R&D financing + M&A option: undisclosed upfront + AbbVie funds KST-6051 program + future exercise payments + downstream development and regulatory milestones; total potential up to $1.45B; sits between licensing and M&A categorically |
| xvii | Vyndamax/Vyndaqel ANDA settlements | Pfizer ↔ Hikma + Dexcel + Cipla (D. Del., April 28 court filings) | All three remaining tafamidis ANDA challengers settled; US generic launch fixed at June 1, 2031 (~2.5 years later than the prior late-2028 management expectation; ahead of Aug 31, 2035 challenged-patent expiry). Multi-billion-dollar topline lift to Pfizer; mixed read for BridgeBio Attruby (clarifies IP overhang but earlier-than-feared generic entry compresses out-years); marginal negative for Alnylam (Amvuttra) and Ionis combination strategies |
| xviii | Saphnelo (anifrolumab-fnia) Pen FDA approval, SC self-administration in SLE | AstraZeneca ↔ Bristol Myers Squibb (legacy Medarex agreement) | AstraZeneca pays BMS mid-teens royalty on US Saphnelo net sales; new SC autoinjector materially expands the addressable population versus the IV-only label, enlarging the BMS royalty stream |
| xix | Rocket Pharmaceuticals PRV cash sale | Rocket Pharmaceuticals (Nasdaq: RCKT) ↔ undisclosed buyer | Asset purchase agreement signed Sun April 26, announced April 28; $180M cash at closing (subject to HSR); PRV awarded with KRESLADI (autologous HSC gene therapy for pediatric severe LAD-I); non-dilutive proceeds fund Danon disease, PKP2-ACM, BAG3-DCM cardiovascular gene therapy programs |
| xx | Survodutide (GLP-1/glucagon dual agonist) Phase 3 SYNCHRONIZE-1 positive in obesity | Zealand Pharma → Boehringer Ingelheim (2011 collaboration; ex-Nordic worldwide exclusive license; Boehringer funds all R&D and commercialization) | 16.6% mean weight loss at 76 weeks vs 3.2% placebo (efficacy estimand, p<0.0001). Zealand eligible for up to EUR 315M outstanding milestones + high single-digit to low double-digit royalties on global sales; Zealand retains Nordic co-promotion right. Asset also carries FDA, NMPA and Taiwan FDA Breakthrough Therapy designations in MASH |
| xxi | Votoplam Huntington's disease PIVOT-HD 24-month interim positive | PTC Therapeutics ↔ Novartis (December 2, 2024 collaboration; closed Q1 2025) | 52% slowing on cUHDRS at 10mg vs propensity-weighted natural history; 28% at 5mg; NfL stayed below baseline. Original deal: US$1.0B upfront + up to US$1.9B milestones + 40/60 US profit/loss share (PTC/Novartis) + tiered double-digit ex-US royalties on net sales. Novartis Phase 3 INVEST-HD initiated (~770 patients, 3:2 vs placebo at 10mg). Separate from PTC's 22% Evrysdi royalty interest from Roche |
| xxii | GSK Q1 2026 royalty income guidance reaffirmation | GSK plc ↔ Novartis (Kesimpta) + Pfizer (Abrysvo) + Pfizer/BioNTech (Comirnaty) | FY2026 royalty income guidance of £800M–£850M reaffirmed at the April 29 Q1 release; directly relevant for royalty-fund modeling of GSK's licensee income streams |
| xxiii | SCOTUS oral argument: Hikma v. Amarin (No. 24-889) | Supreme Court of the United States (oral argument April 29, 2026; ruling expected before July 2026 recess) | First patent-inducement case before SCOTUS since Commil v. Cisco (2015); first skinny-label case since Caraco (2012). Question: whether an ANDA filer's "generic version" framing + reference to total branded sales suffices to plead induced infringement of carved-out method-of-use patents under Hatch-Waxman. The Cox v. Sony (March 2026) shadow suggests the Court may require specific affirmative acts pointing toward the patented use rather than the Federal Circuit's "totality" approach. Ruling will reshape royalty enforceability for method-of-use patents underpinning later-developed indications across pharma royalty stacks. Solicitor General supports Hikma (divided argument granted) |
| xxiv | Chiesi / KalVista acquisition triggers DRI Healthcare Trust change-of-control review on Ekterly synthetic royalty | Chiesi Group ↔ KalVista Pharmaceuticals (announced April 29) ↔ DRI Healthcare Trust (TSX: DHT.UN; royalty agreement closed November 4, 2024 + $22M optional payment elected July 8, 2025) | $1.9B equity at $27.00/share cash tender (36% premium to 30-day VWAP); expected close Q3 2026. DRI invested $127M total ($100M upfront + $22M optional + $5M equity) for tiered worldwide synthetic royalty on all formulations of Ekterly (sebetralstat): 6.00% on net sales up to $500M, 1.10% on $500–750M, 0.25% above $750M, plus up to $57M one-time sales-based milestone if annual worldwide net sales reach $550M before January 1, 2031. DRI publicly stated April 29 that the Chiesi transaction "may constitute a change of control" under the royalty agreement; DRI is reviewing put-option and buyback provisions that may become exercisable. This is the only listed-royalty-fund position in the public market directly impacted by an in-window M&A event. |
| xxv | Teva / Emalex Biosciences acquisition | Teva Pharmaceuticals (NYSE: TEVA) ↔ Emalex Biosciences (private; spun out of Indianapolis-based BioXcel territory; backed by syndicate including Paragon Biosciences) | $700M cash upfront + up to $200M commercial milestones + tiered royalties on global net sales of ecopipam = up to $900M total. Lead asset: ecopipam, first-in-class selective dopamine D1 receptor antagonist for pediatric Tourette syndrome; FDA Orphan Drug + Fast Track designations; Phase 3 met primary efficacy endpoint (p=0.0084); NDA submission anticipated 2H 2026. Teva's largest deal in a decade; expected close Q3 2026; funded from cash on hand. Disclosed alongside Teva Q1 2026 earnings release on April 29 |
| xxvi | AstraZeneca Q1 2026 Alliance Revenue and Collaboration Revenue disclosure | AstraZeneca ↔ Daiichi Sankyo (Enhertu, Datroway) + Amgen (Tezspire) + Sanofi (Beyfortus) + Crestor / Farxiga sales-milestone counterparties | Alliance Revenue $825M (+26% CER): Enhertu $508M (+23% CER, Daiichi profit-share), Tezspire $154M (+18% CER, Amgen), Beyfortus $91M (+11% CER, Sanofi), Datroway $42M (>10x, Daiichi early-launch ramp), Other royalty revenue $29M (+22% CER). Collaboration Revenue $77M: Farxiga sales milestones $44M, Crestor sales milestones $32M |
| xxvii | GSK Q1 2026 royalty income guidance reaffirmation | GSK ↔ Novartis (Kesimpta) + Pfizer (Abrysvo, Comirnaty adjuvant-related) + others | FY2026 royalty income guidance of £800M to £850M reaffirmed; cleanest large-cap pharma royalty-stream disclosure inside the W18 window |
| xxviii | Huahui Health / BeOne Medicines HH160 trispecific antibody global exclusive option, license and collaboration | Huahui Health (private; Beijing) ↔ BeOne Medicines (HKEX: 6160; SHA STAR: 688235); signed by BeOne subsidiary Guangzhou BeOne Medicines Biopharmaceutical | $20M upfront + $100M option exercise payment + up to $374M development and regulatory milestones + up to $1.5B sales-based milestones + tiered royalties on net sales (aggregate up to ~$1.99B before royalties). Preclinical anti-PD-1 / CTLA-4 / VEGF-A symmetrical hexavalent trispecific antibody (anti-PD-1 and anti-CTLA-4 nanobodies fused to N- and C-termini of an anti-VEGF-A IgG1 heavy chain with silent Fc; AACR 2025 Abstract 6060). BeOne's first large-scale early-stage global-rights licensing investment. Royalty-fund relevance: Asia-originated I-O multispecific platform deal with Western-grade biobucks structure; competing trispecific class includes CStone preclinical asset |
| xxix | Pinetree / AstraZeneca PTX-299 option exercise | Pinetree Therapeutics (private; Cambridge MA) ↔ AstraZeneca (LSE / Nasdaq: AZN); under July 2024 exclusive option and global license agreement | $25M option closing payment on Apr 29 exercise; AZ takes exclusive global license to develop and commercialize PTX-299, a first-in-class bispecific antibody EGFR degrader from Pinetree's AbReptor multispecific antibody platform. Underlying July 2024 agreement: up to $45M upfront / near-term + total deal value >$500M + tiered royalties on global net sales. Royalty-fund relevance: clean worked example of an option-to-license structure converting into a licensed asset on schedule, with a discrete trigger payment recognized in window |
| xxx | AUVELITY (AXS-05, dextromethorphan/bupropion) FDA approval in Alzheimer's-disease agitation | Axsome Therapeutics (Nasdaq: AXSM) ↔ Antecip Bioventures II LLC (Tabuteau-controlled vehicle; 2012 exclusive worldwide license, August 2015 amendment) | First non-antipsychotic FDA approval for AD agitation, granted on the April 30 PDUFA target action date; second indication for AUVELITY (originally approved 2022 for MDD). Antecip is contractually entitled to a 3.0% royalty on net sales of products containing the licensed AXS-05 technology, subject to up to 50% reduction for required third-party payments; royalty term to later of last-to-expire valid claim or 10 years from first commercial sale on a country-by-country basis. Patent estate to ≥2043. Antecip is a related-party of CEO Herriot Tabuteau and the agreement is fully terminable by Axsome for convenience. Sole disclosed example in the listed-royaltyco universe of an internally-controlled CNS franchise with a related-party 3% royalty layer; relevant precedent for diligence on related-party royalty structures inside listed-pharma platforms |
| xxxi | LEO Pharma / Replay $50M acquisition; synHSV platform inherits University of Pittsburgh upstream license | LEO Pharma A/S (private; Lundbeck Foundation) ↔ Replay Holdings, Inc. (private; San Diego / London; KKR Health Care Strategic Growth Fund II + OMX Ventures + ARTIS + Lansdowne Partners + SALT + Axial + DeciBio backed); synHSV platform exclusively licensed from University of Pittsburgh (technology developed by Prof. Joe Glorioso) | $50M cash upfront; further consideration not disclosed. LEO Pharma acquires the entire Replay platform, including synHSV (high-payload HSV-1 delivery vector, 8x to 30x AAV payload), uCell (hypoimmunogenic iPSC-derived cell therapy platform), DropSynth (genome-writing platform), and the four Replay product companies (Telaria, rare skin diseases, including the lead preclinical DEB program; Eudora, retinal diseases; Kaleibe, genetic brain disorders; Syena, oncology). Upstream royalty obligation: University of Pittsburgh holds the foundational synHSV exclusive license; specific royalty rate, milestone schedule, and field carve-outs not in the public domain. Royalty-fund relevance: the third HSV-platform M&A event of the 2025–2026 cycle (after Eli Lilly / Scorpion / oncolytic-HSV-program, and Krystal Biotech's Vyjuvek franchise expansion). LEO Pharma is privately held and does not disclose royalty-stack pass-through economics in public filings |
| xxxii | Cue Biopharma / Ascendant Health Ascendant-221 anti-IgE license for ex-Greater China rights | Cue Biopharma, Inc. (Nasdaq: CUE) ↔ Ascendant Health Sciences Ltd. (private; related-company Genesis Life Sciences runs the China Phase 2 study); concurrent $30M Cue PIPE | $15M upfront + up to $676.5M development, regulatory and commercial milestone payments + tiered royalties on net sales; excludes mainland China, Hong Kong, Macau and Taiwan. Asset: Ascendant-221, a humanized anti-IgE monoclonal antibody with dual mechanism of action (neutralizes free IgE + leverages CD23-mediated IgE downregulation pathway to suppress new IgE synthesis); Phase 1 demonstrated suppression of free IgE for >12 weeks with a single dose; Phase 2 dose-ranging study in CSU in China (Genesis-led, readout 2H 2026); Cue plans global Phase 2b in food allergy post-China data. Royalty-fund relevance: positions Ascendant-221 as a next-generation challenger to Novartis Xolair / omalizumab (originally Tanox / Genentech upstream); the anti-IgE class supports a substantial royalty-stack precedent including Sanofi / Regeneron Dupixent licensing structures. Concurrent $30M PIPE funds upfront and clinical advancement |
| xxxiii | Kissei / Orient EuroPharma (OEP) Taiwan REZLIDHIA sub-license; Rigel and Forma / Novo Nordisk royalty cascade | Kissei Pharmaceutical Co., Ltd. (TSE: 4547) ↔ Orient EuroPharma Co., Ltd. (Taipei; OEP Group; subsidiary OEP Pharma in San Diego); under September 2024 Rigel / Kissei head license; Rigel's underlying license originally from Forma Therapeutics (now Novo Nordisk subsidiary) | Sub-license terms not disclosed at signing. Three-tier upstream royalty cascade: (1) OEP pays Kissei sub-license economics (terms not disclosed); (2) Kissei pays Rigel mid-twenty to lower-thirty percent tiered transfer-price payments based on tiered net sales for exclusive supply of REZLIDHIA in the Kissei territory (Japan, Korea, Taiwan), plus up to $152.5M in development, regulatory and commercial milestones (with $10M upfront paid Sep 2024); (3) Rigel pays Forma / Novo Nordisk a portion of sublicensing revenue and ongoing royalties under the August 2022 worldwide license (Forma was acquired by Novo Nordisk October 14, 2022 for $1.1B). Royalty-fund relevance: clean worked example of a four-party Asia sub-license cascade where Western originator royalty economics survive multiple territory-level sub-licensing layers |
| xxxiv | Restore Vision RV-001 first-in-human optogenetic gene therapy interim | Restore Vision Inc. (private; Tokyo / San Diego; Keio University spin-out; CEO Yusaku Katada, MD, PhD) | First-in-human Phase 1/2 trial in advanced retinitis pigmentosa (genotype-agnostic; jRCT2033240611, Japan; n=6 total, two ascending dose cohorts of 3), conducted at Keio University Hospital. Single intravitreal AAV injection delivering "chimeric rhodopsin" (GHCR / coGHCR; G-protein-coupled mammalian-rhodopsin-derived photopigment fusing the high sensitivity of animal rhodopsin with self-regenerating microbial-rhodopsin properties; published Hayashi et al. 2023). Headline efficacy finding: low-dose cohort 100% (3/3) progressed from no light perception (NLP) to light perception (LP) or better within one month post-injection; high-dose cohort 33.3% (1/3) progressed within one month, with one high-dose patient reporting chart-based visual acuity measurable by the Berkeley Rudimentary Vision Test (BRVT), a more advanced functional measurement than LP alone. Dose-dependent trends across visual acuity, full-field stimulus testing (FST), and functional mobility / object-recognition assessments. No dose-limiting toxicities or drug-related serious adverse events to date in either cohort. Data presented at Eyecelerator @ ARVO 2026 and Retinal Therapeutics Innovation Summit (Foundation Fighting Blindness / Casey Eye Institute / OHSU), Denver, May 1, 2026. No public third-party royalty layer disclosed; underlying chimeric rhodopsin IP originates at Keio University and Nagoya Institute of Technology. Royalty-fund relevance: validates the chimeric-rhodopsin optogenetic class against the historically light-intensity-limited microbial-opsin class (GS-030 / Bionic Sight ChrimsonR; RST-001 channelrhodopsin-2); positions a Japanese gene therapy spin-out at the optogenetic-RP frontier alongside US-domiciled Adverum (4D Molecular Therapeutics ophthalmology stack). Restore Vision pre-IPO investors include Remiges Ventures, ANRI, Real Tech Fund, with grant support from AMED |
| xxxv | Contineum Therapeutics PIPE-791 LPA1 antagonist Phase 1b chronic pain readout | Contineum Therapeutics, Inc. (Nasdaq: CTNM); separately, M1 program PIPE-307 is licensed worldwide to Janssen Pharmaceutica NV (Johnson & Johnson, June 2023) | PIPE-791 (oral, brain-penetrant LPA1 receptor antagonist; once-daily 10mg): exploratory Phase 1b randomized, double-blind, placebo-controlled, 4-week crossover trial (NCT06810245); n=43 enrolled (23 COAP + 20 CLBP). Primary endpoint (safety / tolerability) met with no serious AEs; most TEAEs mild-to-moderate, most common headache (n=3) and fatigue (n=2); no clinically meaningful BP changes. Exploratory PI-NRS efficacy data (TP1): COAP arm -1.60 (95% CI -2.49, -0.72) vs placebo -1.27 (95% CI -2.15, -0.39); CLBP arm -1.33 (95% CI -1.83, -0.84) vs placebo -0.55 (95% CI -1.33, 0.22) (cleaner drug-vs-placebo separation in CLBP). PIPE-791 is wholly owned by Contineum; no upstream royalty obligation disclosed; Contineum prioritizing PIPE-791 in IPF (Phase 2 PROPEL-IPF) where the validated comparator is Bristol Myers Squibb's zimilparant (Phase 3 readout expected Q4 2026). Separately and unrelated to the LPA1 readout: PIPE-307 (M1 receptor antagonist; failed in RRMS Phase 2 VISTA in November 2025; J&J retains discretion to advance for MDD) is licensed to Janssen for $50M upfront + $25M equity (June 2023) + >$1B in milestones + low-to-high teens royalty on net sales. Royalty-fund relevance: PIPE-791 sits inside the broader 2026 non-opioid pain royalty-stack rebuild post Vertex Journavx (suzetrigine) / Lilly EP4 / Pfizer SI-449 EP4 / Keythera KF-0210 EP4; if Contineum advances IPF Phase 3 the wholly-owned ownership construct becomes a candidate for synthetic royalty financing |
| xxxvi | SPARC Sezaby Rare Pediatric Disease Voucher cash sale | Sun Pharma Advanced Research Company Limited (BSE: 532872, NSE: SPARC) ↔ undisclosed buyer; Stifel sole financial advisor | Definitive asset purchase agreement signed April 30; US$195M cash at closing (subject to HSR clearance). PRV awarded with the September 2022 FDA approval of Sezaby (phenobarbital sodium injection) for neonatal seizures; SPARC retained the voucher pending strategic monetization. Second PRV transaction in W18 alongside Rocket's US$180M deal three days earlier; together the two transactions establish a US$180–200M post-CNPV PRV pricing band and confirm continued buyer demand for vouchers in the post-September 2024 RPDD-program-expiry environment. Royalty-fund relevance: SPARC is the listed pure-play R&D vehicle of the Sun Pharma group; the proceeds are deployable into SPARC's pipeline rather than parent Sun Pharma operations, providing a non-dilutive funding line at the SPARC entity that runs independent of the parent's US$11.75B Organon acquisition |
| xxxvii | DRI Healthcare Trust formal change-of-control statement on Ekterly synthetic royalty | DRI Healthcare Trust (TSX: DHT.UN) ↔ KalVista Pharmaceuticals (Nasdaq: KALV; royalty agreement closed November 4, 2024 + US$22M optional payment elected July 8, 2025) ↔ Chiesi Group (acquirer announced April 29) | DRI publicly confirmed April 29 that it holds a worldwide royalty on net sales of all formulations of Ekterly (sebetralstat) and that the announced Chiesi acquisition "may constitute a change of control" under the royalty agreement. DRI invested US$127M total (US$100M upfront + US$22M optional + US$5M equity) for a tiered worldwide synthetic royalty: 6.00% on net sales up to US$500M, 1.10% on US$500–750M, 0.25% above US$750M, plus up to US$57M one-time sales-based milestone if annual worldwide net sales reach US$550M before January 1, 2031. DRI is reviewing put-option and buyback provisions that may become exercisable. This is the only listed-royalty-fund position in the public market directly impacted by an in-window M&A event and provides a live worked example of a royalty change-of-control mechanic for the royalty-fund audience |
| xxxviia | ARCHIMED / Esperion Therapeutics PE take-private; OMERS / Athyrium / HCRx / Pharmakon four-counterparty royalty + debt stack inherited | ARCHIMED ↔ Esperion Therapeutics (Nasdaq: ESPR; announced May 1) ↔ OMERS Life Sciences (Aug 2024 European royalty) + Athyrium Capital Management (Apr 2, 2026 Japan royalty) + HealthCare Royalty Partners (Dec 2024 senior secured term loan, joined) + Pharmakon Advisors (Dec 2024 senior secured term loan, lead + Convertible Note + May 2026 take-private debt commitment) | US$3.16/share cash + 1 non-tradeable CVR per share (up to US$100M aggregate: tranche 1 = up to US$40M tied to CY 2027 US bempedoic-acid (NEXLETOL / NEXLIZET) net sales >US$300M with linear interpolation through US$350M; tranche 2 = US$60M digital trigger on annual US ENBUMYST / bumetanide net sales ≥US$160M in any single calendar year through Dec 31, 2030) = up to ~US$1.1B fully diluted equity value; 58% premium to Apr 30 close; first PE-led commercial-stage US-listed biopharma take-private of the 2026 cohort; expected close Q3 2026; debt financing committed by Pharmakon Advisors-managed funds. Inherited royalty stack: OMERS Life Sciences holds a tiered 15% to 25% royalty on Daiichi Sankyo Europe net sales of bempedoic acid in Europe until receiving 1.7x its US$304.7M invested capital; Athyrium Funds hold a tiered 12% to 33% royalty on Otsuka Japan net sales of bempedoic acid + associated regulatory and commercial milestones until receiving 2.0x their US$50M invested capital (effective Jan 1, 2026 onward); after each cap, royalties revert to Esperion / post-merger ARCHIMED. Royalty-fund relevance: cleanest 2026 worked example of a four-counterparty non-dilutive monetisation stack surviving a commercial-stage take-private intact, plus a transferable two-tranche sales-based CVR construct for future PE-led take-privates of commercial-stage biopharma franchises with high revenue dispersion in out-years |
| xxxviii | Merck & Co. Q1 2026 Koselugo amendment-trigger payment from AstraZeneca | Merck & Co., Inc. (NYSE: MRK) ↔ AstraZeneca (Koselugo / selumetinib collaboration; 2017 worldwide collaboration; 2025 amendment) | Merck Q1 2026 release (April 30) booked Koselugo alliance revenue of US$161M (vs US$44M Q1 2025), including a US$150M payment received under the 2025 Koselugo collaboration amendment. Cleanest amendment-trigger disclosure in the W18 window; relevant precedent for diligence on amendment-driven economic shifts in legacy collaborations. Merck also took a US$3.62/share charge for the closed Cidara acquisition; Terns Pharmaceuticals acquisition pending close Q2 2026 (Terns received FDA Breakthrough Therapy Designation for TERN-701 in Ph+ CML on April 27, reinforcing deal value) |
| xxxix | Bristol Myers Squibb Q1 2026: legacy AstraZeneca diabetes royalty income concluded at end-2025 | Bristol Myers Squibb (NYSE: BMY) ↔ AstraZeneca (legacy diabetes royalty stream; concluded December 31, 2025) | BMY Q1 2026 release (April 30) reported non-GAAP EPS US$1.58 (versus US$1.80 prior-year quarter), with management explicitly attributing the step-down to the conclusion of legacy AstraZeneca diabetes royalty income at end-2025. Discrete royalty-stream-cessation data point: relevant for modeling the cliff-edge profile of capped-term royalty contracts as they mature, and a worked example of how a several-hundred-million-dollar annual royalty stream is absorbed at quarterly EPS cadence post-expiry |
| xl | Regeneron Q1 2026: Sanofi Dupixent profit-share step-up scheduled for Q3 2026 | Regeneron Pharmaceuticals (Nasdaq: REGN) ↔ Sanofi (Dupixent collaboration; 2007 antibody collaboration as amended) | REGN Q1 2026 release (April 29) reported Sanofi collaboration revenue US$1.6B, Dupixent global net sales US$4.9B (+33% YoY). Most material guidance: the Sanofi development balance will be fully repaid by end-Q2 2026, after which Regeneron begins receiving its full Dupixent profit share from Q3 2026 onward. This is a known structural step-up but the Q1 release fixed the timing definitively; it materially affects 2H 2026 and FY2027 modeling for any royalty fund or analyst tracking REGN's collaboration-revenue line |
| xla | Sanofi Q1 2026: Beyfortus US royalty liability unwinding | Sanofi (Nasdaq: SNY) ↔ Sobi (legacy Sobi-funded RSV programme structure; previously disclosed as a financial liability on the Sanofi balance sheet) | Sanofi Q1 2026 release (April 23, in W17 by date but referenced in W18 follow-on commentary) included €40M financial income from unwinding of the Beyfortus US royalty liability under the Sobi / Sanofi structure. Royalty-fund relevance: discrete worked example of how a royalty liability mature carries through to the income statement of a Big Pharma licensee. CEO commentary on the Q1 call signaled BD/M&A activity will increase financial expenses in 2026 and may slip later than budgeted; this is read-through-relevant for the broader Big Pharma BD-spending cadence into HLTH Europe and BIO San Diego |
| xlb | AbbVie Q1 2026: US$744M IPR&D expense materially above expectations | AbbVie (Nasdaq: ABBV) ↔ RemeGen (RC148 PD-1 × VEGF bispecific; in-window close) + Capstan Therapeutics (closed Q1) + Kestrel Therapeutics (April 28 warrant + acquisition option) | AbbVie Q1 2026 release (April 29) reported US$744M IPR&D + milestones expense, materially above the company's prior cadence and Street expectations, driven by the RemeGen RC148 close, the Capstan close, and the Kestrel warrant. FY2026 EPS guidance updated to US$13.96 to US$14.16 to incorporate these BD-driven expense step-ups. Royalty-fund relevance: AbbVie is the most BD-active Big Pharma counterparty in the W18 window (Kestrel hybrid R&D financing + acquisition option already covered separately); the IPR&D expense disclosure is a quantitative anchor for the cumulative cost of AbbVie's 2026 BD push |
| xlc | Genmab Q1 2026: DARZALEX worldwide net trade sales US$3,964M | Genmab A/S (Nasdaq: GMAB; CSE: GMAB) ↔ Johnson & Johnson (Janssen; 2012 exclusive worldwide license; legacy ~20% royalty rate, with stepped reductions at higher US/ex-US sales tiers) | J&J reported (released alongside Genmab disclosure) DARZALEX worldwide net trade sales of US$3,964M for Q1 2026 (US US$2,208M + ROW US$1,756M). Genmab earns up to a ~20% royalty under the exclusive J&J license. Largest single-antibody royalty stream tracked anywhere in the W18 window; remains the highest-revenue royalty-bearing biologic asset in the listed pharma universe and a benchmark comparator for any out-licensed-antibody royalty modeling exercise. The asset's continued double-digit revenue growth supports a multi-year royalty cliff modeling approach for SC-formulation patents and the post-2030 biosimilar entry assumption set |
| xld | Nxera Pharma Q1 2026: US$22.5M Neurocrine NBI-1117570 milestone + Lilly milestone + Holling Bio Taiwan QUVIVIQ approval | Nxera Pharma Co., Ltd. (TSE: 4565; Tokyo / Cambridge UK) ↔ Neurocrine Biosciences (multi-program muscarinic agonist collaboration) + Eli Lilly (multi-target metabolic disease collaboration) + Holling Bio-Pharma Corp. (Taiwan APAC commercial sublicense) | Nxera Q1 2026 release (May 1) confirmed three royalty / milestone-relevant items: (1) US$22.5M milestone payment from Neurocrine triggered by Phase 2 first-patient-dosed in NBI-1117570 (oral dual M1/M4 receptor agonist, schizophrenia), recognised in full as Q1 FY2026 revenue; (2) undisclosed development milestone from Eli Lilly under the multi-target metabolic disease collaboration, recognised as Q1 2026 revenue (Nxera retains downstream milestone plus royalty stream and Centessa equity following Lilly's Mar 31 Centessa close); (3) Holling Bio-Pharma (Taiwan) TFDA approval of QUVIVIQ (daridorexant), triggering an APAC sublicensing milestone within Nxera's commercial network. Royalty-fund relevance: cleanest in-window worked example of an Asia-headquartered drug discovery platform earning multi-counterparty royalty income across both the Neurocrine muscarinic agonist franchise and the Lilly metabolic platform; positions Nxera as a transferable comp for cross-border platform licensing royalty stack design |
| xli | Taiho Pharmaceutical / Cullinan Therapeutics zipalertinib NDA acceptance | Taiho Pharmaceutical Co., Ltd. (private; Otsuka group) ↔ Cullinan Therapeutics, Inc. (Nasdaq: CGEM; original 2022 Taiho-Cullinan collaboration on CLN-081 / zipalertinib) | FDA accepted the zipalertinib NDA on April 30 in EGFR exon 20 insertion mutation NSCLC (post-platinum-chemotherapy setting). Cullinan retains 50/50 US profit/loss share under the original collaboration; Taiho holds ex-US rights and pays Cullinan tiered royalties on ex-US net sales. Milestone-trigger clocks now begin against the PDUFA action date. Asset positions against Takeda's mobocertinib (voluntarily withdrawn 2024) and Johnson & Johnson's amivantamab in the EGFR exon 20 niche; clean late-stage US 50/50 economics structure for an Asia-originated asset |
| xlii | CHMP April 2026 plenary outcomes (date-flag: published April 24) | EMA Committee for Medicinal Products for Human Use (plenary April 20–23, 2026; outcomes published April 24) | Strictly W17 by publication date but extensive analyst and trade-press coverage carried into W18; included here for completeness. Five new positive opinions beyond Santhera AGAMREE (already covered in W18): Sanofi Cenrifki (tolebrutinib) in non-relapsing secondary progressive MS (first major regulatory win for Sanofi's BTK inhibitor); Novartis Itvisma (onasemnogene abeparvovec) SMA broader-age formulation; Arrowhead Redemplo (plozasiran) for FCS (Arrowhead retains worldwide rights, EU MA expected Q2 2026); Intas ranibizumab biosimilar Rexatilux; Viatris palbociclib generic. Indication extensions: AbbVie Aquipta and Skyrizi, BMS Opdivo (1L AVD cHL), AbbVie Venclyxto. Three negatives matter: Soleno Therapeutics (SLNO) withdrew the EU MAA for Viokat (diazoxide choline) in Prader-Willi; Novartis withdrew Pluvicto's pre-chemo asymptomatic mCRPC extension (label data only, meaningful for Endocyte-legacy royalty trajectory); CHMP refused BMS Opdualag PD-L1 ≥1% melanoma extension |
No new HCRx, RPRX, Sagard, NovaQuest, DRI, Oberland, OrbiMed Royalty, Marathon, or Blackstone Life Sciences standalone royalty origination transactions were inked in window. The Ligand / XOMA combination is the only royalty-platform-level event inside the five-day window. Separately, DRI Healthcare Trust's existing US$127M Ekterly synthetic royalty position enters change-of-control review on the Chiesi / KalVista acquisition announcement (April 29); this is the only listed-royalty-fund position in the public market directly impacted by an in-window M&A event, with put-option and buyback provisions potentially exercisable.
The Jazz / Ziihera FDA filing acceptance materially de-risks the existing March 2, 2026 Royalty Pharma / Zymeworks US$250M non-recourse royalty-backed note (repaid from 30% of Zymeworks' worldwide tiered Ziihera royalties from Jazz and BeOne); an FDA approval at the August 25, 2026 PDUFA action date is the next disclosed catalyst on note repayment timing. The GSK / TESARO vs AnaptysBio Jemperli dispute is the more consequential royalty-fund event of the window: the Sagard Healthcare Royalty Partners US$300M deployed against AnaptysBio's GSK royalty entitlement is the single most exposed listed royalty-fund position to a near-term binary trial event in the current public market, with full reversion of dostarlimab rights to AnaptysBio the most adverse outcome for both GSK and Sagard.
Two listed-royaltyco events bookend the five-day window. The Ligand / XOMA consolidation removes XOMA from the listed-royaltyco set on close. Inside W18, Protagonist's April 28 opt-out under the Takeda rusfertide collaboration is the highest-priority royalty-structure event of the week: it converts a 50:50 US profit share into a worldwide tiered royalty, with $200M opt-out cash, $200M on FDA approval, $75M further approval milestone, up to $975M in additional milestones, and tiered 14–29% royalties on worldwide net sales. The 14–29% disclosed band is one of the rare disclosed high-end royalty ranges in 2026 dealmaking.
The Pfizer Vyndamax ANDA settlements (April 28, D. Del.) with Hikma, Dexcel, and Cipla fix US generic entry at June 1, 2031, ahead of the Aug 31, 2035 challenged-patent expiry but ~2.5 years later than management's prior late-2028 expectation. The franchise-lift implication is multi-billion-dollar topline for Pfizer, with mixed read for BridgeBio Attruby (clarifies IP overhang but compresses out-years) and marginal negative for Alnylam (Amvuttra) and Ionis combination strategies.
The Chiesi / KalVista acquisition (April 29; US$1.9B equity) brings Italian large-cap Chiesi to the rare-disease-M&A counterparty set alongside Sun Pharma, with the directly-relevant collateral effect being the change-of-control review on DRI Healthcare's US$127M Ekterly synthetic royalty position. The ARCHIMED / Esperion take-private (May 1; up to US$1.1B fully diluted) is the first PE-led commercial-stage US-listed biopharma take-private of 2026, with a four-counterparty inherited royalty + debt stack (OMERS Europe, Athyrium Japan, HCRx co-lender, Pharmakon lead lender + take-private debt financier) acquired intact. The Teva / Emalex acquisition (April 29; up to US$900M) for the NDA-ready ecopipam Tourette syndrome asset is Teva's largest deal in a decade and confirms the W18 theme of late-stage-asset bolt-ons across CNS and rare-disease franchises. The JADA-system divestiture (Organon / Boston Scientific, January 2026, $440M upfront + earn-out to up to $465M) is confirmed in the Sun Pharma 8-K disclosure as a positive cash-balance contributor through closing.
Royalty-collateral regulatory designations and approvals. OSE Immunotherapeutics received FDA Orphan Drug Designation for pegrizeprument (VEL-101) in heart-transplant rejection prevention on April 27, with potential milestone implications under OSE's April 2021 worldwide license to Veloxis Pharmaceuticals. Immutep (April 27) received FDA Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma. AstraZeneca (April 27) received FDA approval for the Saphnelo Pen subcutaneous self-administration formulation in SLE, expanding the addressable population and the mid-teens BMS royalty stream payable on US Saphnelo net sales under the legacy Medarex agreement. Taiho Pharmaceutical / Cullinan Therapeutics (CGEM) (April 30) received FDA acceptance of the zipalertinib NDA in EGFR exon 20 insertion mutation NSCLC; Cullinan retains 50/50 US economics under the original Taiho collaboration and all milestone-trigger clocks now begin against the PDUFA action date.
M&A: Sun Pharma / Organon. Up to US$11.75B Enterprise Value. India's Largest Outbound Pharma Acquisition (April 26)
On Sunday April 26 (Mumbai / Jersey City), Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA, BSE: 524715) and Organon & Co. (NYSE: OGN) announced a definitive agreement under which Sun Pharma will acquire all outstanding Organon shares for US$14.00 per share in cash, valuing Organon at US$3.99B in equity and US$11.75B on an enterprise-value basis (assuming Organon's 31 December 2025 balance sheet of US$8.6B gross debt and US$574M cash, prior to the Q1 2026 net cash benefit of the JADA divestiture). The transaction is expected to close in early 2027, subject to Organon stockholder approval and customary regulatory clearances. Primary source: Organon SEC Form 8-K Exhibit 99.1, April 27, 2026.
This is the largest outbound acquisition by an Indian drugmaker on record, exceeding Sun Pharma's own 2014–2015 Ranbaxy transaction in scale and being executed without equity dilution. Dilip Shanghvi explicitly framed the financing decision as a contrast to Ranbaxy: that deal used Sun Pharma stock; this one uses cash and committed debt financing from Citigroup Global Markets Asia, JPMorgan Chase Bank, and MUFG Bank.
For a royalty-finance audience the transaction is consequential on four grounds. First, it consolidates an established-brands and biosimilars cash platform with material residual upstream royalty obligations into a single entity that has not historically been an acquirer of biosimilar assets. Second, it brings the Organon–Samsung Bioepis biosimilar partnership inside a generics-native operator, with implications for how the next generation of biosimilar profit-share architecture is structured. Third, the Roivant–Dermavant 2024 contingent consideration on Vtama (up to US$950M of commercial milestones plus tiered royalties on net sales to former Dermavant shareholders) becomes a Sun Pharma obligation post-close. Fourth, it adds a Top-3 global women's-health franchise (Nexplanon, NuvaRing, Jada-system-divested obstetric platform residuals) to a company whose innovative-medicines exposure has historically been concentrated in dermatology, ophthalmology, and oncodermatology.
Deal Structure
| Term | Detail |
|---|---|
| Acquirer | Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA, BSE: 524715) |
| Target | Organon & Co. (NYSE: OGN), Jersey City NJ |
| Per-share cash consideration | US$14.00 per share |
| Equity value | ~US$3.99B |
| Enterprise value | US$11.75B (includes assumption of Organon US$8.6B gross debt; US$574M cash as of 31 Dec 2025) |
| Transaction form | Reverse triangular merger; Organon survives as wholly-owned subsidiary of Sun Pharma |
| Financing | Sun Pharma cash on hand plus committed bank financing |
| Financing banks | Citigroup Global Markets Asia, JPMorgan Chase Bank N.A., MUFG Bank Ltd. |
| Sun Pharma financial advisors | J.P. Morgan Securities LLC, Jefferies LLC |
| Sun Pharma legal counsel | White & Case LLP (US); AZB & Partners (India) |
| Organon lead financial advisor | Morgan Stanley & Co. LLC |
| Organon financial advisor | Goldman Sachs & Co. LLC |
| Organon legal counsel | Sullivan & Cromwell LLP (US); Cyril Amarchand Mangaldas (India) |
| Closing conditions | Organon stockholder approval; HSR clearance; international competition clearances; customary closing conditions |
| Expected close | Early 2027 |
| Pro forma Sun Pharma + Organon revenue | US$12.4B combined (FY24-25 Sun + CY2025 Organon) |
| Pro forma global ranking | Top-25 global pharma; Top-3 global Women's Health; 7th largest global biosimilar player |
| Pro forma innovative-medicines share | 27% of revenue |
| Geographic reach | 150 countries; 18 markets each generating >US$100M in revenue |
| Pro forma net leverage | 2.3x Net Debt / EBITDA post-close (EBITDA and cash flow approximately doubling vs. Sun standalone) |
Organon: 2025 Stand-Alone Operating Profile
| Metric | FY 2025 |
|---|---|
| Revenue | US$6.2B |
| Adjusted EBITDA | US$1.9B (margin ~30.7%) |
| Adjusted gross margin | 60.1% |
| Total debt (31 Dec 2025) | US$8.64B |
| Cash and equivalents (31 Dec 2025) | US$574M |
| Net leverage | ~4.0x adjusted EBITDA |
| Q1 2026 cash bridge event | JADA system divestiture completed January 2026, US$440M upfront cash + potential earn-out to a US$465M aggregate ceiling, with proceeds applied to debt reduction |
| Recent capital actions | US$419M of 2031 notes repurchased and cancelled in 2025; quarterly dividend reduced to US$0.02/share in February 2026 |
| Q1 2026 reported revenue (consensus / company commentary) | Continued mature-product erosion; biosimilar growth offsets; Vtama and Emgality cited as 2025 partial offsets |
Strategic Logic: Two Layers
Layer 1: A generics-into-Established-Brands play. Sun Pharma has been the world's largest specialty generics company for nearly a decade, with vertically integrated operations across five continents and a leading generic-business presence in the US and global emerging markets. Innovative medicines (dermatology / ophthalmology / oncodermatology) account for ~20% of Sun standalone revenue. Organon's portfolio of >70 products across women's health and general medicines reinforces Sun's generic / branded-generic positioning while extending the innovative-medicines share to 27% pro forma. The 140-country Organon commercial footprint plus six EU + emerging-markets manufacturing facilities mesh with Sun's global emerging-markets presence; the US, Europe, China, Canada, and Brazil combine to anchor pro forma revenue with 18 markets each above US$100M.
Layer 2: An entry into biosimilars at scale. Shanghvi explicitly addressed Sun Pharma's prior absence from biosimilars, attributing it to historical lack of clarity on US substitution and interchangeability rules. With those rules now developed, the Samsung Bioepis–Organon partnership immediately positions Sun Pharma as the 7th largest global biosimilar player post-close, with a US-active portfolio anchored on Hadlima (high- and low-concentration adalimumab biosimilar; SB5 originator), Renflexis (infliximab; SB2), and three additional Samsung Bioepis molecules, etanercept (Brenzys/Eticovo, SB4), bevacizumab (Aybintio, SB8), and trastuzumab (Ontruzant, SB3), distributed by Organon under longstanding development-and-commercialisation collaborations.
Upstream IP and Royalty Stack: Vtama (Tapinarof) Inherited Obligation
The cleanest discrete royalty obligation Sun Pharma will inherit is the contingent consideration tail from Organon's October 2024 acquisition of Dermavant Sciences from Roivant. Original deal terms:
| Layer | Detail |
|---|---|
| Originator | GSK (originally synthesised tapinarof, the aryl hydrocarbon receptor (AhR) modulating agent that became Vtama) |
| Out-licensee | Dermavant Sciences (a Roivant company), Long Beach CA / Raleigh-Durham NC / Dallas / Phoenix |
| First FDA approval | May 2022 (mild, moderate, severe plaque psoriasis in adults) |
| Second FDA approval | Q4 2024 (atopic dermatitis, ages ≥2; triggered the US$75M AD-approval milestone) |
| Organon acquisition (closing Oct 28, 2024) | Aggregate consideration up to ~US$1.2B: US$175M upfront, US$75M AD-approval milestone, up to US$950M in commercial milestones, plus tiered royalties on net sales to former Dermavant shareholders |
| Japan ex-licensee | Japan Tobacco (separate license; not part of Organon contractual chain) |
| Commercial trajectory | "#1 branded topical for plaque psoriasis within two months of launch" per Dermavant; FY (Mar 2024) Vtama revenue of US$75.1M; Organon-cited contribution to 2025 partial offset of mature-product erosion |
Post-close royalty stack on Vtama net sales (assumed by Sun Pharma):
| Layer | Direction | Counterparty | Disclosed rate / basis |
|---|---|---|---|
| Vtama net sales (US + ex-Japan international where applicable) | n/a | Sun Pharma (post-close) | 100% recorded |
| Tiered royalty on net sales | Outflow from Sun Pharma | Former Dermavant shareholders (Roivant being the majority holder) | Tiered, percentage range not publicly disclosed |
| Commercial milestones | Outflow from Sun Pharma | Former Dermavant shareholders | Up to US$950M remaining contingent (net of milestones already triggered, including the US$75M AD-approval milestone in Q4 2024) |
| Japan | No flow to / from Sun Pharma | Japan Tobacco | Separate licence; outside Organon (now Sun Pharma) territory |
This structure is materially analogous to the Amneal / Kashiv 12-year, 25%-of-gross-profit synthetic royalty disclosed in W17, in that it sits inside an M&A as deferred consideration with a long contingent tail, but is closer to a net-sales tiered royalty than a gross-profit hurdle. For Sun Pharma post-close, the Vtama royalty tail represents the largest discrete upstream obligation in the inherited Organon portfolio.
Upstream IP and Commercial Economics: Samsung Bioepis Biosimilars
The Samsung Bioepis–Organon collaboration originated as an MSD–Samsung Bioepis arrangement in 2013, transferred to Organon at the 2021 spin-off, and covers commercial activities (manufacturing and supply by Samsung Bioepis; Organon as the marketing partner across the US and selected international markets). Specific profit-share or transfer-pricing terms have never been publicly disclosed by Organon, Samsung Bioepis, or in the original Merck filings; the relationship is consistently described in regulatory filings as a "development and commercialization collaboration" rather than as a royalty pass-through.
| Biosimilar | Originator product | Markets where Organon commercialises | Approx. role |
|---|---|---|---|
| Hadlima (adalimumab-bwwd, SB5) | Humira (AbbVie) | US (launched July 2023, both 50 mg/mL and 100 mg/mL high-concentration formulations); ex-US under various brands in 24 markets | Marketing partner; manufacturing by Samsung Bioepis |
| Renflexis (infliximab, SB2) | Remicade (J&J) | US, EU; FY 2020 Merck revenue ~US$135M | Marketing partner |
| Brenzys / Eticovo (etanercept, SB4) | Enbrel (Amgen) | Canada (Brenzys = market leader pre-Sun); EU as Eticovo | Marketing partner |
| Aybintio (bevacizumab, SB8) | Avastin (Roche) | EU | Marketing partner |
| Ontruzant (trastuzumab, SB3) | Herceptin (Roche) | US (launched April 2020); EU; Brazil; first WHO-prequalified biosimilar (Dec 2019) | Marketing partner |
The 2024 US Department of Veterans Affairs five-year Hadlima contract (exclusive supplier across the active ingredient class) is in place at close.
For Sun Pharma post-close, the operational implication is that biosimilar revenue is recognised as net product sales on the Sun Pharma P&L, but with a meaningful share of gross profit transferring back to Samsung Bioepis under the development-and-commercialisation collaboration. The economic split has not been publicly disclosed; industry-comparable structures suggest a 50/50 to 60/40 (Organon-retained) gross-profit split is the typical range for biosimilar marketing partnerships of this vintage.
Other Embedded Tails: Lilly / Emgality, Forendo, Atozet
Beyond Vtama and the Samsung Bioepis collaboration, Sun Pharma will inherit several smaller contractual tails:
- Eli Lilly / Emgality (galcanezumab) co-promotion: Organon expanded the original European collaboration in August 2024 (US$22.5M consideration) to add sole promotion and distribution rights in Canada, Colombia, Israel, South Korea, Kuwait, Mexico, Qatar, Saudi Arabia, Taiwan, Turkey, and the UAE. Lilly retains the originator economics; Organon (now Sun Pharma) earns a distribution / co-promotion margin in the territories.
- Forendo Pharma (Nov 2021 acquisition): A women's-health discovery-stage acquisition focused on intracrinology; pipeline status (HSD17B1 inhibitor for endometriosis) not publicly material.
- Atozet (ezetimibe + atorvastatin) loss of exclusivity: Cited in Organon Q4 2025 commentary as a 2025 revenue headwind in EU and Japan; relevant to pro forma generic-erosion modelling.
- JADA system (postpartum hemorrhage device): Divested January 2026 to Boston Scientific for US$440M upfront + earn-out up to US$465M aggregate; net proceeds applied to debt reduction. Transaction is closed pre-Sun-deal-signing and the cash is on Organon's 31 March 2026 balance sheet.
Read-Through for the 2026 Royalty and Biosimilar Markets
First, biosimilar M&A is now an Indian-acquirer category. With Sun Pharma anchoring its first biosimilar position via Organon, Indian large-cap pharma is now a credible counterparty in biosimilar consolidation alongside the historical US/EU mid-cap acquirer set (Sandoz, Coherus, Fresenius Kabi, Celltrion / Hong Kong-listed counterparties). For the 2026–2028 wave of biosimilar LOEs (Stelara, Eylea, Xolair), Indian acquirers can be modelled as bidders; that materially expands the buyer universe at any future biosimilar-asset auction.
Second, the Vtama tail becomes a future monetisation candidate. The former Dermavant shareholders (Roivant being the majority holder) hold a tiered net-sales royalty plus up to US$950M in remaining commercial milestones on a recently-launched topical with peak-sales potential >US$1B if AD growth converts. Roivant's prior royalty-monetisation track record (notably the Pfizer-related Sumitomo–Myovant transaction, plus the 2023 sale of various subsidiaries) makes it a structural seller of long-dated royalty tails. RPRX, HCRx, DRI, and Sagard would all be plausible counterparties on a post-2027 Vtama royalty monetisation.
Third, the deal does not directly involve a royalty-fund counterparty at signing, but the Organon balance sheet (US$8.6B gross debt at 31 Dec 2025, post-JADA-divestiture and 2031-note repurchase activity) is a structural opportunity: the post-close 2.3x net leverage profile is comfortably below covenant limits but does benefit from non-dilutive royalty-monetisation optionality on Nexplanon (the long-acting reversible contraceptive) and on the Samsung Bioepis biosimilar profit share, both of which represent classic synthetic-royalty candidates.
Fourth, the Indian outbound M&A premium is now competitive with US/EU mid-cap M&A. Organon's US$14.00/share consideration is approximately 53% above the 30-day VWAP prior to bid speculation, and the US$11.75B EV approximates 6.2x FY2025 adjusted EBITDA. That is consistent with, and in fact slightly below, recent 2025 mid-cap pharma M&A multiples (the BioMarin / Amicus deal at 11.0x trailing EBITDA on a smaller franchise, the Sobi / Arthrosi deal at higher multiples on earlier-stage assets), suggesting Sun Pharma is acquiring at the lower end of the multi-asset platform M&A multiple range.
Disclosure Gaps
- Specific Vtama net-sales royalty tier breakpoints and rates remain undisclosed in any Roivant or Organon SEC filing.
- The Organon–Samsung Bioepis biosimilar profit-share split is not publicly broken out.
- Sun Pharma has not publicly disclosed the planned post-close treatment of Organon's standalone US$8.6B debt stack, specifically, whether the financing is structured as a refinancing (replacing Organon's existing 2028, 2031, and 2034 senior notes at consolidated Sun Pharma cost-of-capital) or as a debt assumption pending tender activity. The pro forma 2.3x net leverage suggests refinancing economics.
- No disclosure on whether any of the Samsung Bioepis biosimilar margin is structured to flow back to Merck (MSD) under the original 2013 spin-out arrangement; this is an open question for any third-party post-close diligence.
M&A Closing: BioMarin / Amicus Therapeutics. US$4.8B Rare-Disease Acquisition Closes (April 27)
On Monday April 27 (San Rafael CA), BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced the completion of its previously-announced US$4.8B all-cash acquisition of Amicus Therapeutics (formerly Nasdaq: FOLD) at US$14.50 per share. The transaction was originally announced December 19, 2025 (covered in WTS 2025-W51), Amicus stockholders approved the merger on March 2, 2026 (74.79% of shares represented; 99.97% of votes cast in favour), and the FTC granted early termination of the HSR waiting period on February 11, 2026. French FDI clearance, the final outstanding closing condition (covered in WTS 2026-W17), was received during the week ending April 24, enabling the April 27 close. Primary source: BioMarin SEC Form 8-K, April 27, 2026.
For a royalty-finance audience the close converts a year-pending obligation into an active intra-BioMarin franchise consolidation, with three concurrent royalty-stack consequences worth tracing: (i) the Dimerix DMX-200 US royalty pass-through obligation (low-teens to low-twenties tiered) is now a BioMarin obligation, (ii) the WuXi Biologics exclusive cipaglucosidase commercial drug-substance manufacturing agreement is preserved as a successor-in-interest matter, and (iii) the 2027–2037 Galafold US exclusivity tail, secured via the December 2025 Aurobindo / Lupin Galafold patent-litigation settlements, now sits inside BioMarin's enzyme-therapies unit alongside Vimizim, Naglazyme, Aldurazyme, and Brineura.
Closing Mechanics
| Term | Detail |
|---|---|
| Transaction structure | All-cash merger; Amicus survives as wholly-owned BioMarin subsidiary; FOLD common stock cancelled and converted into right to receive US$14.50/share in cash |
| Per-share cash consideration | US$14.50 |
| Total equity value | ~US$4.8B |
| Financing | BioMarin cash on hand + US$3.7B non-convertible debt (Morgan Stanley Senior Funding sole lead arranger; original bridge commitment converted into syndicated term financing) |
| BioMarin gross-leverage target | <2.5x within two years post-close |
| Original announcement | December 19, 2025 |
| Amicus stockholder approval | March 2, 2026 (special meeting; 234,593,492 in favour) |
| HSR clearance | February 11, 2026 (early termination) |
| French FDI clearance | Received w/e April 24, 2026 |
| Japan competition clearance | Received Q1 2026 |
| Closing date | April 27, 2026 |
| Expected updated FY2026 guidance | May 4, 2026 Q1 earnings call |
Inherited Commercial Portfolio
| Product | Indication | 2025 Amicus revenue | Key economics |
|---|---|---|---|
| Galafold (migalastat) | Fabry disease, GLA-amenable variants (~35–50% of Fabry patients globally) | US$521.7M (+US$63.6M YoY; ~12% growth) | First and only oral chaperone for Fabry; approved in >40 countries; US exclusivity through Jan 30, 2037 following Aurobindo / Lupin / Teva settlements; GlobalData consensus 2031 sales US$840M |
| Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) | Late-onset Pompe disease in adults ≥40 kg not improving on current ERT | US$112.5M (+US$42.3M YoY; ~60% growth) | bis-M6P-enriched rhGAA + small-molecule chaperone (CHART platform); reimbursed in 15 countries pre-close; GlobalData consensus 2031 sales US$691M |
| Combined Galafold + Pombiliti revenue (most recent four-quarter rolling) | n/a | ~US$634M | BioMarin disclosed US$599M as the four-quarter trailing figure at announcement; Q4 2025 FOLD update brings the rolling four-quarter total to ~US$634M |
Pipeline Inheritance: DMX-200 (FSGS, Phase 3)
The Dimerix DMX-200 US licensing agreement was signed by Amicus on April 30, 2025 (effective May 1, 2025), making it the most recent royalty-bearing asset that BioMarin assumes via the close.
| Term | Detail |
|---|---|
| Asset | DMX-200, small-molecule chemokine receptor 2 (CCR2) inhibitor in combination with an angiotensin II receptor blocker (ARB) backbone |
| Indication | Focal segmental glomerulosclerosis (FSGS), rare and fatal kidney disease; no FDA-approved therapy |
| Pivotal trial | ACTION3 (Phase 3, multi-centre, randomised, double-blind, placebo-controlled); enrolment completed Q4 2025 |
| Primary endpoint | Proteinuria (FDA-aligned at March 2025 Type C meeting) |
| Originator | Dimerix Limited (ASX: DXB) |
| Territory | United States (Dimerix retains rest-of-world) |
| Original Amicus upfront paid (May 2025) | US$30M |
| Aggregate milestone potential | Up to US$560M in success-based milestones, comprising: |
| - Development & regulatory milestones (FSGS) | Up to US$75M until FDA approval |
| - First commercial sale milestone | US$35M |
| - Commercial sales milestones (FSGS) | Up to US$410M |
| - Future-indication milestones | Up to US$40M |
| Royalty rate to Dimerix | Tiered low-teens to low-twenties percentages on US net sales, subject to customary reductions and offsets |
| Royalty term | Until the latest of: (i) US patent-rights expiry, (ii) US regulatory exclusivity expiry, (iii) an agreed period after first commercial sale |
The Phase 3 ACTION3 readout is expected in 2026, with potential FDA filing in late 2026. BioMarin assumes the Dimerix royalty pass-through obligation effective at close; the May 2025 US$30M upfront has already been paid and is therefore already off the contingent-consideration ledger.
This is a meaningful structural feature for BioMarin: post-close, BioMarin has a first-in-class FSGS asset in late-stage development that complements Galafold (Fabry, kidney involvement) and Pombiliti + Opfolda (Pompe, multi-system) within the rare-disease franchise, but it carries an upstream tiered royalty obligation that is materially higher than typical late-stage in-licence economics. The low-teens-to-low-twenties Dimerix tier is at the upper end of the 2024 DrugPatentWatch reference range (12–15% for proof-of-concept / Phase 2 in-licence; high-teens for Phase 3 in-licence) and reflects (a) the rarity of the indication, (b) the absence of approved competition at signing, and (c) Dimerix's retention of the ROW commercialisation flag, which gives Dimerix a structural negotiating premium relative to a global out-licensee.
For a future BioMarin synthetic-royalty financing on DMX-200 (a structurally credible 2027–2028 transaction if the ACTION3 readout is positive), the gross royalty base for a third-party royalty buyer would be net sales less the Dimerix tier, meaning a buyer pricing a hypothetical 5% synthetic royalty on net sales would be pricing it on the residual ~80% of net sales after the Dimerix pass-through.
Inherited Manufacturing Architecture: WuXi Biologics
The cipaglucosidase alfa commercial drug-substance manufacturing programme, initiated at WuXi Biologics in 2012 and operationalised under the February 2019 exclusive commercial manufacturing agreement, survives the close with WuXi Biologics as the exclusive commercial drug-substance manufacturing partner and key commercial drug-product supplier. The agreement carries an initial five-year term with two-year auto-renewals until cancellation; manufacturing infrastructure spans WuXi's EU, US, and China sites; the Pombiliti drug substance is CHO-derived from a cell line developed in collaboration between Amicus and WuXi.
This is structurally relevant for two reasons. First, the 2022 FDA action-date delay for the original Pombiliti BLA was driven specifically by COVID-related delays to the WuXi China-site preapproval inspection; that history is now embedded in BioMarin's regulatory file and any future expansion of cipaglucosidase indications (paediatric, infantile-onset, alternative dose forms) carries the same manufacturing-site dependency. Second, for any future BioMarin synthetic-royalty financing on Pombiliti, the manufacturing concentration in WuXi creates a discrete structural risk that royalty buyers will price into bid-ask spreads; the BIOSECURE Act trajectory and US–China supply-chain politics are direct inputs.
Royalty Stack Reconstruction: Galafold
Galafold (migalastat) was developed entirely in-house by Amicus following multiple sponsorship transfers in the 2008–2014 period (Amicus → Shire → Amicus → GSK → Amicus, the GSK interlude having been a 2011 worldwide collaboration that returned to Amicus in 2014). The molecule was originally isolated as a fermentation product of Streptomyces lydicus (PA-5726, 1988, 1-deoxygalactonojirimycin); there is no public academic upstream royalty obligation in Amicus's pre-acquisition filings.
| Layer | Direction | Counterparty | Disclosed rate / basis |
|---|---|---|---|
| Net product sales | n/a | BioMarin (post-close) | 100% recorded |
| Academic / NIH upstream | None publicly identified | n/a | 0% |
| US generic licence (post-2037) | n/a | Aurobindo, Lupin, Teva | Royalty-free generic launch on or after January 30, 2037 per Dec 2025 settlements; pre-2037 settlement royalties undisclosed |
| Net royalty position | n/a | n/a | No upstream royalty outflow on Galafold |
For royalty-finance underwriting, this is a clean asset: Galafold is the rare combination of a launched, growing rare-disease drug with a 12-year-runway US exclusivity and no upstream royalty layer. It is a structurally natural candidate for a future BioMarin synthetic-royalty financing if BioMarin elects to use part of the Galafold cash flow to accelerate post-close deleveraging.
Royalty Stack Reconstruction: Pombiliti + Opfolda
The cipaglucosidase / CHART platform IP was acquired by Amicus via the November 2013 Callidus Biopharma acquisition, which provided the differentiated peptide-tagging technology underlying the bis-M6P enrichment. No academic upstream royalty obligation has been publicly identified in Amicus's pre-acquisition filings.
The Opfolda (miglustat) small-molecule component is itself a re-purposed asset: miglustat was originally developed by Actelion Pharmaceuticals and is independently approved for Type I Gaucher disease and Niemann-Pick disease type C. The Pombiliti + Opfolda combination uses miglustat as a chaperone / enzyme stabiliser administered before the cipaglucosidase infusion. Whether Amicus's commercial use of miglustat in the combination triggered an Actelion (now J&J via the 2017 Janssen acquisition) royalty or licensing obligation is not publicly disclosed in Amicus's pre-acquisition SEC filings.
| Layer | Direction | Counterparty | Disclosed rate / basis |
|---|---|---|---|
| Net product sales | n/a | BioMarin (post-close) | 100% recorded |
| Cipaglucosidase / CHART platform IP | Inherited via 2013 Callidus acquisition | n/a | None publicly identified |
| Miglustat in Pombiliti + Opfolda combination | Possibly outflow from BioMarin | Potentially Actelion / J&J (status not publicly disclosed) | Open question; structural risk that a residual Actelion / J&J obligation is in place at the supply-agreement layer |
| WuXi Biologics manufacturing | COGS (not royalty) | WuXi Biologics | Commercial supply economics (manufacturing margin), not royalty |
Read-Through
First, the rare-disease consolidation cycle is structurally favourable for follow-on royalty-fund deal flow. BioMarin's stated <2.5x gross-leverage target within two years implies meaningful cash-flow application to debt reduction; Galafold and Pombiliti are the two most mature monetisable assets in the inherited portfolio. A 2027 synthetic-royalty financing on either is a structurally credible scenario.
Second, the DMX-200 readout is now a BioMarin catalyst, not an Amicus catalyst. The ACTION3 Phase 3 trial is expected to read out in 2026; positive data would trigger Dimerix's first development milestone and would establish DMX-200 as the first FDA-approved FSGS therapy. The implication for the broader rare-kidney royalty market is direct: HCRx, RPRX, and Sagard all hold or have evaluated kidney-disease royalty positions (Filspari via Ligand, Vanrafia, Crysvita, Roctavian-adjacent) and DMX-200 would expand the comparable set.
Third, the WuXi Biologics dependency is an unhedged structural risk. BIOSECURE Act dynamics, US–China supply-chain politics, and the 2022 PRC-site inspection precedent all point to a non-trivial probability that BioMarin will need to dual-source cipaglucosidase commercial drug substance over a 3–5 year horizon. That is a capital-intensive shift that competes for the same capital allocation as deleveraging.
Listed-Royalty Consolidation: Ligand to Acquire XOMA Royalty for ~US$739M Cash + CVR (April 27)
On Monday April 27 (Jupiter FL / Emeryville CA), Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) and XOMA Royalty Corporation (Nasdaq: XOMA), the two publicly-listed biotech royalty aggregators, announced a definitive agreement under which Ligand will acquire XOMA Royalty for US$39.00 per share of common stock in cash, for a total equity value of ~US$739 million, plus one non-transferable Contingent Value Right (CVR) per share entitling holders to 75% of the net proceeds from XOMA's pending Janssen Biotech (now Johnson & Johnson Innovative Medicine) TREMFYA litigation. The cash purchase price represents a ~14% premium to XOMA's 30-trading-day VWAP as of April 24, 2026. Primary source: XOMA SEC Form 8-K Exhibit 99.1, April 27, 2026.
For a royalty-finance audience this is the most structurally consequential transaction of the cycle to date. The two listed royalty aggregators have been the primary public-equity vehicles for retail and small-institutional access to the biotech royalty asset class for over a decade; their consolidation eliminates one of two listed comparables and makes Ligand the sole listed pure-play royalty aggregator at scale, with a combined portfolio of more than 200 assets (Ligand's pre-deal ~100 + XOMA's ~120) and seven new commercial products joining the Ligand commercial royalty book.
Deal Structure
| Term | Detail |
|---|---|
| Acquirer | Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), Jupiter FL |
| Target | XOMA Royalty Corporation (Nasdaq: XOMA), Emeryville CA |
| Per-share cash consideration | US$39.00 per share of common stock |
| Total equity value | ~US$739M |
| Premium to VWAP | ~14% premium to XOMA's 30-day VWAP as of April 24, 2026 |
| CVR | One non-transferable CVR per common share entitling the holder to a portion of 75% of net proceeds from certain pending litigation at XOMA Royalty (i.e. the Janssen/J&J TREMFYA breach of contract claim) |
| Series X Convertible Preferred Stock | Converted into common stock prior to closing at stated fixed price (BVF Partners, holding ~21% of common and ~44% on a fully-diluted-conversion basis, has agreed to convert) |
| Series A and Series B Preferred Stock | Redeemed at closing |
| BVF Partners voting agreement | In place; supports the transaction |
| XOMA director / officer voting agreements | In place |
| Boards' approval | Unanimous (both Ligand and XOMA) |
| Expected close | Q3 2026, subject to XOMA stockholder approval and customary regulatory clearances |
| Financing | Ligand cash on hand + drawing on existing credit facility |
| Ligand lead financial advisor | Stifel |
| Ligand financial advisor | Citi |
| Ligand legal counsel | Paul Hastings LLP |
| Ligand strategic-communications advisor | Collected Strategies |
| XOMA lead financial advisor | Leerink Partners |
| XOMA financial advisor | H.C. Wainwright & Co. |
| XOMA legal counsel | Gibson, Dunn & Crutcher LLP |
Pro Forma Ligand Guidance Update
| Item | Pre-deal 2026 guidance | Post-deal 2026 guidance | Comment |
|---|---|---|---|
| Total revenue | US$245M – US$285M | US$270M – US$310M | Net +US$25M midpoint; reflects late-Q3 2026 close |
| Royalty revenue | US$200M – US$225M | US$225M – US$250M | Net +US$25M midpoint |
| Captisol revenue | US$35M – US$40M | Unchanged | n/a |
| Contract revenue | US$10M – US$20M | Unchanged | n/a |
| Adjusted EPS | US$8.00 – US$9.00 | US$8.50 – US$9.50 | +US$0.50 midpoint accretion in 2026 |
| 2027 expected adjusted EPS accretion | n/a | +US$1.50 / share | Full-year contribution in first year post-close |
Ligand characterises the transaction as immediately accretive to adjusted EPS and as a meaningful increment to the long-term 23%+ royalty-receipt CAGR target reaffirmed at its December 2025 Investor Day.
XOMA Royalty Portfolio at Close: Commercial Assets
XOMA reported US$50.5M total cash receipts for FY 2025 (US$33.6M commercial payments / royalties + US$16.9M milestones and fees). Royalty receipts grew +68% YoY, driven by Vabysmo and Ojemda, with new contributions from Miplyffa following its late-2024 NPC approval. Seven commercial products are in the portfolio at close:
| Commercial product | Partner | Indication | Royalty rate (XOMA) | 2025 XOMA cash | 2026 / peak sales context |
|---|---|---|---|---|---|
| Vabysmo (faricimab-svoa) | Roche | Wet AMD, DME, RVO | 0.5% of net sales | US$22.5M | 2026 sales projected ~US$5.8B; peak ~US$8.3B (largest XOMA contributor; structurally Ligand's largest single royalty post-close) |
| Ojemda (tovorafenib) | Day One Biopharmaceuticals | Pediatric LGG (BRAF-altered) | Mid-single-digit | US$12.4M | 2026 sales projected ~US$231M; peak ~US$910M; CHMP positive opinion Feb 26, 2026 |
| Miplyffa (arimoclomol) | Zevra Therapeutics | Niemann-Pick Disease Type C | Mid-single-digit | US$2.9M | 2026 sales projected ~US$130M; peak ~US$392M; EU MAA pending |
| Ixinity (coagulation factor IX) | Medexus Pharmaceuticals | Hemophilia B | Mid-single-digit | US$1.7M | Mature category |
| Xaciato (clindamycin phosphate vaginal gel 2%) | Organon | Bacterial vaginosis | High single-digit | Newly launched | Inherited counterparty; transition unclear post-Sun-Pharma-Organon close |
| DSUVIA (sufentanil sublingual tablet) | Talphera | Acute pain (DoD focused) | 37.5% – 75% on DoD sales | Minimal post-Alora discontinuation | Structurally impaired (Alora 2024 manufacturing-driven product withdrawal) |
| DARÉ to PLAY / sildenafil cream 3.6% | Daré Bioscience | Female sexual arousal disorder | Royalty | Newly launched | First-in-class; discussions ongoing with FDA on Phase 3 endpoints for adjacent indications |
XOMA Royalty Portfolio at Close: Late-Stage Pipeline
XOMA's late-stage pipeline includes ~120 development assets, with 14 in late-stage development. The most material inheritance for Ligand:
| Asset | Partner | Indication | Stage | XOMA economics |
|---|---|---|---|---|
| Mezagitamab | Takeda | ITP, IgA nephropathy (anti-CD38 mAb) | Phase 3 | Originally mid-single-digit royalty + US$16.25M milestones; reduced via Dec 2025 Takeda revenue-share trade to low-single-digit royalty + up to US$13M milestones in exchange for: |
| Nine Takeda externalised assets (incl. osavampator, volixibat, OHB-607) | Takeda | Multi-indication | Various | Low-to-mid single-digit royalty + up to US$853M aggregate milestones across the nine programs |
| Ersodetug (formerly RZ358) | Rezolute Bio | Tumour-associated hyperinsulinism (Phase 3); congenital hyperinsulinism (Phase 3 missed primary endpoint, FDA engagement ongoing) | Phase 3 | XOMA already received US$12M in milestones; eligible for high-single-digit to mid-teen royalties on net sales |
| Seralutinib | Gossamer Bio | Pulmonary arterial hypertension | Phase 3 (topline Feb 2026) | Royalty rate undisclosed |
| Volixibat | Mirum / former Takeda asset | Primary sclerosing cholangitis (PSC); Q2 2026 Phase 2b readout | Phase 2b | Inside Takeda externalised-portfolio basket |
| REC-4881 | Recursion Pharmaceuticals | Familial adenomatous polyposis | Phase 2 | Royalty inside Recursion-Repare basket |
| Sildenafil Cream 3.6% | Daré | Female sexual arousal disorder | Phase 3 (endpoint discussions ongoing) | Combined with the launched lower-strength formulation |
The TREMFYA Litigation and the CVR
The CVR mechanism preserves for XOMA's selling stockholders an asymmetric upside on the Janssen / J&J Innovative Medicine TREMFYA breach-of-contract litigation, while Ligand acquires the underlying portfolio without paying a premium for an uncertain litigation outcome.
| Element | Detail |
|---|---|
| Defendant | Janssen Biotech (now part of J&J Innovative Medicine) |
| Plaintiff | XOMA Royalty Corporation |
| Underlying contract | A 2003-vintage agreement with MorphoSys (now a Novartis subsidiary post the 2024 acquisition) involving phage display and HuCAL antibody library technologies |
| Asset at issue | TREMFYA (guselkumab), J&J's IL-23 inhibitor for plaque psoriasis, psoriatic arthritis, and ulcerative colitis; 2025 J&J global TREMFYA net sales US$3.7B (per J&J Q4 2025 release) |
| XOMA's claim | Breach of contract; XOMA alleges entitlement to royalty on TREMFYA net sales arising from the 2003 phage-display / HuCAL agreement chain |
| XOMA management's directional rate guidance | "Similar phage-display structures historically settle in low single digits"; XOMA noted the agreement structure was different and could affect remuneration if XOMA prevails |
| Contingent CVR economics | 75% of net proceeds of any litigation-related recovery flows to former XOMA common stockholders via the CVR; 25% retained by Ligand |
| CVR transferability | Non-transferable |
| Litigation costs (XOMA disclosed in 2025 G&A) | ~US$1.1M of incremental G&A in 2025 attributable to the case |
The CVR construct mirrors several recent biotech M&A precedents (Servier / Day One, Sprix CVR pass-through; Garda / Assertio, Sprix milestone CVR; the original Chimerix / Oncoceutics CVR architecture) where the acquirer pays only for the hard portfolio and writes the contingent litigation-or-milestone path back to the selling shareholders. The structural innovation here is that the underlying contingent value is a royalty entitlement on a >US$3B/year already-launched product, not a milestone tied to a future approval, so the present value of the CVR is materially higher than typical CVR constructs but is offset by the extreme dispersion of likely outcomes (XOMA could prevail on a low-single-digit royalty on global TREMFYA sales, settle for a lump-sum, or lose entirely).
Royalty Stack Reconstruction: Vabysmo (XOMA's Single Largest Asset)
Vabysmo represents the single largest XOMA royalty income contributor (~US$22.5M cash receipts in 2025; ~67% of 2025 royalty cash flow) and is the most material asset transferring to Ligand. The Vabysmo royalty chain is structurally one of the cleaner small-percentage layered architectures in commercial biotech royalty, anchored by phage-display platform IP licensed to Genentech in the early 2000s.
| Layer | Direction | Counterparty | Disclosed rate / basis |
|---|---|---|---|
| Net product sales (global) | n/a | Roche / Genentech | 2026 projected ~US$5.8B; peak ~US$8.3B |
| XOMA royalty (post-close: Ligand) | Inflow | Ligand | 0.5% of global net sales |
| Affitech upstream | Outflow from XOMA (now Ligand) | Affitech | Final cumulative milestones of US$6.0M paid to Affitech in March 2025 based on 2024 Vabysmo sales; ongoing royalty pass-through (rate undisclosed) |
| Vabysmo royalty-backed debt | Pass-through senior to Ligand | HCRx (royalty-backed loan to XOMA) | US$113M outstanding at year-end 2025; XOMA management indicated full repayment expected by end of 2030 at current Vabysmo trajectory; Vabysmo receipts return to XOMA (post-close: Ligand) thereafter |
The implication for Ligand post-close: the Vabysmo royalty stream is largely encumbered through ~2030, meaning Ligand's incremental free cash flow from the XOMA acquisition in years 1–4 comes primarily from Ojemda, Miplyffa, Xaciato, and milestone receipts rather than from Vabysmo. The post-2030 unlocking of Vabysmo receipts is a meaningful structural inflection.
Royalty Stack Reconstruction: Ojemda
Ojemda (tovorafenib, pan-RAF inhibitor) is the second-largest XOMA contributor and was acquired by XOMA via a layered transaction sequence:
| Hop | Date | Detail |
|---|---|---|
| Hop 1: Viracta → XOMA | March 2021 | Viracta Royalty Purchase Agreement; XOMA paid US$13.5M upfront for the right to receive milestones, royalties, and other payments related to Day One's tovorafenib (Ojemda) and Denovo's vosaroxin |
| Hop 2: Day One Biopharmaceuticals → market | April 2024 | Ojemda accelerated FDA approval for paediatric LGG with BRAF alterations; activated XOMA royalty stream |
| Hop 3: CHMP positive opinion | Feb 26, 2026 | Conditional MAA recommendation in EU |
| Effective net XOMA economics on Ojemda | n/a | Up to US$54M in residual milestone potential + mid-single-digit royalty on net sales (excluding ~US$5M payments retained by Viracta) |
Read-Through for the 2026 Royalty-Finance Market
First, listed-royalty-on-listed-royalty consolidation has now happened. Ligand and XOMA were the two principal listed pure-play royalty aggregators; they have now consolidated. Royalty Pharma (Nasdaq: RPRX) remains the listed market-cap leader at very different scale (~US$30B+ market cap, ~US$3B+ annual royalty revenue), but RPRX is structurally too large for an XOMA-style acquisition to materially move the dial. Below RPRX, the listed-royalty-aggregator universe is now effectively a single-issuer market in Ligand. That is a structural change.
Second, the CVR construct converts a royalty-litigation claim into a stand-alone tradable instrument. While the XOMA CVR is non-transferable, the structure, 75% of net litigation proceeds flowing back to selling stockholders, 25% to the acquirer, is now available as a precedent for any future M&A involving a royalty target with an unresolved upstream contractual dispute. Expect to see this construct replicated.
Third, the BVF Partners voting commitment confirms the transaction at approval. BVF, holding ~21% of common stock and ~44% on a fully-diluted basis, has agreed to convert its Series X Convertible Preferred Stock into common stock prior to closing and to vote in favour of the transaction. Combined with the unanimous board recommendation and the director / officer voting agreements, this materially de-risks the path to Q3 2026 close.
Fourth, the post-close Ligand royalty book is now structurally dominated by three categories:
- Late-stage clinical pipeline (XOMA's 14 late-stage assets, Ligand's pre-deal Filspari + Ohtuvayre + Capvaxive + Qarziba + Zelsuvmi)
- Listed-partner commercial assets (Vabysmo / Roche; Ojemda / Day One; Filspari / Travere; Ohtuvayre / Verona; Capvaxive / Merck; Miplyffa / Zevra)
- Captisol and NITRICIL platform technologies
This combination plus the US$1B of deployable capital Ligand reaffirmed at its December 2025 Investor Day positions Ligand to compete at scale with HCRx, Sagard, and DRI for new deal flow.
Fifth, Filspari and FSGS converge with the BioMarin / Amicus close. Ligand holds a 9% royalty on worldwide net sales of Filspari (sparsentan, IgAN approval since September 2024 plus the April 14, 2026 FSGS approval). With BioMarin closing on Amicus on the same Monday, BioMarin now also holds the upstream-licensee position on Dimerix's DMX-200 (also FSGS, Phase 3-pending). The two listed-royalty-aggregator and rare-kidney-disease industry-structure events landed within hours of each other, and the FSGS market, one of the most structurally compelling rare-kidney royalty categories of the cycle, is now anchored by two distinct royalty positions on two distinct molecular mechanisms.
Disclosure Gaps
- The CVR's exact economic mechanic on litigation proceeds (e.g., gross vs net of Ligand's litigation costs, treatment of any pre-closing settlement, post-close Ligand control of litigation strategy) is not yet in the public 8-K but will be in the definitive proxy filings.
- Specific Vabysmo Affitech upstream royalty rate is not publicly disclosed.
- The Phase 3 ACTION3 readout for DMX-200 (Dimerix / BioMarin-Amicus) is the natural read-across catalyst for any Filspari competitive-positioning analysis; Travere's CHMP opinion on Filspari for IgAN and the FDA's pending FSGS approval signals overlap directly with the timeline of BioMarin's inherited DMX-200 Phase 3 obligation.
M&A: Eli Lilly / Ajax Therapeutics. Up to US$2.3B Cash. Type II JAK2 Bolt-On to Lilly Oncology (April 27)
On Monday April 27 (Indianapolis / New York / Cambridge MA), Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. (private) announced a definitive agreement under which Lilly will acquire Ajax for up to US$2.3B in cash, inclusive of an upfront payment and subsequent payments contingent on the achievement of specified clinical and regulatory milestones. The component split between upfront and contingent milestones is not disclosed. The transaction is subject to customary closing conditions including HSR clearance. Primary source: Lilly investor relations release, April 27, 2026.
Lilly was a founding strategic investor in Ajax and participated in the May 2024 US$95M Series C alongside Goldman Sachs Alternatives (which led the round), Vivo Capital, RA Capital Management, Point72, EcoR1 Capital, Boxer Capital, Schrödinger Inc. (NASDAQ: SDGR), and Inning One Ventures. The transaction is, on its face, a strategic-investor-to-acquirer conversion: Lilly is purchasing the company in which it already held an equity stake and on whose board it had visibility through several rounds of private financing. This is the second such Lilly transaction within a seven-day window, following the April 20, 2026 acquisition of Kelonia Therapeutics for up to US$7.0B (US$3.25B upfront + US$3.75B clinical, regulatory, and commercial milestones; in vivo CAR-T platform; lead asset KLN-1010 anti-BCMA in Phase 1 multiple myeloma). The Kelonia transaction was itself the second 2026 Lilly cell-therapy acquisition, following Orna Therapeutics for up to US$2.4B in February 2026, and sits alongside the broader Lilly Oncology bolt-on cadence (Centessa Pharmaceuticals up to US$7.8B; Insilico Medicine collaboration US$2.75B).
Lead asset: AJ1-11095 (oral, once-daily, first-in-class Type II JAK2 inhibitor)
AJ1-11095 is currently in a Phase 1 clinical trial (AJX-101) in patients with myelofibrosis previously treated with a Type I JAK2 inhibitor; first proof-of-concept clinical data are expected to be presented later in 2026. The Phase 1 trial began in late 2024 and dose selection for future clinical development is expected in 2026. Differentiation versus the established class is mechanistic: all currently approved JAK2 inhibitors for MPNs (ruxolitinib / Jakafi, fedratinib / Inrebic, pacritinib / Vonjo, momelotinib / Ojjaara) bind the Type I conformation of JAK2, which provides clinical and symptomatic relief but with non-durable benefit and frequent loss of response in second-line use. AJ1-11095 binds the Type II conformation of JAK2 and has been shown in preclinical studies to maintain efficacy against MPN cells that become resistant to chronic Type I JAK2 inhibition. AJ1-11095 received FDA Orphan Drug Designation for myelofibrosis in December 2025.
Upstream IP and Royalty Stack: Schrödinger Co-Discovery Collaboration
The deep structural feature of the Lilly / Ajax transaction for a royalty-finance audience is the Schrödinger upstream layer. Ajax was co-founded around a 2019 collaboration with Schrödinger that applied Schrödinger's computational drug-discovery platform (the same platform used in the Nimbus / Takeda zasocitinib programme that Takeda acquired for US$4B in 2023) to the JAK2 target. AJ1-11095 was designed by Ajax through this collaboration using structure-based drug design and computational methods at scale.
| Layer | Term |
|---|---|
| Schrödinger equity in Ajax | Held since founding round (continued through Series C in 2024); preserved through close of the Lilly transaction |
| Schrödinger milestone rights | Eligible for milestone payments under the Ajax / Schrödinger collaboration agreement |
| Schrödinger royalty rights on net sales | Single-digit royalties on net sales of products developed under the collaboration |
| Collaboration scope | Initial collaboration on JAK2 (resulting in AJ1-11095); July 2025 expansion added an additional JAK family target with the same milestone-and-royalty economics, with Ajax leading clinical development and commercialization |
Net effect: post-close, Lilly inherits the contractual royalty stack to Schrödinger on AJ1-11095 commercial sales (and on the second JAK family target if it advances). This sits alongside Schrödinger's documented track record of platform-coupled cash realizations from co-founded and partnered programs:
| Past Schrödinger realization | Counterparty / event | Cash received by Schrödinger |
|---|---|---|
| Takeda acquisition of Nimbus Lakshmi (TYK2 inhibitor / TAK-279 / zasocitinib), 2023 | Nimbus → Takeda (US$4.0B upfront + US$2.0B in milestones at US$4B and US$5B annual sales thresholds); Schrödinger held 3.8% fully diluted equity stake in Nimbus at end-2022 | ~US$147.3M total cash distribution (US$111.3M Q1 2023 + ~US$36M Q2 2023) |
| Lilly acquisition of Morphic Therapeutics (2024) | Lilly → Morphic | ~US$47.6M to Schrödinger (equity stake) |
| Structure Therapeutics (publicly traded co-founded company) | Lead asset aleniglipron oral GLP-1 receptor agonist (Phase 3 initiation mid-2026); ACCG-2671 amylin agonist Phase 1 | Equity stake retained |
| Ajax / Lilly (W18) | Lilly → Ajax (up to US$2.3B) | Equity stake preserved through close + milestone rights + single-digit royalties on net sales (the W18 event itself) |
Schrödinger has not historically monetized these royalty interests via a synthetic royalty or royalty-backed note; the realizations have been through (i) acquisition cash distributions from co-founded entities and (ii) ongoing royalty / milestone receipts on partnered programs. Across the documented history, the Schrödinger platform-coupled receipts are typically structured as equity stakes plus milestone rights plus single-digit royalties on the resulting commercial assets, which is the same structure now being applied to AJ1-11095 inside the Lilly oncology platform. Aggregated across the Nimbus / Takeda (~US$147.3M) and Morphic / Lilly (~US$47.6M) realisations, Schrödinger has captured approximately US$195M in platform-coupled cash distributions since 2023, before any AJ1-11095 milestone or royalty receipts begin and before the Structure Therapeutics equity stake (publicly traded; aleniglipron Phase 3 initiation mid-2026) is realised. The Ajax / Lilly transaction extends the same architecture to a fourth program and supports the longer-running thesis that computational-platform-coupled royalty layers are durable, sublicensable, and survive the acquisition of the operating company through preserved equity, milestone rights, and royalty entitlements.
Strategic Logic for Lilly Oncology
Lilly Oncology under Jacob Van Naarden (executive vice president, head of corporate business development) has used the operating-cash windfall from the GLP-1 franchise (Mounjaro / Zepbound) to fund a sequence of mid-to-late-stage oncology bolt-ons. The Ajax transaction sits in the early-clinical / proof-of-concept tranche of that strategy alongside Loxo-era Lilly hematology assets, and is positioned as both first- and second-line entry into the JAK2 inhibitor market for MPNs. MPN epidemiology supports a meaningful commercial opportunity even without first-line displacement of ruxolitinib; the second-line market is structurally accessible for a Type II inhibitor with preserved activity in Type I–resistant disease.
Read-Through
The Lilly / Ajax transaction is the third-smallest of the six W18 M&A transactions on a committed-deal-value basis (ahead of Teva / Emalex and Chiesi / KalVista on upfront cash component) but carries two structural read-throughs of interest to royalty-fund analysts: (1) the durability and visibility of computational-platform-coupled royalty rights at the upstream layer (Schrödinger's accumulated royalty stack now spans Structure Therapeutics, Nimbus / Takeda, and Ajax / Lilly), and (2) the extension of the Lilly oncology bolt-on cadence into JAK family targets, which is a category historically dominated by Incyte (ruxolitinib license to Novartis; fedratinib / Inrebic via Celgene / Bristol-Myers Squibb).
Disclosure gaps
- No financial advisor was named by either side in the press release. Legal counsel only: Ropes & Gray LLP (Lilly); Cooley LLP (Ajax lead, with team led by Kevin Cooper, Sangitha Palaniappa, Brandon Fenn, Kenneth Krisko, and Stephanie Palmer) and Kirkland & Ellis LLP (additional Ajax counsel). Cooley previously advised Ajax on its 2021 US$40M Series B and 2024 US$95M Series C financings. The absence of a disclosed sell-side or buy-side financial advisor is unusual for a transaction of this size and is consistent with the strategic-investor-to-acquirer conversion framing: Lilly already held an equity stake and a board-level information set in Ajax through prior funding rounds, so an arm's-length financial-advisor mandate may not have been engaged.
- The upfront / milestone split of the up to US$2.3B aggregate consideration is not disclosed.
- The specific Schrödinger milestone schedule and royalty rate band on AJ1-11095 are not separately re-disclosed at the program level beyond the single-digit-percentage descriptor.
- The Ross Levine / Memorial Sloan Kettering Cancer Center IP layer (Dr. Levine serves on the Ajax board, has provided advisory services, holds equity interests, and MSK has intellectual property rights and other financial interests related to Ajax via the Levine lab licenses) has not been separately quantified. Ajax governance composition at announcement also includes Schrödinger CEO Ramy Farid (board member) and Goldman Sachs Alternatives' Amit Sinha (Head of Life Sciences Investing) and Ming Cheah (joined the Ajax board concurrent with the May 2024 Series C).
- Primary-source filing status: Lilly filed only an Item 2.02 earnings 8-K on April 30, 2026 (Acc# 0000059478-26-000043); the merger agreement was not attached as an exhibit. Q1 2026 acquired IPR&D charges aggregated US$584M across Orna, Centessa, Kelonia, and Ajax (not itemized at the deal level). Schrödinger Q1 2026 10-Q filing scheduled for May 5, 2026 (outside W18 window), where any incremental disclosure on AJ1-11095 royalty terms would surface. SDGR FY2024 10-K (Acc# 0001490978-25-000049) discloses only company-wide "single-digit range" royalties under collaboration agreements at the platform level.
License restructuring: Protagonist Therapeutics / Takeda. Rusfertide US Opt-Out Converts 50:50 Profit Share to Worldwide Tiered 14–29% Royalty + US$475M Near-Term + Up to US$975M Further Milestones (April 28)
On Tuesday April 28 (Newark CA / Osaka), Protagonist Therapeutics, Inc. (Nasdaq: PTGX) announced its election to exercise the US opt-out right under the January 2024 worldwide license, development, and commercialization agreement with Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) for rusfertide, the first-in-class subcutaneous hepcidin mimetic peptide for polycythemia vera (PV). The opt-out converts the prior 50:50 US profit share into a global royalty-and-milestone structure under which Takeda assumes worldwide commercial responsibility for rusfertide. Rusfertide is currently under FDA Priority Review for PV with a PDUFA action date in Q3 2026. Primary source: Protagonist Therapeutics press release, April 28, 2026.
This is the highest-priority royalty-structure event of W18 for a royalty-finance audience: it is the rare 2026 disclosure that names a specific tiered royalty band of 14% to 29% on worldwide net sales, replacing what had been a more conventional 50:50 US profit share architecture. Disclosed high-end royalty bands at this scale are uncommon in current dealmaking and are structurally important for any royalty-fund analysis of Protagonist (whose other monetized asset, icotrokinra, sits inside a separate Janssen / J&J Innovative Medicine collaboration).
Restructured deal economics
| Term | Detail |
|---|---|
| Original agreement | January 2024 worldwide license, development, and commercialization agreement; US$300M upfront previously paid to Protagonist |
| Original US economics | 50:50 US profit share (Protagonist co-promotion right in the United States) |
| Original opt-out optionality | 90-day window beginning 120 days after NDA filing |
| Election | Protagonist exercises US opt-out right (April 28, 2026) |
| Cash on opt-out election | US$200M payable to Protagonist |
| Cash on FDA approval (PV) | US$200M |
| Further approval milestone | US$75M |
| Near-term aggregate (opt-out + approval + milestone) | US$475M |
| Further development, regulatory, and commercial milestones | Up to US$975M (including US$25M per ex-US approval) |
| Worldwide royalty rate | Tiered 14% to 29% on worldwide net sales of rusfertide (replacing US profit share) |
| Top-tier breakpoint | 29% rate at ≥US$1.5B annual net sales (per Protagonist 8-K supporting presentation) |
| Weighted-average royalty at $1.5B | 21% (per Protagonist illustrative scenario) |
| Counterfactual (had Protagonist not opted out) | 50:50 US profit/loss share + 10–17% ex-US royalty (now superseded) |
| Third-party upstream | 1% royalty payable to a third party on rusfertide net sales |
| Asset | Rusfertide, first-in-class subcutaneous hepcidin mimetic peptide |
| Indication (initial) | Polycythemia vera (PV); FDA Priority Review |
| PDUFA target action date | Q3 2026 |
| Post-opt-out commercialization | Takeda holds worldwide commercial responsibility |
Royalty stack reconstruction
| Layer | Direction | Counterparty | Disclosed terms |
|---|---|---|---|
| Net product sales (worldwide) | n/a | Takeda (post-opt-out) | 100% recorded by Takeda |
| Tiered royalty inflow to Protagonist | Inflow | Protagonist | 14% to 29% tiered on worldwide net sales; 29% at ≥$1.5B annual; 21% weighted-avg at $1.5B |
| Cash milestones to Protagonist | Inflow | Protagonist | US$475M near-term + up to US$975M further (including US$25M per ex-US approval) |
| Upstream third-party royalty | Outflow | Undisclosed third party | 1% on net sales (per Protagonist disclosure) |
Illustrative pre-tax royalty receivable (per Protagonist's own sensitivity scenario, excluding the 1% third-party pass-through):
| Annual net sales | Pre-tax royalty receivable to Protagonist |
|---|---|
| US$1.0B | US$200M |
| US$1.5B | US$300M (21% weighted-avg) |
| US$2.5B | US$600M |
| US$3.5B | US$900M |
Read-through for the 2026 royalty-finance market
First, the 14–29% tiered band sits at the high end of the 2026 disclosed-royalty distribution. For comparison, the BioMarin / Amicus DMX-200 inheritance is "low-teens to low-twenties" tiered (covered above); the Jazz / Zymeworks Ziihera license is 10–20% tiered (covered above); the Schrödinger / Ajax single-digit royalty under the Lilly transaction is at the low end (covered above); the XOMA / Mezagitamab Takeda externalised basket is low-to-mid single-digit (covered above). The Protagonist / Takeda rusfertide structure now establishes a clear high-end 2026 reference point: 29% top-tier rate at ≥US$1.5B annual net sales, with a 21% weighted-average rate at the breakpoint. The floor of the band (14%) still sits above most 2026 out-license royalty floors.
Second, the structural pattern is "opt-out converts profit share into royalty," and rusfertide is now the worked example. US profit-share / co-promotion rights are common in late-stage out-licenses; what is rare is the disclosed mechanic of converting that profit-share into a fixed tiered-royalty structure on opt-out. Protagonist's own disclosure quantifies the value-capture: at US$1.5B annual net sales, the opt-out delivers ~US$300M annual pre-tax royalty receivable (versus the counterfactual 50:50 US profit share which would have flowed through Takeda's US commercial cost structure). Royalty-fund underwriters can now use this disclosed band as a benchmark when modelling future opt-outs in similar 50:50 architectures.
Third, rusfertide is a structurally credible synthetic-royalty target post-approval. With a Q3 2026 PDUFA action date, a worldwide tiered royalty layer with disclosed top-tier breakpoint, and a defined US$475M near-term cash inflow, Protagonist is a clean candidate for a future synthetic-royalty financing on a portion of its rusfertide royalty stream. Royalty Pharma, HCRx, DRI, NovaQuest, and Sagard would all be plausible counterparties on a post-approval Protagonist royalty monetization. No royalty-fund position on rusfertide has been publicly disclosed at the time of opt-out.
Disclosure gaps
- The intermediate tier breakpoints between 14% and the top-tier 29% (i.e., the net-sales thresholds at which the royalty rate steps up from 14% through the intermediate tiers) are not in the public domain.
- The identity of the 1% third-party upstream royalty counterparty has not been re-disclosed at the opt-out announcement.
- The contractual treatment of the prior 50:50 US profit-share accruals from January 2024 through the April 28 opt-out is not disclosed.
- The specific Q3 2026 PDUFA action date has not been re-disclosed since the original Priority Review acceptance.
Licensing collaboration: Eli Lilly / Profluent Bio. AI-Designed Recombinases for Genetic Medicine. Up to US$2.25B in Milestones + Tiered Royalties (April 28)
On Tuesday April 28 (Indianapolis / Berkeley CA), Eli Lilly and Company (NYSE: LLY) and Profluent Bio, Inc. (private) announced a multi-program strategic collaboration with exclusive license options under which Profluent will design and optimize site-specific recombinases via its AI platform for kilobase-scale DNA editing across rare and common diseases. Lilly receives committed R&D funding plus exclusive license options on selected programs. Primary source: Profluent press release via BusinessWire, April 28, 2026.
Deal structure
| Term | Detail |
|---|---|
| Acquirer / licensee | Eli Lilly and Company (NYSE: LLY) |
| Licensor / discovery partner | Profluent Bio, Inc. (private; Berkeley CA) |
| Asset class | AI-designed site-specific recombinases for kilobase-scale DNA editing |
| Therapeutic scope | Rare and common diseases (multi-program; specific targets undisclosed) |
| Stage | Preclinical / discovery |
| Geography | Worldwide |
| Upfront cash | Undisclosed |
| Committed R&D funding | Yes, terms undisclosed |
| Aggregate development and commercial milestones | Up to US$2.25 billion |
| Royalty on net sales | Tiered royalties on net sales (rate undisclosed) |
| Equity component | None |
Royalty stack and structural read-through
The Lilly / Profluent collaboration is the largest pure traditional out-license of the five-day window by aggregate biobucks ceiling and is the second AI-platform-coupled royalty-bearing structure of W18 alongside the Schrödinger / Ajax / Lilly AJ1-11095 inheritance (covered above) and the D. E. Shaw Research / Relay / Pfizer zovegalisib triplet (covered below). Profluent's recombinase-design platform sits in the same structural category as Schrödinger's structure-based drug-discovery platform: the platform-coupled royalty layer is durable, sublicensable, and survives the underlying research-collaboration term where applicable.
For royalty-fund underwriting of Profluent's eventual commercial output, the post-license royalty base on any approved recombinase-derived therapy would be Lilly's net sales less the Profluent tiered royalty, with no separately-disclosed third-party academic upstream identified at the platform level. This is structurally consistent with the broader 2026 pattern of computational-platform-coupled upstream royalty layers as the under-appreciated structural feature of recent dealmaking.
Disclosure gaps
- The upfront cash component, the structure of committed R&D funding, the per-program milestone breakdown, and the tiered royalty rate band are all undisclosed at the announcement date.
- The number of programs covered by the exclusive license options is not specified.
- No royalty-fund position on the Profluent platform has been publicly disclosed.
- Primary-source filing status: Lilly filed only an Item 2.02 earnings 8-K on April 30, 2026 (Acc# 0000059478-26-000043); no Item 1.01 8-K with collaboration agreement exhibit. Profluent is private with no SEC registration. The Profluent collaboration is not separately quantified in the Q1 2026 acquired IPR&D charges aggregate of US$584M (which itemizes Orna, Centessa, Kelonia, and Ajax) and is presumably captured in R&D expense rather than IPR&D. Refined disclosure may appear in the Lilly Q1 2026 10-Q (early May 2026, outside W18 window).
Hybrid R&D financing + M&A option: AbbVie / Kestrel Therapeutics. Pan-KRAS Inhibitor KST-6051. Warrant + Exclusive Acquisition Option, Up to US$1.45B (April 28)
On Tuesday April 28 (North Chicago IL / Watertown MA), AbbVie Inc. (NYSE: ABBV) entered into a warrant agreement and exclusive acquisition option on Kestrel Therapeutics, Inc. (private), under which AbbVie funds development of Kestrel's lead asset KST-6051, an oral pan-KRAS inhibitor, in exchange for future exercise payments and downstream development and regulatory milestones. Total potential deal value up to US$1.45 billion. The first patient was dosed in the Phase 1 clinical trial of KST-6051 in patients with KRAS-driven malignancies the same day. Primary source: Kestrel Therapeutics first-patient-dosed press release, April 28, 2026.
Deal structure
| Term | Detail |
|---|---|
| Acquirer / option holder | AbbVie Inc. (NYSE: ABBV) |
| Target / licensee | Kestrel Therapeutics, Inc. (private; Watertown MA) |
| Lead asset | KST-6051, oral pan-KRAS inhibitor |
| Stage at signing | Phase 1 (first patient dosed April 28, 2026, KRAS-driven solid tumours) |
| Structure | Warrant agreement + exclusive acquisition option (hybrid R&D financing + M&A option) |
| Upfront cash | Undisclosed |
| AbbVie funding obligation | Funds the KST-6051 program |
| Future exercise payment | Yes, terms undisclosed |
| Downstream development and regulatory milestones | Yes, terms undisclosed |
| Total potential deal value | Up to US$1.45 billion |
| Geography | Worldwide |
Read-through
The AbbVie / Kestrel structure is the single most structurally novel deal of W18. It sits between a traditional licensing collaboration (where the licensee retains operational control of an asset funded by the licensor) and an outright acquisition (where the licensor owns the resulting commercial product). The warrant-plus-option mechanic is uncommon in the 2024–2026 pharma dealmaking sample set and is structurally analogous to a venture-debt-with-warrant-coverage architecture, applied to a clinical-stage R&D financing. For Kestrel, the structure preserves operational independence through the Phase 1 readout window while delivering AbbVie's balance sheet for cost coverage; for AbbVie, the structure converts an early-clinical-stage bet into a controlled-exposure option that can be exercised based on the Phase 1 data.
For royalty-finance underwriting, the structure is interesting because Kestrel retains formal ownership of KST-6051 until exercise, meaning a future synthetic-royalty financing on KST-6051 between signing and exercise would price against Kestrel's economics, not AbbVie's. Post-exercise (if AbbVie exercises the acquisition option), KST-6051 becomes an internal AbbVie pan-KRAS asset with the standard AbbVie post-exercise-milestone-and-royalty payment obligations to former Kestrel shareholders.
This is the second AbbVie KRAS-related transaction of 2026 alongside the prior Mirati Therapeutics integration (closed March 2024 at US$10.1B) which brought adagrasib (Krazati, KRAS G12C) into AbbVie Oncology. KST-6051 as a pan-KRAS asset (versus G12C-selective) sits in a structurally adjacent but not directly competitive category. No royalty-fund position on KST-6051 has been publicly disclosed.
Disclosure gaps
- The upfront, future exercise payment, and individual milestone breakpoints are all undisclosed.
- The composition of Kestrel's pre-existing investor base and any prior synthetic-royalty or royalty-backed financing on KST-6051 is not disclosed.
- The exercise mechanic (whether option exercise is conditioned on specific clinical data thresholds) is not disclosed.
- Primary-source filing status: AbbVie filed only an Item 2.02 earnings 8-K on April 29, 2026 (Acc# 0001551152-26-000013); no Item 1.01 8-K with warrant or option agreement exhibit. The earlier April 3, 2026 AbbVie pre-announcement 8-K (Acc# 0001551152-26-000011) discloses Q1 2026 acquired IPR&D and milestones expense of US$744M pre-tax aggregate (US$0.41 EPS impact), which captures Kestrel + EvolveImmune + other Q1 BD activity but is not itemized at the deal level. The warrant-plus-option construct was apparently not deemed individually material under Item 1.01 thresholds. Refined disclosure may appear in the AbbVie Q1 2026 10-Q (early May 2026, outside W18 window).
Asia licensing collaboration: Huahui Health / BeOne Medicines. HH160 Trispecific Antibody (PD-1 / CTLA-4 / VEGF-A). US$20M Upfront + US$100M Option Exercise + Up to US$1.9B Milestones + Tiered Royalties (April 30)
On Thursday April 30 (Beijing), Huahui Health, Ltd. (private; Beijing-based; founded 2015) and BeOne Medicines (HKEX: 6160; SHA STAR: 688235; formerly BeiGene) announced a global exclusive option, license and collaboration agreement for HH160, a preclinical anti-PD-1 / CTLA-4 / VEGF-A trispecific antibody. The agreement was signed by BeOne's subsidiary Guangzhou BeOne Medicines Biopharmaceutical. Primary source: Huahui Health joint release via PR Newswire, April 30, 2026.
Deal structure
| Term | Detail |
|---|---|
| Licensor | Huahui Health, Ltd. (private; Changping, Beijing) |
| Licensee | BeOne Medicines (HKEX: 6160; SHA STAR: 688235), via subsidiary Guangzhou BeOne Medicines Biopharmaceutical |
| Asset | HH160: symmetrical hexavalent trispecific antibody targeting PD-1, CTLA-4, and VEGF-A |
| Stage | Preclinical |
| Upfront cash | US$20 million |
| Option exercise payment | US$100 million upon BeOne's exercise of the option |
| Development and regulatory milestones | Up to US$374 million |
| Sales-based milestones | Up to US$1.5 billion |
| Total contingent biobucks | Up to ~US$1.99 billion before royalties (US$120M near-term + US$1.874B contingent) |
| Royalty rate | Tiered royalties on net sales (specific rate band not disclosed) |
| Territory | Worldwide (global exclusive option covering development, manufacturing, and commercialization) |
| Counterparty press release | April 30, 2026 |
Asset construct
HH160 was first publicly described in AACR 2025 Abstract 6060 (Liu et al., Cancer Research 2025; 85 (8_Supplement_1): 6060). The molecule is a symmetrical hexavalent trispecific antibody constructed by fusing anti-PD-1 and anti-CTLA-4 nanobodies to the N- and C-termini of the heavy chain of an anti-VEGF-A human IgG1 antibody with a silent Fc. The asset is built on Huahui Health's proprietary PolyBoost multispecific antibody platform.
The mechanistic thesis is the combination of anti-VEGF-A antiangiogenic activity (the bevacizumab-validated mechanism) with dual immune checkpoint blockade of PD-1 and CTLA-4 (the ipilimumab + nivolumab class), in a single molecule with potential for tumour-localised drug distribution and reduced systemic side-effect profile relative to triple-agent combination dosing. The combination of anti-VEGF agents and ICIs has previously demonstrated enhanced efficacy in HCC, NSCLC, and cervical cancer.
Strategic significance for BeOne
This is BeOne's first large-scale early-stage global-rights licensing investment. BeOne's existing oncology pipeline already includes a deep portfolio of internally-developed bispecifics, multispecifics, ADCs, degraders, and small molecules (including the BG-T187 anti-EGFR x MET trispecific, BG-C137 anti-FGFR2b ADC, BG-C354 anti-B7H3 ADC, BG-C9074 anti-B7H4 ADC, and the BGB-53038 pan-KRAS inhibitor); the HH160 license adds a Western-grade-economics in-licensed I-O multispecific to the platform.
The structure is also notable for the Asia-originated, Western-economics-shaped deal architecture: a US$20M upfront with a US$100M option exercise gate is small by US-licensee standards on a preclinical asset, but the up-to-US$1.9B contingent biobucks ceiling and tiered global royalty are at parity with US-originated 2026 trispecific class deals. The Citeline coverage of the deal noted multiple competing trispecific class candidates from Chinese originators chasing the same target combination, including a CStone Pharmaceuticals preclinical asset.
Read-through
For a royalty-finance audience, the Huahui / BeOne transaction crystallises three points:
- Asia-originated I-O multispecifics now transact at Western-economics-shaped term sheets. The aggregate up-to-US$1.99B contingent ceiling on a preclinical antibody is consistent with the 2024–2026 distribution of Western-licensee in-licenses on Chinese-originated preclinical I-O assets (e.g., the multiple Akeso bispecific licensing transactions through 2024–2025).
- Trispecific I-O is now a contested late-stage class. Multiple Chinese-originated PD-1 / CTLA-4 / VEGF-A trispecific antibody candidates are advancing through preclinical into early-clinical development, with competing intellectual property and structural-format positions across Huahui (PolyBoost), CStone, and additional disclosed and undisclosed players.
- BeOne's BD pivot to global-rights in-licensing. Until this deal, BeOne's external transactions had been weighted toward Asia-Pacific co-development and supply arrangements; the global exclusive option structure on HH160 represents a new BD posture for BeOne and a shift consistent with the company's 2025–2026 strategy of building a self-originated and licensed-in late-stage oncology pipeline ahead of the Sonrotoclax (Bcl-2) and Tislelizumab (PD-1) commercial-stage continuation.
Disclosure gaps
- Specific tiered royalty rate band on net sales is not disclosed.
- The split between development and regulatory milestones (within the US$374M ceiling) is disclosed as one combined ceiling.
- Whether Huahui Health retains any retained territory rights (e.g., Greater China rights) is described as a global exclusive option in the public release; explicit territory carve-outs, if any, are not in the press materials.
- No financial advisor names disclosed.
Option exercise: Pinetree Therapeutics / AstraZeneca PTX-299 EGFR Degrader. US$25M Option Closing Payment Triggers Exclusive Global License (April 29)
On Wednesday April 29 (Cambridge MA), Pinetree Therapeutics, Inc. (private; founded 2019) announced that AstraZeneca plc (LSE / Nasdaq / STO: AZN) had exercised its option under the companies' July 23, 2024 exclusive option and global license agreement to obtain an exclusive global license to develop and commercialize PTX-299, a first-in-class bispecific antibody degrader targeting EGFR. Primary source: Pinetree Therapeutics press release via PR Newswire, April 29, 2026.
Deal economics (cumulative across original July 2024 + April 29, 2026 option exercise)
| Term | Detail |
|---|---|
| Original agreement date | July 23, 2024 |
| Original upfront / near-term payments | Up to US$45 million |
| Original total deal value (incl. milestones) | More than US$500 million |
| Original royalty structure | Tiered royalties on global net sales |
| Option exercise date | April 29, 2026 |
| Option closing payment | US$25 million |
| Future eligibility | Additional development, regulatory, and commercial milestone payments |
| Asset | PTX-299: bispecific antibody EGFR degrader from Pinetree's AbReptor™ multispecific antibody platform |
| Indication framing | EGFR-driven cancers, including TKI-resistant settings |
| Post-exercise responsibility | AstraZeneca assumes global development and commercialization |
Strategic context
The option exercise validates Pinetree's AbReptor antibody-based protein degradation platform, which is designed to selectively degrade membrane-bound and extracellular proteins via antibody-mediated mechanisms (a category structurally distinct from small-molecule TPDs and PROTACs). The platform's positioning as transformative and modular for membrane and extracellular targets is the core IP rationale for the AstraZeneca alignment.
For AstraZeneca, the exercise extends the company's targeted oncology footprint into a degrader-format EGFR asset, complementing the existing Tagrisso (osimertinib) franchise (third-generation EGFR-TKI) and the Datroway TROP2 ADC (datopotamab deruxtecan; Daiichi Sankyo collaboration), and aligning with the broader 2025–2026 industry pivot to membrane-protein degraders as a resistance-bypass mechanism in EGFR-TKI-experienced disease.
Royalty-fund read-through
The Pinetree / AstraZeneca exercise is the cleanest 2026 W18 worked example of an option-to-license structure converting into a licensed asset on a discrete trigger event with a clearly disclosed cash payment. For royalty-fund analysts, the exercise-trigger payment ($25M) sits at the upper end of the typical 5%–15% ratio of option-exercise to total-aggregate-deal-value benchmark across 2024–2026 preclinical option-license transactions. Pinetree remains private; no listed-royalty-fund position on PTX-299 has been disclosed.
Disclosure gaps
- The specific tiered royalty rate band on global net sales is not disclosed at either the original July 2024 announcement or the April 29, 2026 exercise update.
- The specific milestone schedule across development, regulatory and commercial categories is disclosed only at aggregate level.
- No financial advisor names disclosed at exercise.
Related-party global license: OSR Holdings / BCM Europe AG (BCME). VXM01 Oral VEGFR-2 Immunotherapy. Up to US$815M in Milestones, US$30M IP Buyback, 29.7% Equity-Pledge Collateral Structure (April 29)
On Wednesday April 29 (Bellevue WA), OSR Holdings, Inc. (Nasdaq: OSRH) and BCM Europe AG (BCME) (private; Switzerland-based; OSRH's largest shareholder at approximately 29.7%) signed a definitive global exclusive license agreement for VXM01, OSRH's Phase 3-ready oral immunotherapy targeting VEGFR-2. The agreement builds on a binding term sheet originally dated January 13, 2025, restructured March 23-27, 2026 (to put OSRH at parent level as direct counterparty), and now executed in definitive form. Originally developed by Vaximm AG, a wholly-owned Swiss subsidiary of OSR Holdings. Primary source: OSR Holdings press release via PharmiWeb, April 29, 2026.
Deal structure
| Term | Detail |
|---|---|
| Licensor | OSR Holdings, Inc. (Nasdaq: OSRH) at parent level |
| Sublicensor | Vaximm AG (wholly-owned Swiss subsidiary of OSRH) |
| Licensee | BCM Europe AG (BCME) (private; Switzerland; OSRH's largest shareholder at ~29.7%) |
| License grant | Exclusive global license to develop, manufacture, commercialize, and sublicense VXM01 |
| IP ownership consolidation | OSRH to acquire full VXM01 IP from Vaximm AG for US$30 million under separate asset purchase agreement |
| Milestone payments | Up to US$815 million in development, regulatory, and commercial milestones, payable directly to OSRH (parent) |
| Royalty structure | OSRH receives 100% of downstream royalties after BCME recovers its investment and preferred return |
| Put option (OSRH → BCME) | OSRH may require BCME to purchase up to US$15 million of OSRH common stock at US$10.00 per share, exercisable no earlier than six months following effective date |
| Collateral pledge (BCME → OSRH) | BCME and affiliates pledge 100% of their entire unencumbered ~29.7% OSRH shareholding as collateral for performance of milestone payment obligations of up to US$815M |
| Counterparty alignment | Related-party transaction approved by Board including independent directors following independent fairness opinion provided by Avance Life Sciences |
| Development plan | BCME funds development; engages global pharmaceutical partners for sublicensing transaction; preferred return then royalty pass-through to OSRH |
Lead asset and development context
VXM01 is a clinical-stage oral immunotherapy targeting VEGFR-2, designed to induce a targeted immune response against tumour vasculature and modulate the tumour microenvironment. The program has demonstrated encouraging clinical activity and immune activation in studies in glioblastoma and pancreatic cancer, two of the most aggressive and treatment-resistant solid tumours. The asset is positioned as Phase 3-ready following prior Phase 1/2 work; specific Phase 3 trial design and timing are not disclosed in the W18 announcement materials.
Capital-structure significance
The OSR / BCME structure is unusual on three dimensions. First, the pledge of 100% of BCME's 29.7% OSRH equity stake as collateral for the up-to-US$815M milestone obligation ceiling is the cleanest 2026 worked example of a controlling-shareholder cross-collateralisation between an out-licensed asset and the parent's equity ownership; it structurally aligns BCME's economic incentives with OSRH public-shareholder returns. Second, the OSRH put option to BCME at US$10.00 per share sits well above the W18 trading price of approximately US$0.71 per share (per InvestingPro data referenced at the time of the announcement), reflecting alignment around long-term value potential of VXM01 rather than current market levels. Third, the OSRH parent-level milestone-and-royalty receipt structure simplifies flow-of-funds versus prior Vaximm-subsidiary-level economics, shifting capital-allocation control to the parent.
Royalty-fund read-through
For a royalty-finance audience, OSR / BCME has limited near-term royalty-fund counterparty significance because (i) OSR Holdings' market capitalisation is approximately US$25M, well below the typical specialist-royalty-fund minimum-deployment threshold; (ii) the milestone economics are contingent on BCME successfully sublicensing VXM01 to a global pharmaceutical partner, which is the structural execution risk; and (iii) the related-party nature of the BCME / OSRH relationship adds governance complexity that synthetic-royalty buyers typically discount. However, the collateralised-equity-pledge structure is a structurally novel mechanism that may inform future related-party or controlling-shareholder licensing transactions across the listed-microcap-pharma universe.
Disclosure gaps
The OSR Holdings 8-K (Form 8-K, CIK 0001840425, Acc# 0001213900-26-049967, filed April 30, 2026; Items 1.01, 7.01, 9.01; Exhibits 10.1 Global Exclusive License Agreement, 10.2 Pledge Agreement, 99.1 press release) is the most disclosure-rich filing of the W18 window but leaves the following royalty-relevant items unspecified at the narrative and press-release level:
- The "preferred return" threshold rate that BCME must achieve before royalty pass-through to OSRH activates, not disclosed in the 8-K narrative, the Exhibit 99.1 press release, or the Avance Life Sciences fairness opinion summary. The detailed waterfall is presumably in the full text of Exhibit 10.1 (Global Exclusive License Agreement) and would require parsing of that exhibit for [***] redactions; this is the single highest-priority unresolved royalty-rate question of W18 and is a candidate for clarification in OSRH's next quarterly filing.
- Specific tiered royalty rate band on net sales (downstream of BCME's investment recovery and preferred return) is not disclosed.
- The specific Phase 3 trial design, indication sequencing (glioblastoma vs pancreatic cancer first), and clinical timeline for VXM01 are not disclosed.
- The identity of the prospective global pharmaceutical sublicensee that BCME is engaging for VXM01 is not disclosed.
Phase 3 readout: Pfizer / ELREXFIO® (elranatamab). MagnetisMM-5 Met Primary PFS Endpoint at Interim Analysis in 2L+ RRMM (April 29)
On Wednesday April 29, Pfizer Inc. (NYSE: PFE) reported positive topline results from the Phase 3 MagnetisMM-5 study of ELREXFIO® (elranatamab) as monotherapy versus standard-of-care daratumumab plus pomalidomide and dexamethasone (DPd) in 2L+ RRMM (n=497). Primary PFS endpoint met with statistically significant and clinically meaningful improvement at interim analysis; OS immature; no new safety signals. Primary source: Pfizer investor relations press release, April 29, 2026.
ELREXFIO is a BCMA x CD3 bispecific antibody discovered and developed at Pfizer; no third-party upstream royalty obligation has been publicly disclosed. 2025 global sales: US$74M versus in-class rival Tecvayli (J&J) at US$670M. The MagnetisMM-5 readout positions ELREXFIO for a 2L+ label expansion that materially broadens the addressable patient population. Sitting alongside the Vyndamax franchise tail to June 2031 and the Seagen-acquired ADC franchise (where multiple upstream royalty obligations to Genmab, Astellas, and Memorial Sloan Kettering remain in force), ELREXFIO is the cleanest 2026 example of an internally-discovered Pfizer growth-portfolio asset moving through earlier-line label expansion without third-party royalty leakage. MagnetisMM-32 (1L post-daratumumab) is the next disclosed registrational catalyst.
ANDA settlement: Pfizer / Vyndamax (tafamidis). Hikma + Dexcel + Cipla Settlements Fix US Generic Entry at June 1, 2031. Multi-Billion-Dollar Franchise Lift; Mixed Read for BridgeBio Attruby (April 28)
On Tuesday April 28 (D. Del. court filings), Pfizer Inc. (NYSE: PFE) settled the last of three pending Vyndamax® (tafamidis) ANDA cases against Hikma Pharmaceuticals plc (LSE: HIK), Dexcel Pharma Technologies Ltd., and Cipla Limited (NSE: CIPLA, BSE: 500087). The court filings closed the patent litigation versus all three challengers, fixing US generic launch at June 1, 2031, approximately 2.5 years later than management's prior late-2028 expectation and ahead of the August 31, 2035 challenged-patent expiry. Primary source: Pfizer investor relations release, April 28, 2026.
Settlement structure (consolidated across all three counterparties)
| Term | Detail |
|---|---|
| Brand owner | Pfizer Inc. (NYSE: PFE) |
| ANDA challengers settled | Hikma Pharmaceuticals plc; Dexcel Pharma Technologies Ltd.; Cipla Limited |
| Asset | Vyndamax® / Vyndaqel® (tafamidis), TTR stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) |
| Court | US District Court for the District of Delaware |
| Settlement date (final) | April 28, 2026 |
| US generic entry date (settled) | June 1, 2031 |
| Challenged-patent expiry (US) | August 31, 2035 |
| 2025 Vyndaqel/Vyndamax franchise revenue (Pfizer disclosed) | Multi-billion-dollar (Pfizer's leading transthyretin amyloid cardiomyopathy franchise) |
Read-through
For Pfizer, the settlements deliver a multi-billion-dollar topline lift to the Vyndamax / Vyndaqel franchise relative to the prior generic-entry assumption, with the IP overhang now meaningfully clarified. The June 1, 2031 launch date sits inside Pfizer's longer-dated revenue trajectory at a moment when the company faces other patent-cliff exposures (notably the IRA-driven negotiation pressure on multiple oncology assets); the franchise is positioned to deliver predictable cash flow through to mid-2031. To put a number on the franchise lift: 2025 reported Vyndamax / Vyndaqel franchise revenue ran at approximately US$5.5B globally (Pfizer's leading transthyretin amyloid cardiomyopathy franchise). Holding the franchise flat at roughly US$5.0B annualised through the 2.5-year extension period (mid-2028 prior management expectation versus June 1, 2031 settlement-fixed date), and applying a typical 60% to 70% Year 1 generic erosion under the prior late-2028 case, the implied incremental net revenue captured under the new June 2031 launch date relative to the late-2028 counterfactual sits in the rough range of US$8B to US$10B in cumulative US net product sales across 2029, 2030, and the first five months of 2031, before considering the pricing-power tailwind from a longer branded-only window in the run-up to generic entry. The illustrative figure is not a Pfizer-disclosed sensitivity and is presented as a triangulation only.
For BridgeBio Pharma (Nasdaq: BBIO), the read is mixed. On the constructive side, the settlements clarify the long-disputed TTR-stabilizer IP overhang and validate the durability of method-of-use protection on the broader TTR-stabilizer category, which supports the launch trajectory of BridgeBio's Attruby (acoramidis) (FDA approved Q4 2024 for ATTR-CM). On the constraining side, the earlier-than-feared US generic entry on tafamidis (June 1, 2031 vs the previously-feared 2032 to 2035 range) compresses the out-years for the broader TTR-stabilizer category, with implications for Attruby's long-tail revenue modelling and for any synthetic-royalty financing BridgeBio may pursue against Attruby net sales. BBIO traded approximately +6.6% on the filing.
For Alnylam Pharmaceuticals (Nasdaq: ALNY), the read is marginally negative. The Pfizer settlements consolidate the TTR-stabilizer category around tafamidis (and behind it, Attruby) for the 2026–2031 commercial window, which compresses the runway for Alnylam's Amvuttra (vutrisiran) to capture share in 1L ATTR-CM via combination strategies. The Alnylam ATTR franchise has been growing on the back of Amvuttra's HELIOS-B Phase 3 ATTR-CM data, but the post-settlement landscape favours sustained tafamidis franchise economics through 2031.
For Ionis Pharmaceuticals (Nasdaq: IONS), the read is also marginally negative: Ionis's eplontersen (Wainua, in collaboration with AstraZeneca) likewise faces a more durable competitive backdrop in the TTR-stabilizer-comparator window through 2031.
For royalty funds, the settlement is a clean illustration of how method-of-use IP enforcement on a multi-billion-dollar rare-disease asset translates directly into franchise-life extension and into the commercial-trajectory assumptions that underpin synthetic-royalty pricing on adjacent assets in the same indication. No royalty-fund position on Vyndamax / Vyndaqel has been publicly disclosed.
Disclosure gaps
- The specific commercial terms of each individual ANDA settlement (whether any of the three challengers received an authorized-generic licence pre-2031, whether any side payments were exchanged, whether there are any volume or price restrictions on entry) are typically not in the as-filed court orders and require subsequent SEC and EMA disclosure to fully reconstruct.
- The interaction between the Vyndamax / Vyndaqel franchise erosion curve and the April 29 SCOTUS oral argument in Hikma v. Amarin (covered below) is structurally relevant: if SCOTUS narrows the induced-infringement pleading standard for skinny-label ANDA filings, that ruling could reshape the strategic calculus for future TTR-stabilizer ANDA filings post-2031 (e.g., on later-developed indications or formulations).
M&A: Chiesi Group / KalVista Pharmaceuticals. US$1.9B Cash Tender at US$27.00/Share (36% Premium). DRI Healthcare Trust US$127M Ekterly Synthetic Royalty Position Enters Change-of-Control Review (April 29)
On Wednesday April 29 (Parma / Framingham MA), Chiesi Group, an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) announced a definitive agreement under which Chiesi will acquire KalVista via a tender offer at US$27.00 per share in cash, valuing KalVista equity at approximately US$1.9 billion. The cash consideration represents a 36% premium to KalVista's 30-day volume-weighted average share price as of April 28, 2026 (and approximately a 40% premium to the Tuesday April 28 closing price). The transaction was unanimously approved by both companies' boards of directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. Primary source: KalVista SEC Form 8-K Exhibit 99.1, April 29, 2026.
The acquisition adds EKTERLY® (sebetralstat), KalVista's first-and-only oral on-demand therapy for hereditary angioedema (HAE) attacks, to Chiesi's global rare-disease portfolio. Sebetralstat is a plasma kallikrein inhibitor approved by the U.S. FDA on July 3, 2025 for the on-demand treatment of HAE attacks in adult and adolescent patients aged 12 years and older. The oral on-demand mechanism is structurally differentiated against the prior standard of injectable on-demand therapies (icatibant, ecallantide) and the emerging long-acting prophylactic class (Takeda Takhzyro, BioCryst Orladeyo, KalVista's own pipeline).
Deal structure
| Term | Detail |
|---|---|
| Acquirer | Chiesi Group (private; Italian large-cap; B Corp certified) |
| Target | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) |
| Consideration | US$27.00 per share in cash via tender offer + second-step merger |
| Equity value | ~US$1.9 billion |
| Premium | 36% to 30-day VWAP (as of April 28, 2026); ~40% to Tuesday April 28 closing price |
| Funding | Cash; tender offer mechanics |
| Approvals | Unanimous approval by both boards; subject to majority share tender + customary regulatory clearances |
| Expected close | Q3 2026 |
The royalty-fund-relevant consequence: DRI Healthcare Trust change-of-control review
The structurally most important feature of the Chiesi / KalVista announcement for a royalty-fund audience is that DRI Healthcare Trust (TSX: DHT.UN; TSX: DHT.U) holds a synthetic royalty interest in worldwide net sales of all formulations of Ekterly, originated in November 2024 with subsequent expansion in July 2025. This is the only listed-royalty-fund position in the public market directly impacted by an in-window M&A event in W18.
DRI publicly stated on April 29, 2026: "Based on publicly available information, the Transaction, if consummated, may constitute a change of control under DRI Healthcare's royalty agreement. DRI Healthcare is currently reviewing the announced Transaction and evaluating its rights and obligations under the royalty agreement, including a put option and buyback provisions that may become exercisable in connection with the Transaction."
DRI Healthcare's Ekterly royalty stack reconstruction
| Layer | Detail |
|---|---|
| Original transaction date | November 4, 2024 (synthetic royalty financing closed) |
| Original aggregate purchase price | Up to US$179 million (US$100M upfront + up to US$57M sales-based milestone + one-time US$22M optional payment upon US approval) |
| Equity component | Additional US$5 million investment in KalVista common stock via private placement |
| Optional payment election | KalVista elected the US$22 million optional payment on July 8, 2025 following FDA approval (July 3, 2025) |
| Total DRI invested capital | US$127 million ($100M + $22M optional + $5M equity) |
| Royalty tier 1 | 6.00% of annual global net sales up to and including US$500M (stepped up from 5.00% on optional-payment election) |
| Royalty tier 2 | 1.10% of annual global net sales above US$500M and up to and including US$750M |
| Royalty tier 3 | 0.25% of annual global net sales above US$750M |
| Sales-based milestone | Up to US$57M (stepped up from US$50M on optional-payment election), payable if annual worldwide net sales of sebetralstat reach or exceed US$550M in any calendar year before January 1, 2031 |
| Royalty term | Worldwide; all formulations of sebetralstat |
| Change-of-control mechanics | Put option and buyback provisions identified by DRI as potentially exercisable in connection with the Chiesi transaction |
The structural setup is the canonical synthetic-royalty financing: front-loaded high-rate tier on early commercial revenue, with steep step-down at scale to make the economics work for both the issuer (KalVista) and the royalty buyer (DRI). The 6.00% / 1.10% / 0.25% tier structure means DRI's blended rate compresses materially as Ekterly scales toward and past the US$750M threshold; the sales-based milestone is the kicker that compensates for the step-downs if the asset reaches blockbuster scale before January 2031.
Other Ekterly royalty obligations
KalVista's prior disclosures also include a Japan-territory commercialization license to Kaken Pharmaceutical Co., Ltd. signed April 2025: KalVista received a US$11.0 million upfront payment on June 20, 2025 and is eligible for an additional US$11.0 million regulatory-milestone payment anticipated in early 2026, plus up to US$2.0 million in commercial milestones, plus mid-twenties percentage royalty on Japan National Health Insurance (NHI)-priced sales. The Kaken Japan-territory royalty layer is independent of the DRI worldwide synthetic royalty and is paid by Kaken to KalVista (not from KalVista to a third-party buyer).
Strategic logic for Chiesi
For Chiesi, Ekterly slots cleanly into the existing rare-disease and respiratory portfolio: Chiesi already markets Lamzede® (velmanase alfa) in alpha-mannosidosis and Elfabrio® (pegunigalsidase alfa) in Fabry disease (the latter via Protalix BioTherapeutics partnership), alongside the cystic fibrosis bronchitol franchise and the broader Chiesi Global Rare Diseases (formerly Chiesi Genetic Disorders) commercial infrastructure. The HAE category is a high-value rare-disease market (estimated 1 in 50,000 prevalence; mostly diagnosed; chronic-prophylactic treatment-eligible patient population in the tens of thousands globally) where the on-demand pill is structurally differentiated against injectable on-demand and long-acting prophylactic competitors. The acquisition gives Chiesi a near-term commercial revenue contributor with established launch trajectory (Ekterly approved July 2025; first full year of US sales in 2026) and a meaningful ex-US expansion runway via the EU label and the Kaken Japan partnership.
Read-through
For a royalty-finance audience, the Chiesi / KalVista transaction crystallises three structural points:
- Synthetic-royalty change-of-control provisions are now under live test. DRI's public confirmation that put-option and buyback provisions "may become exercisable" is the cleanest worked example in the W18 window of how synthetic-royalty contractual architecture survives an upstream-licensor M&A event. The specific economics of the put / buyback are not in the public domain, but the standard synthetic-royalty CoC mechanism is a return-of-capital-plus-IRR put back to the acquirer at the royalty buyer's option, with the acquirer typically having a corresponding buyback right at a defined valuation. DRI's published portfolio-level return architecture and prior change-of-control precedents in the synthetic-royalty class (Lupkynis under Aurinia / Otsuka, Vonjo under CTI BioPharma / Sobi, Egrifta under Theratechnologies-related transactions) cluster around a buyback cap of approximately 1.75x to 2.0x invested capital or a defined IRR floor in the 12% to 15% range, whichever results in the higher repayment. Applied to the US$127M Ekterly position, that comparable-precedent band implies a buyback ceiling in the rough range of US$220M to US$255M payable by Chiesi at closing if DRI elects to put and Chiesi elects to buy back, on top of the US$1.9B equity consideration; the actual contractual mechanics may step up or down from this band based on the specific Ekterly synthetic-royalty agreement, which is not in the public domain.
- Italian large-cap pharma joins the rare-disease M&A counterparty set alongside Sun Pharma (Organon, India) and Chiesi (KalVista, Italy) inside the same five-day W18 window. Both transactions are cash-funded and structurally targeted: the Sun Pharma deal acquires women's-health-and-biosimilar scale, the Chiesi deal acquires a launched rare-disease asset.
- The HAE category re-prices. The implied US$1.9B equity valuation represents a meaningful multiple of consensus 2026E Ekterly sales (Street ~US$200M); peak-sales assumptions for Ekterly across HAE on-demand and into adjacent indications (bradykinin-mediated angioedema, ACE inhibitor-induced angioedema) embed a category-leadership thesis that Chiesi presumably underwrote at signing.
Disclosure gaps
- The specific contractual mechanics of the DRI put-option and buyback provisions are not in the public domain.
- The Chiesi internal financing structure (cash on balance sheet versus committed debt) is not disclosed; Chiesi is privately held and does not publish a quarterly balance sheet.
- The expected commercial-product transfer mechanics from KalVista's US commercial infrastructure to Chiesi US are not disclosed.
- No financial advisor was named on either side in initial press materials.
M&A: ARCHIMED / Esperion Therapeutics. US$3.16/Share Cash + Up to US$100M Two-Tranche CVR. Up to ~US$1.1B Total Equity Value. First PE-Led Take-Private of the 2026 Cohort; OMERS / Athyrium / HCRx Royalty Stack Inherited (May 1)
On Friday May 1 (Ann Arbor MI / Paris), ARCHIMED, a healthcare-focused private equity firm, and Esperion Therapeutics, Inc. (Nasdaq: ESPR) announced a definitive merger agreement under which an affiliate of ARCHIMED will acquire all outstanding Esperion shares for US$3.16 per share in cash at closing, plus one non-tradeable contingent value right (CVR) per share entitling holders to up to US$100 million in aggregate across two contingent milestone payments tied to U.S. net sales performance. Total equity value on a fully diluted basis assuming full milestone achievement: approximately US$1.1 billion. The cash consideration represents a 58% premium to Esperion's closing share price on April 30, 2026. The transaction was unanimously approved by the Esperion board and is expected to close in Q3 2026, subject to Esperion stockholder approval and customary regulatory clearances; Esperion will be delisted from Nasdaq on close. Debt financing has been committed by funds managed by Pharmakon Advisors, Esperion's existing senior secured lender. Esperion canceled its previously scheduled Q1 2026 earnings call; the Q1 10-Q is expected May 7, 2026. Primary source: Esperion press release, May 1, 2026; SEC Form 8-K Exhibit 99.1 (SEC EDGAR CIK 1434868).
The transaction is the first private-equity-led take-private of a US-listed commercial-stage biopharma in the 2026 dealmaking cohort, and the most directly royalty-stack-relevant in-window M&A event after the Chiesi / KalVista announcement two days earlier. Esperion's commercial portfolio (NEXLETOL® and NEXLIZET® bempedoic acid franchise, plus the recently acquired Corstasis Therapeutics intranasal-loop-diuretic ENBUMYST® franchise) carries a layered royalty-financing capital stack built up across 2024–2026 from OMERS Life Sciences (Europe), Athyrium Capital Management (Japan), HealthCare Royalty Partners (co-lender on the senior secured term loan), and Pharmakon Advisors (lead senior secured lender, now also debt financier of the take-private). The combination of two-tranche sales-based CVR plus four-counterparty inherited royalty stack puts Esperion / ARCHIMED on the short list of W18 transactions where the structural reading is materially independent of the equity-deal economics.
Deal structure
| Term | Detail |
|---|---|
| Acquirer | ARCHIMED (Paris-based healthcare-focused private equity; current PE fund vintage Med Platform II / III) |
| Target | Esperion Therapeutics, Inc. (Nasdaq: ESPR) |
| Per-share cash consideration | US$3.16 per share at closing |
| Cash premium | 58% to April 30, 2026 closing share price (US$2.00); Esperion repriced to US$3.10 to US$3.14 on May 1 trading |
| CVR consideration | One non-tradeable CVR per share, entitling holders to up to US$100 million in aggregate across two tranches (see below) |
| Aggregate equity value | Up to ~US$1.1 billion fully diluted (assuming full CVR milestone achievement) |
| Transaction form | Reverse triangular merger; Esperion survives as wholly-owned subsidiary of ARCHIMED-managed acquisition vehicle |
| Financing | Cash from ARCHIMED-managed funds + committed debt financing from Pharmakon Advisors-managed funds |
| Approvals | Unanimous Esperion board approval; subject to Esperion stockholder approval + HSR clearance + customary regulatory clearances |
| Expected close | Q3 2026 |
| Post-close status | Esperion delisted from Nasdaq; Q1 2026 earnings call canceled; Q1 10-Q expected May 7, 2026 |
CVR mechanics: two-tranche, sales-based, no transferability
The CVR is the structural feature that distinguishes the Esperion / ARCHIMED transaction from the more conventional M&A in W18, and it is the single most important detail for a royalty-finance audience because it functions as a synthetic milestone overlay on the bempedoic-acid and bumetanide commercial trajectories that ARCHIMED is acquiring.
| Tranche | Trigger asset | Period | Threshold | Payout |
|---|---|---|---|---|
| Tranche 1: Bempedoic acid CVR | NEXLETOL® and NEXLIZET® and any other bempedoic-acid product | CY 2027 U.S. net sales | If 2027 U.S. net sales >US$350M: full payout. If 2027 U.S. net sales >US$300M and <US$350M: linear interpolation between US$0 and US$40M | Up to US$40M aggregate |
| Tranche 2: Bumetanide CVR | ENBUMYST® and any other bumetanide product | Any single calendar year through Dec 31, 2030 | Annual U.S. net sales ≥US$160M in any single calendar year | US$60M aggregate (one-time) |
| CVR aggregate cap | n/a | n/a | n/a | US$100M |
| Transferability | n/a | n/a | n/a | Non-tradeable |
The bempedoic-acid CVR is structurally a single-year-of-observation linear-step instrument indexed to a specific calendar year (CY 2027), with full payout above a sharply-bounded threshold and zero payout below US$300M, making it less of a long-dated royalty-equivalent and more of a binary one-year sales hurdle. The bumetanide CVR is structurally a multi-year-of-observation digital instrument with a four-year evaluation window (the Corstasis / ENBUMYST acquisition closed in Q1 2026; first full year of US sales is 2026, with the threshold observable through 2030). Neither tranche carries an interpolation band beyond the bempedoic-acid US$300M to US$350M segment; both are otherwise binary.
For a synthetic-royalty buyer the bempedoic-acid CVR is not a synthetic royalty in the conventional sense (no percentage-of-net-sales rate, no royalty term, no audit rights, no minimum-royalty floor); it is a sales-conditional cash bonus to former equity holders. The two CVR tranches together effectively give selling Esperion shareholders a call option on US commercial outperformance of the two acquired franchises, with the strike prices set high enough (ENBUMYST US$160M is roughly 5x current consensus year-one sales) that the CVR is structurally analogous to the out-of-the-money tranche of a classic CVR-mechanic M&A like Bristol Myers Squibb / Celgene 2019 or Chiesi / KalVista's own pipeline construct.
Inherited royalty stack: four-counterparty capital structure
The capital structure ARCHIMED is acquiring inside Esperion includes four discrete external royalty-financing or debt counterparties, each with distinct seniority, cap mechanics, and reversion provisions. This is the single feature of the Esperion balance sheet that has the most direct read-through to royalty-fund underwriting models.
| Counterparty | Date | Asset | Geography | Capital | Royalty rate / loan economics | Cap / reversion |
|---|---|---|---|---|---|---|
| OMERS Life Sciences | August 2024 (Royalty Purchase Agreement) | Bempedoic acid (DSE-licensed) | Europe | US$304.7M cash | 15% to 25% tiered royalty on Daiichi Sankyo Europe (DSE) net sales of bempedoic acid in Europe | Until OMERS receives 1.7x invested capital; thereafter all future DSE royalties revert to Esperion |
| Athyrium Capital Management | April 2, 2026 (Royalty Financing Agreement) | Bempedoic acid (Otsuka-licensed) | Japan | US$50M cash | 12% to 33% tiered royalty on Otsuka Japan net sales of bempedoic acid + associated regulatory and commercial milestones | Until Athyrium Funds receive 2.0x invested capital; thereafter all future Japan royalties and milestones revert to Esperion |
| Athyrium Capital Management + HealthCare Royalty Partners | December 2024 (lead) + April 2026 amendment | Senior secured term loan facility | n/a | Initial US$150M facility (Athyrium lead, HCRx joined) + amended +US$25M in April 2026 | Senior secured term loan economics; not disclosed at the rate / OID level | Loan amortisation; secured by all Esperion collateral including the post-OMERS / post-Athyrium-Japan residual royalty interests |
| Pharmakon Advisors | December 2024 + April 2026 amendment + May 2026 take-private debt financing | Convertible Note + take-private debt commitment | n/a | US$100M Convertible Note (December 2024) + +US$25M term loan amendment (April 2026) + take-private debt commitment (May 1, 2026) | Convertible note, term loan, and take-private debt; specific rate / OID / conversion economics not consolidated in single public disclosure | Continues as Esperion / post-merger ARCHIMED senior debt counterparty |
The structural significance of this stack for a royalty-fund audience is that Esperion has, over an 18-month period, executed a disciplined non-dilutive monetisation of three discrete revenue streams (Europe via OMERS, Japan via Athyrium, US-collateralised debt via Pharmakon and HCRx), retaining the US bempedoic-acid royalty stream and the post-cap reversion rights on Europe and Japan. ARCHIMED is acquiring Esperion at a moment when (i) the OMERS Europe royalty is in mid-recoupment (DSE Europe sales ramping; OMERS recoupment progress not separately disclosed), (ii) the Athyrium Japan royalty is in early-stage recoupment (effective from January 1, 2026 onward; Otsuka Japan launch trajectory still establishing), and (iii) the Pharmakon-led senior secured stack carries forward as the take-private debt financing source. The four-counterparty stack is materially more complex than the typical commercial-stage biopharma take-private balance sheet, and the Q3 2026 closing process will require contractual consent or notification under each of the four counterparty agreements (the specific change-of-control provisions for each are not in the public domain at the same level of detail as the DRI / KalVista provisions covered above).
Lead asset and commercial trajectory: bempedoic acid franchise
NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid + ezetimibe fixed-dose combination) are oral LDL-C-lowering therapies originally approved by the FDA in February 2020 for use as adjunctive therapy in patients with heterozygous familial hypercholesterolaemia or established atherosclerotic cardiovascular disease who require additional LDL-C lowering. The label was expanded in March 2024 to include cardiovascular outcomes data from the CLEAR Outcomes trial, supporting use in primary prevention as well as in established ASCVD. Q1 2026 sales not yet released (10-Q expected May 7, 2026); FY 2025 US net product revenue was approximately US$190M to US$200M based on prior quarterly cadence. A May 2 post-hoc analysis of the CLEAR Outcomes trial reported a 22% reduction in ischemic stroke risk with bempedoic acid, providing additional commercial-positioning support but not a label-changing event.
The Corstasis / ENBUMYST acquisition closed in Q1 2026; ENBUMYST is the first FDA-approved intranasal loop diuretic for treatment of edema associated with cardiovascular, hepatic, and renal disease, approved in January 2026 (Corstasis private; full approval-package details not in the same public domain as the bempedoic-acid franchise). The Athyrium Japan royalty financing was structured specifically to fund the Corstasis / ENBUMYST acquisition.
Strategic logic for ARCHIMED
ARCHIMED's investment thesis on Esperion clusters around three points that are publicly inferable from the deal structure rather than disclosed in the press release. First, the fixed-cost structure of a commercial-stage cardiometabolic franchise with established prescriber base and existing sales infrastructure is a more efficient unit-economics profile under PE ownership than under the cost discipline expected by listed-equity investors at Esperion's pre-deal market capitalisation. Second, the Corstasis / ENBUMYST integration creates a logical adjacency for cross-sell into the existing bempedoic-acid prescriber base (cardiologists treating ASCVD with persistent edema). Third, the CVR construct allows ARCHIMED to underwrite the deal at the cash-leg consideration alone, with the CVR functioning as upside-distribution to former equity holders rather than required deal economics. The 58% cash premium and the absence of contingent floor on the CVR mean the equity-leg trade is structurally tight to ARCHIMED's underwriting case.
Royalty-fund read-through
For a royalty-finance audience the Esperion / ARCHIMED transaction crystallises four structural points distinct from those drawn in the Chiesi / KalVista section:
- The four-counterparty royalty / debt stack is acquired intact. Unlike the DRI / KalVista situation where a single synthetic royalty triggers a change-of-control put / buyback, the Esperion stack does not have a single dominant royalty buyer; instead, four counterparties (OMERS, Athyrium, HCRx, Pharmakon) each hold differentiated capital instruments. The transaction does not appear to trigger an automatic put / buyback of the OMERS Europe or Athyrium Japan royalty interests, both of which run to a multiple-of-invested-capital cap and remain economically attached to the underlying license counterparties (DSE in Europe, Otsuka in Japan). The Pharmakon and HCRx debt instruments roll forward as ARCHIMED debt obligations.
- The bempedoic-acid CVR is a clean public-comp data point for two-stage CVR design in cardiometabolic M&A. The combination of (i) a bounded one-year hurdle ($300M to $350M of CY 2027 US net sales) with linear interpolation and (ii) a multi-year digital hurdle ($160M ENBUMYST through 2030) is a transferable structural template for future PE-led take-privates of commercial-stage biopharma franchises with high revenue dispersion in out-years.
- PE-led take-privates of commercial-stage US-listed biopharma return as a 2026 deal type. ARCHIMED's transaction is the first of the 2026 cohort and validates a thesis that public-market discount to intrinsic value at the small / mid-cap commercial-stage biopharma cohort had become wide enough to attract dedicated healthcare PE capital. The implication for royalty-fund underwriters: the universe of commercial-stage biopharma counterparties from which synthetic royalties are originated may shift toward PE-owned entities whose change-of-control regime (in subsequent secondary buyouts or strategic exits) may be different from public-company change-of-control.
- OMERS, Athyrium, HCRx and Pharmakon all retain their original economics. The structural reading is that the underlying capital-stack design held together through a take-private event without forced restructuring, which is a constructive proof point for the durability of capped-recoupment royalty financings as a commercial-stage biopharma capital instrument.
Disclosure gaps
- The specific change-of-control mechanics in the OMERS Royalty Purchase Agreement, the Athyrium Royalty Financing Agreement, and the Pharmakon / HCRx senior secured loan and convertible note documents are not disclosed at the level of put-option strike, buyback cap, or IRR floor.
- The cumulative aggregate payments OMERS has received toward its 1.7x invested-capital recoupment cap as of close are not separately disclosed.
- The specific financial advisors to Esperion and ARCHIMED were not named in the May 1 press materials at issue date.
- The specific Pharmakon take-private debt facility size, tenor, and pricing are not disclosed.
- The CVR may not pay; the bumetanide US$160M annual net-sales threshold is approximately 5x to 7x consensus year-one ENBUMYST sales and approximately 2x to 3x consensus year-three sales; the bempedoic-acid US$300M to US$350M CY 2027 US net-sales threshold is approximately 1.5x current LTM US net sales.
M&A: Teva Pharmaceuticals / Emalex Biosciences. US$700M Cash Upfront + Up to US$200M Milestones + Royalties on Global Net Sales of Ecopipam = Up to US$900M. NDA-Ready First-in-Class D1 Antagonist for Pediatric Tourette Syndrome (April 29)
On Wednesday April 29 (Parsippany NJ / Chicago), Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE / TASE: TEVA), and Emalex Biosciences (private) announced a definitive agreement for Teva to acquire Emalex, including its lead asset ecopipam. Upon closing, Teva will pay US$700 million in cash, and Emalex's shareholders will be eligible to receive up to an additional US$200 million based on future commercial milestones, plus tiered royalties on global net sales of ecopipam, subject to regulatory approval. Total potential consideration: up to US$900 million. The transaction is expected to close in Q3 2026, subject to customary closing conditions including necessary regulatory approvals. Teva will fund the upfront payment using cash on hand. The transaction is Teva's largest deal in approximately a decade. Primary source: Teva investor relations press release, April 29, 2026.
Deal structure
| Term | Detail |
|---|---|
| Acquirer | Teva Pharmaceuticals (NYSE / TASE: TEVA) |
| Target | Emalex Biosciences (private; Chicago-based; Paragon Biosciences-backed) |
| Upfront cash | US$700 million at closing |
| Commercial milestones | Up to US$200 million subject to regulatory approval |
| Royalties | Tiered royalties on global net sales of ecopipam, subject to regulatory approval (specific rate band not disclosed) |
| Total potential consideration | Up to US$900 million |
| Funding | Cash on hand |
| Expected close | Q3 2026 |
Lead asset: ecopipam
Ecopipam is a first-in-class selective dopamine D1 receptor antagonist in development for pediatric Tourette syndrome. The asset has FDA Orphan Drug Designation and Fast Track Designation. The pivotal Phase 3 trial in children with Tourette syndrome met its primary efficacy endpoint with statistical significance (p=0.0084), and the NDA submission is anticipated in 2H 2026. The mechanism is differentiated from current standard-of-care: existing Tourette pharmacotherapies (haloperidol, pimozide, aripiprazole) target D2 receptors, with associated extrapyramidal and metabolic-side-effect liabilities. Ecopipam's selective D1 antagonism is mechanistically positioned to address the repetitive and compulsive behavioural pathways implicated in tic generation while avoiding D2-mediated motor side effects.
Strategic logic for Teva
The Emalex acquisition fits inside Teva CEO Richard Francis's Pivot to Growth strategy, announced in May 2023, the four pillars of which are: delivering on growth engines; stepping up innovation; sustaining the generics powerhouse; and focusing the business. Teva's existing CNS franchise centres on AUSTEDO® (deutetrabenazine) for tardive dyskinesia and Huntington's chorea, AJOVY® (fremanezumab-vfrm) for migraine prophylaxis, and UZEDY® (risperidone) long-acting injectable for schizophrenia; collectively these three brands grew 41% year-over-year in local currency in Q1 2026. Ecopipam extends the CNS franchise into the pediatric Tourette syndrome indication, which is a structurally underserved category in the U.S. (estimated 200,000+ children in the moderate-to-severe Tourette population, with limited well-tolerated pharmacological options).
The deal economics ($700M upfront on a roughly $900M total potential consideration; royalties on top) are aggressive for an asset that has not yet been NDA-filed, but reflect: (i) the late-stage de-risking from a positive Phase 3 primary endpoint readout, (ii) the FDA Orphan Drug + Fast Track regulatory tailwind, (iii) Teva's view that the commercial infrastructure already supporting AUSTEDO can absorb the ecopipam launch with limited incremental SG&A, and (iv) the strategic premium of a launch-ready CNS asset in a year where Teva's late-stage pipeline gating event (olanzapine LAI FDA decision, expected 2H 2026) is the only other near-term registrational catalyst.
Royalty stack and structural read-through
The disclosed deal structure includes "tiered royalties on global net sales of ecopipam" payable from Teva to former Emalex shareholders, subject to regulatory approval. The specific rate band is not disclosed. This is the third 2026 W18 transaction with a disclosed downstream-earnout-plus-royalty structure to former target shareholders (the others being the Sun Pharma / Organon Vtama upstream royalty inherited from Roivant–Dermavant, and the BioMarin / Amicus DMX-200 upstream royalty inherited from Dimerix). For royalty-fund analysts, the Emalex shareholder royalty entitlement is not a synthetic royalty available for monetisation unless Paragon Biosciences or other Emalex equity holders subsequently transact the entitlement to a royalty buyer; this would be a future-state opportunity, not a current monetisable position.
The Emalex deal also confirms the Teva strategic pivot toward late-stage-asset bolt-ons funded through external balance-sheet capital. In Q1 2026, Teva also disclosed continued execution under its March 3, 2026 strategic funding agreement with Blackstone Life Sciences (US$400M four-year duvakitug development financing) and the January 11, 2026 Royalty Pharma funding agreement for TEV-'408 anti-IL-15 antibody (up to US$500M). Q1 2026 recognised US$30M of R&D-expense reimbursement under the Blackstone agreement. Combined external development funding plus the Emalex acquisition put up to US$1.6 billion of acquisition and development capital across Teva's late-stage assets, with the broader 2027 financial targets (mid-single-digit revenue CAGR, 30% non-GAAP operating margin, 2.0x net debt to EBITDA, 80% cash-to-earnings conversion) maintained.
Disclosure gaps
- The royalty rate band on ecopipam global net sales payable from Teva to former Emalex shareholders is not disclosed.
- The Phase 3 efficacy magnitude (effect size on tic severity scales such as YGTSS) and safety profile beyond the headline p-value is not in the as-released materials and will be available at NDA submission and at peer-reviewed publication.
- No financial advisor was named on either side in initial press materials.
Public follow-on: Sagimet Biosciences. US$175M Priced at $6.00 (April 27). Strategic Pivot to Acne; MASH Development Conditioned on Non-Dilutive Financing
On Monday April 27, Sagimet Biosciences (Nasdaq: SGMT) priced an upsized US$175.0 million underwritten public offering of 29,166,700 Series A common shares at $6.00 per share, which closed April 28. Joint book-running managers were Leerink Partners, TD Cowen, Guggenheim Securities, and Oppenheimer & Co. Co-lead managers: Canaccord Genuity, H.C. Wainwright & Co., Jones. Named participants disclosed alongside an unidentified leading life-sciences investor: Balyasny Asset Management, Blue Owl Healthcare Opportunities, BVF Partners, Caligan Partners, Coastlands Capital, Farallon Capital, Great Point Partners, and Woodline Partners. Sagimet shares jumped approximately 38% intraday to US$8.12 on April 27 (above the US$6.00 offering price) on heavy volume past 48 million shares, breaking the 200-day moving average for the first time since early February. Primary source: Sagimet IR pricing release, April 27, 2026.
Use of proceeds: U.S. Phase 3 of denifanstat (oral FASN inhibitor) in moderate-to-severe acne, planned to initiate 2H 2026 (subject to mid-2026 IND clearance, n=800 with 2:1 randomization, 533 active vs 267 placebo); TVB-3567 Phase 2 (second-generation FASN inhibitor with separate patent family); topical FASN program advancement. Cash runway extended through 2028 to support Phase 3 acne readouts.
Same-day strategic pivot
Sagimet announced on April 27, alongside the offering pricing, a strategic pivot from MASH to dermatology: "Further MASH development to be undertaken only upon securing non-dilutive funding." Sagimet's CFO Thierry Chauche stated explicitly: "We are prioritizing our dermatology franchise in our capital allocation, and we plan to pursue non-dilutive funding options for our MASH program." The denifanstat / resmetirom combination program (FASCINATE-2 Phase 2b previously positive; Phase 1 PK with Madrigal's resmetirom completed December 2025) is Phase 2-ready 2H 2026 only if external non-dilutive financing is secured. For a royalty-finance audience, this is a direct invitation to royalty buyers and synthetic-royalty financiers to underwrite the MASH program; possible structures include synthetic royalty on future U.S. denifanstat / combo MASH net sales, royalty-backed note against the in-flight Greater China royalty stream (covered below), or a development-funding agreement of the type Royalty Pharma and Blackstone Life Sciences regularly underwrite.
Sagimet / Ascletis Bioscience Greater China license: royalty stack reconstruction
The denifanstat asset has a long-standing out-licensed Greater China commercialisation arm that creates Sagimet's first concrete royalty income stream. Ascletis Bioscience Co. Ltd. (parent: Ascletis Pharma Inc., HKEX: 1672) commercialises denifanstat as ASC40 in Greater China.
| Layer | Detail |
|---|---|
| Counterparty | Sagimet → Ascletis Bioscience (Hangzhou, China) |
| Territory | Greater China (mainland China, Hong Kong, Macau, Taiwan) |
| Aggregate milestones | Up to US$122 million in development and commercial milestones |
| Royalty rate band | High single-digit to mid-teens tiered royalty on Greater China net sales |
| Lead indication (China) | Moderate-to-severe acne vulgaris; NMPA NDA accepted December 2025; approval anticipated within 12 months |
| Asset code (Ascletis) | ASC40 (= denifanstat) |
| Phase 3 efficacy (Ascletis trial, n=480) | 33.2% IGA treatment success vs 14.6% placebo (p<0.0001); 57.4% vs 35.4% total lesion reduction; 63.5% vs 43.2% inflammatory; 51.9% vs 28.9% non-inflammatory |
| Phase 3 long-term safety (n=240, 52 weeks) | Generally well tolerated; improvements across all measured efficacy endpoints |
| Milestone economics | Most milestones tied to revenue achievement; smaller milestone due upon potential approval |
The Ascletis royalty stream is the cleanest near-term royalty-fund-financeable revenue stream on the Sagimet asset base, with NMPA approval potentially within 12 months and meaningful US-readout-disconnected Greater China commercial trajectory.
Royalty stack on rest-of-world rights
Outside Greater China, Sagimet retains worldwide rights on denifanstat and on its second-generation FASN inhibitor TVB-3567. No upstream royalty obligation has been publicly disclosed on either molecule; both are internally-discovered Sagimet assets with composition-of-matter patents (denifanstat to 2032 with potential PTE extension to 2037; TVB-3567 separate patent family).
Private financing: Fathom Therapeutics (formerly Atommap). US$47M Series A (April 27)
On Monday April 27, Fathom Therapeutics (formerly Atommap) closed an oversubscribed US$47 million Series A led by Sutter Hill Ventures, with Chemistry, Alexandria Venture Investments, and Empire State Development's NY Ventures participating. Fathom is building a physics- and AI-enabled small-molecule design platform branded Microcosmos, combining quantum-chemistry-grounded representations with machine learning for molecular property prediction. The disclosed pipeline focus is targeted protein degraders against an undisclosed historically undruggable target, with the lead program reported in animal efficacy. Primary source: Fathom Therapeutics PR Newswire release, April 27, 2026.
Fathom has no commercial assets, no Phase 1 program, and no current royalty obligations.
Private financing: Coultreon Biopharma (formerly Onco3R Therapeutics). US$125M Oversubscribed Series A. Galapagos-Originated SIK3 Inhibitor; Sofinnova / Forbion / Novo Holdings Syndicate (April 28)
On Tuesday April 28 (Leuven, Belgium), Coultreon Biopharma (private; formerly Onco3R Therapeutics BV) announced the closing of an oversubscribed US$125 million Series A financing, led by Sofinnova Investments, with Forbion and Novo Holdings as co-leads, joined by Galapagos NV (Euronext: GLPG; Nasdaq: GLPG), Regeneron Ventures, Balyasny Asset Management, Luma Group, Samsara BioCapital, Longwood Fund, and Finchley Healthcare Ventures. Primary source: Coultreon Biopharma corporate press release, April 28, 2026.
Proceeds will fund Phase 2 development of COL-5671 (formerly O3R-5671), a highly selective, oral once-daily SIK3 (salt-inducible kinase 3) inhibitor currently in Phase 1, into psoriasis and ulcerative colitis Phase 2 clinical trials, with potential clinical proof-of-concept readouts in 2027.
Deal structure and royalty stack reconstruction
| Term | Detail |
|---|---|
| Transaction | Series A financing (oversubscribed) |
| Aggregate gross proceeds | US$125 million |
| Lead investor | Sofinnova Investments |
| Co-leads | Forbion; Novo Holdings |
| Syndicate participants | Galapagos NV, Regeneron Ventures, Balyasny Asset Management, Luma Group, Samsara BioCapital, Longwood Fund, Finchley Healthcare Ventures |
| Use of proceeds | COL-5671 Phase 2 in psoriasis + ulcerative colitis (proof-of-concept 2027); broader pipeline advancement |
| Board addition | Max Klement (Partner, Novo Holdings Venture Investments) joins Coultreon Board of Directors |
Asset origination and upstream IP layer (Galapagos)
The structural feature of the transaction for a royalty-finance audience is the Galapagos upstream layer:
| Hop | Date | Detail |
|---|---|---|
| Hop 1: Origination | n/a | COL-5671 originally developed by Galapagos NV (Belgium-based, dual-listed) within its SIK platform; originally targeted under the Onco3R Therapeutics name for autoimmune disease and cancer |
| Hop 2: Galapagos pipeline trim | 2025 | Galapagos elected to trim its research pipeline; spun out the SIK assets into Onco3R |
| Hop 3: Asset transfer to Coultreon | April 2025 | Ownership of COL-5671 fully transferred to Coultreon (then Onco3R); Galapagos provided an initial seed investment at the same time |
| Hop 4: Series A closing + corporate rebrand | April 28, 2026 | Onco3R rebranded to Coultreon Biopharma; US$125M Series A closes; Galapagos participates as a syndicate investor |
Galapagos retains an equity interest in Coultreon through both the original seed investment (April 2025) and the Series A participation (April 28, 2026); the specific Galapagos ownership percentage post-Series A has not been publicly disclosed. The Coultreon press release verbatim states "COL-5671 was initially developed by Galapagos NV, and ownership was fully transferred to Coultreon in April 2025, when Galapagos provided an initial seed investment", framing the April 2025 transfer as a full ownership transfer with concurrent equity investment. Galapagos's interest in Coultreon is structured as equity only; no royalty, milestone, or contingent-value pass-through obligation back to Galapagos has been disclosed in primary filings. The April 28, 2026 in-window event is the Series A close + corporate rebrand, not a licensing event; the underlying COL-5671 asset transfer occurred April 2025, out-of-window for W18.
COL-5671: Mechanism, prior clinical signal, and competitive context
COL-5671 is a highly selective oral SIK3 inhibitor; selectivity over SIK1 and SIK2 is positioned as the differentiating safety feature versus pan-SIK approaches. Mechanism-of-action: SIK3 inhibition reduces transcription of pro-inflammatory cytokines TNFα and IL-23, while increasing expression of the immunoregulatory cytokine IL-10.
Prior Phase 1 signal (presented at ECCO Stockholm, February 2026): in healthy volunteers, COL-5671 demonstrated TNFα inhibition characterized by Coultreon as "as efficiently as monoclonal antibodies." At the 15 mg dose (third highest of four doses evaluated), TNFα inhibition remained higher than 90% at 24 hours post-dose. Once-daily oral dosing supported by extensive toxicology.
The competitive context: TNFα inhibition is the mechanism of AbbVie's Humira (adalimumab), Amgen's Enbrel (etanercept), and Johnson & Johnson's Remicade (infliximab), all injectable biologics with multi-billion-dollar peak sales histories. IL-23 inhibition is the mechanism of Tremfya (J&J) and Skyrizi (AbbVie), both injectable. An oral once-daily small molecule with mechanistically validated suppression of both TNFα and IL-23 plus IL-10 induction would compete directly across the immunology biologic franchise if the Phase 2 readouts hold.
The April 28 readout sits structurally adjacent to the Oruka Therapeutics ORKA-001 EVERLAST-A Phase 2a readout (also April 27, plaque psoriasis, IL-23p19 mAb at 63.5% PASI 100; covered above). Both signal continued investor and big-pharma attention to the IL-23 axis in autoimmune disease, with Oruka anchored in injectable biologic territory and Coultreon positioning a small-molecule alternative.
Read-through
For a royalty-finance audience, Coultreon is structurally interesting on three dimensions:
- The Galapagos spin-out template. Galapagos's Q4 2025 / 2026 pipeline-trim activity has already produced multiple spin-outs and out-licenses; the Coultreon transaction is now a worked example of how a previously-Galapagos-internal asset can be capitalized at meaningful Series A scale (US$125M) under a top-tier syndicate. Galapagos retains an equity interest, suggesting Galapagos has elected to participate in the asset's upside via the spin-out vehicle rather than monetize fully.
- The big-pharma syndicate composition. Regeneron Ventures and Novo Holdings as co-anchors alongside Sofinnova / Forbion is structurally significant: this is a syndicate that signals the asset is on the Big Pharma scouting radar, with potential out-license / strategic-acquisition optionality post-Phase 2 proof-of-concept (2027 expected). The Beeline Medicines comparison from earlier in April (US$300M debut + five BMS-licensed assets) is the closer recent precedent for big-pharma-anchored autoimmune startup financings.
- The Galapagos/Gilead context. Galapagos's own broader corporate dynamics include the March 2026 cost-splitting agreement with Gilead over Gilead's US$7.8B acquisition of inflammatory specialist Ouro Medicines. That agreement reframes Galapagos's role inside the Gilead immunology footprint and increases the strategic value of any preserved Galapagos equity position in spin-outs like Coultreon.
No third-party royalty-fund position on COL-5671 has been publicly disclosed. If COL-5671 advances through Phase 2 to a 2027 clinical proof-of-concept and a subsequent 2028+ Phase 3, the asset would be a structurally credible synthetic-royalty target in the post-PoC window, particularly for funds with autoimmune-franchise focus.
Disclosure gaps
- The specific terms of the April 2025 Galapagos-to-Coultreon (then Onco3R) asset transfer agreement, including any milestone, royalty, or contingent-value payment obligations to Galapagos beyond the equity interest, have not been publicly disclosed.
- Galapagos's post-Series A ownership percentage of Coultreon has not been disclosed.
- Series A pre- and post-money valuation has not been publicly disclosed.
IPO pricing: Avalyn Pharma. US$300M Upsized at US$18.00/Share. Inhaled Antifibrotics for Pulmonary Fibrosis (April 29 / 30)
On Wednesday April 29 (Boston), Avalyn Pharma Inc. (Nasdaq: AVLN) priced an upsized initial public offering of 16,666,667 shares of common stock at US$18.00 per share, for gross proceeds of approximately US$300 million before underwriting discounts and commissions. The underwriters were granted a 30-day option to purchase up to 2,500,000 additional shares at the IPO price. Joint book-running managers: Morgan Stanley, Jefferies, Evercore ISI, Guggenheim Securities. Shares began trading on the Nasdaq Global Select Market on Thursday April 30 under the ticker AVLN. On Friday May 1, 2026, Avalyn announced the closing of the IPO with the full exercise by the underwriters of their over-allotment option to purchase 2,500,000 additional shares, taking the aggregate offering to 19,166,667 shares at $18.00 = US$345 million in aggregate gross proceeds (vs the US$300M base announced at pricing). Primary source: Avalyn pricing press release, April 30, 2026.
The IPO was upsized from the initial range of 11.8M shares at US$16-18 (~US$201M) to 16.7M shares at US$18 (US$300M), reflecting strong demand on the deal. Avalyn is a clinical-stage biopharmaceutical company developing inhaled formulations of established antifibrotic medicines:
- AP01: optimised inhaled formulation of pirfenidone, in MIST Phase 2b in progressive pulmonary fibrosis (PPF), with prior Phase 1b ATLAS data and an ongoing open-label extension supporting tolerability and durability versus oral pirfenidone.
- AP02: optimised inhaled formulation of nintedanib, in AURA Phase 2 in idiopathic pulmonary fibrosis (IPF).
- AP03: inhaled fixed-dose combination of pirfenidone and nintedanib (preclinical / early development).
The mechanistic and commercial thesis is that local-lung delivery of approved antifibrotic mechanisms can preserve lung-function efficacy while reducing systemic side effects (especially the GI tolerability burden of oral pirfenidone and nintedanib that drives high real-world discontinuation in the IPF and PPF treated populations). No third-party royalty-fund position on Avalyn programs has been publicly disclosed; AP01 and AP02 are reformulations of off-patent active pharmaceutical ingredients with formulation- and delivery-specific IP rather than composition-of-matter coverage on the molecule itself.
Verified upstream license (Avalyn S-1/A; SEC Acc# 0001193125-26-189477): AP01, AP02, and AP03 all depend on the PARI License Agreement, an exclusive license to PARI Pharma's eFlow® and eRapid® Nebulizer System technology platform. Risk Factor disclosure verbatim references "the timing and amount of the milestone, royalty or other payments we must make to PARI" and a separate "confidential settlement agreement" royalty obligation (likely a prior-litigation IP settlement). Specific PARI royalty rates and milestone schedules are redacted under confidential treatment in the underlying license exhibit; the qualitative disclosure is the deepest publicly verifiable granularity. The royalty cascade flows only to (1) PARI for the device platform and (2) the unnamed settlement counterparty; the pirfenidone and nintedanib APIs themselves are off-patent and carry no innovator-royalty layer.
Private placement (PIPE): Climb Bio. US$110M with Specialist Healthcare Syndicate (April 28)
On Tuesday April 28, Climb Bio, Inc. (Nasdaq: CLYM) announced the closing of a US$110.0 million private placement (PIPE) under a Securities Purchase Agreement (Form 8-K filed April 28, Item 1.01; SEC Acc# 0001193125-26-183711). Pricing structure: 9,481,000 common shares at US$9.50 per share + 2,106,000 pre-funded warrants at US$9.4999 per pre-funded warrant (PFW exercise price US$0.0001/share). Closing date April 29, 2026. Reg D Rule 506 / 4(a)(2). Lead investor RA Capital Management affiliate with a separate Exchange Agreement establishing a 33.0% ownership cap; other investors capped at 4.99% / 9.99% with an overall 19.99% cap. Lead placement agents: Leerink Partners and Piper Sandler, with Raymond James, BTIG, Baird, and H.C. Wainwright as additional placement agents. Investor list: Adage, ADAR1, Affinity, Ally Bridge, Cormorant, Driehaus, Great Point, RA Capital, Redmile, Sirenia, Woodline. Resale Registration Rights Agreement (Exhibit 10.2) requires Climb to file a Form S-3 no later than 45 days after closing, with reasonable best efforts to declare effective at the earliest possible date and remain effective until full resale or Rule 144 eligibility without volume / manner-of-sale limits; liquidated damages apply for missed deadlines. Use of proceeds, asset-level milestone disclosures, and program-specific royalty obligations were not detailed in the 8-K. No third-party royalty-fund position on Climb Bio programs has been publicly disclosed. Primary source: Climb Bio SEC Form 8-K, April 28, 2026.
Private financings: Vivacta, mbiomics, Lighthouse, Fathom (in addition to Coultreon, covered above)
Vivacta Biotechnology (Shanghai) >US$50M Series A and A+ (April 29)
On Wednesday April 29 (Shanghai), Vivacta Biotechnology (Shanghai) Co., Ltd. (private; spin-off of Grit Biotherapeutics) closed combined Series A and A+ financings totaling more than US$50 million. Co-led by Loyal Valley Capital (Series A) and Decheng Capital (Series A+), with participation from OrbiMed, Hankang Capital, Eisai Innovation Inc., C&D Emerging Industry Equity Investment, and existing shareholders Qiming Venture Partners, Beijing Shunxi, and Apricot Capital. Mr Xie Ronggang from Loyal Valley Capital and a partner from DC Global Ventures joined the Vivacta board upon Series A+ closing. Primary source: Vivacta PR Newswire release, April 29, 2026.
Lead asset: GT801, a next-generation in vivo CAR-T therapy targeting CD19, currently in active Phase 1 clinical development across hematologic malignancies and autoimmune indications (initial human data orally presented at ASH 2025 in December 2025). The platform is built on Grit Biotherapeutics' proprietary CLAMP (Controllable Ligand Attachment Modification and Purification) technology, which enables site-specific antibody conjugation to lipid nanoparticle surfaces with precise ligand density control (CLAMP described in a 2025 Nature Nanotechnology publication). The mechanism uses T-cell-targeted lipid nanoparticles (T-LNPs) encapsulating chemically modified mRNA encoding a CAR gene, designed to reprogram a patient's circulating T cells directly in the body following IV administration, bypassing ex vivo manufacturing.
For a royalty-finance audience, Vivacta's Series A and A+ sit in the same in vivo CAR-T category that Lilly is consolidating via the up-to-US$7B Kelonia Therapeutics acquisition that closed in W17, alongside AstraZeneca's EsoBiotec acquisition (2025) and AbbVie's up-to-US$2.1B Capstan Therapeutics acquisition (2025). The Western-pharma in vivo CAR-T M&A cadence creates a structurally credible exit path for Chinese-originated in vivo CAR-T platforms with positive early-clinical signals; GT801's proximity to additional Phase 1 data and to potential global development partnerships is the medium-term commercial-finance question. No third-party royalty-fund position on GT801 has been publicly disclosed.
mbiomics €30M Series A total / €12M third close (April 28)
On Tuesday April 28, mbiomics (private; European-based microbiome therapeutics) closed the third tranche of its Series A at €12 million, bringing the total Series A to €30 million. Existing investors MIG Fonds and Bayern Kapital participated. Primary source: mbiomics corporate press release, April 28, 2026.
Lighthouse Pharmaceuticals US$12M Series A (April 28)
On Tuesday April 28, Lighthouse Pharmaceuticals (private; US-based) closed a US$12 million Series A led by Double Point Ventures. Lead asset: LHP588, a small molecule targeting P. gingivalis in Alzheimer's disease (Phase 2). The mechanistic thesis follows the gingipain-inhibition hypothesis previously pursued by Cortexyme / Quince Therapeutics' atuzaginstat (COR388) in the GAIN trial, which failed to meet its primary endpoint in 2021 but produced subgroup signal in patients with detectable P. gingivalis DNA. LHP588 represents a structurally differentiated next-generation attempt to validate the periodontal-pathogen-as-driver hypothesis in AD pathogenesis. No third-party royalty-fund position on LHP588 has been publicly disclosed. Primary source: Lighthouse Pharmaceuticals PR Newswire release, April 28, 2026.
Fathom Therapeutics US$47M Series A (April 27)
(Covered in dedicated section above.)
Smaller-ticket structural M&A in window
LakeShore Biopharma amended take-private (April 29)
On Wednesday April 29, LakeShore Biopharma announced an amendment to the merger agreement for its previously-announced going-private transaction. The amended consideration represents approximately US$2.7 million in implied equity (reduced versus the original November 2025 agreement). Buyer group: Oceanpine entities and multiple rollover investors. Distressed micro-cap going-private amendment; advisers not disclosed in the publicly available materials. Primary source: LakeShore Biopharma SEC Form 6-K Exhibit 99.1, April 29, 2026.
Shionogi / Torii Pharmaceutical absorption merger (April 27)
On Monday April 27 (Osaka), Shionogi & Co., Ltd. (TYO: 4507) and Torii Pharmaceutical Co., Ltd. (TYO: 4551) signed an internal absorption merger agreement under which Torii will be merged into Shionogi. Torii is a wholly-owned Shionogi subsidiary; the merger is intra-group, and no external consideration was disclosed. Planned effective date: April 1, 2027. The merger is included in W18 only as an internal corporate-structure event for completeness; it is not an arm's-length transaction and has no royalty-fund counterparty implications. Primary source: Shionogi corporate press release, April 27, 2026.
M&A: IMG Pharma / Matsumoto Pharmaceutical. Japanese OTC Bolt-Up (April 27)
On Monday April 27 (Tokyo), private Japanese specialty operator IMG Pharmaceutical Co., Ltd. signed a definitive agreement to acquire Matsumoto Pharmaceutical Co., Ltd., a 1948-vintage Kansai-region OTC manufacturer with 50+ registered drug approvals across Japanese Class 1, 2, and 3 categories and two Kansai-region production facilities. Financial terms were not disclosed. Primary source: IMG Pharma joint release via PR Newswire APAC, April 27, 2026.
Matsumoto rolls into IMG Medical Group's Kobe Biomedical Innovation Cluster (KBIC) R&D platform, which spans dental-pulp stem cell (DPSC) work, iPSC programs, placenta-derived bioactives, and NAD-related compounds. The transaction has no direct royalty component or Western counterparty exposure, and is included here as one of the additional definitive M&A agreements signed inside the April 26–30 window.
Royalty-collateral regulatory event: AstraZeneca / Saphnelo Pen (anifrolumab-fnia) FDA Approval, SC Self-Administration in SLE. BMS Mid-Teens US Royalty Stream Expanded (April 27)
On Monday April 27 (Cambridge UK), AstraZeneca plc (LSE / Nasdaq: AZN) announced that the U.S. FDA had approved the Saphnelo Pen subcutaneous self-administration formulation of anifrolumab-fnia for the treatment of adult patients with moderate-to-severe systemic lupus erythematosus (SLE) who are receiving standard therapy. The new dosage form is a 120 mg once-weekly subcutaneous autoinjector. Primary source: AstraZeneca media release, April 27, 2026.
The structural significance for a royalty-finance audience is that AstraZeneca pays Bristol Myers Squibb (NYSE: BMY) a mid-teens royalty on US Saphnelo net sales under the legacy Medarex agreement, as updated in 2025. AstraZeneca acquired global rights to Saphnelo through an exclusive license and collaboration agreement with Medarex in 2004; the option for Medarex to co-promote expired on its acquisition by BMS in 2009. The 2025 amendment is itself a structural change worth noting: prior framing had described the obligation as a low-to-mid-teens royalty on sales dependent on geography; the post-2025 framing is specifically mid-teens on US sales. The new SC autoinjector materially expands the addressable population versus the IV-only label that had been on market since the original Saphnelo approval (July 2021), enlarging the BMS royalty stream. The Saphnelo Pen formulation enables home administration in eligible patients, removing the infusion-clinic barrier that has historically constrained SLE-biologic uptake.
| Layer | Counterparty | Term |
|---|---|---|
| Net product sales (US) | AstraZeneca | Recorded by AstraZeneca |
| US royalty to BMS (legacy Medarex, as updated 2025) | BMS (inflow) | Mid-teens percentage of US Saphnelo net sales |
| Self-administration formulation expansion | n/a | Saphnelo Pen approved April 27, 2026 (FDA) |
| Patient base | n/a | More than 40,000 patients treated globally across approved SLE indications and formulations |
TULIP-SC Phase 3 supporting data: 367 adults aged 18–70 with moderate-to-severe SLE, 1:1 randomization (anifrolumab vs placebo) under standard background therapy; pre-specified secondary/exploratory endpoints showed 29.0% DORIS remission and 40.1% LLDAS low-disease-activity rates.
This is a clean illustration of how an FDA label expansion on an existing royalty-bearing asset translates directly into expanded royalty-stream economics to the upstream licensor counterparty, without requiring a new licensing transaction. No third-party royalty-fund position on Saphnelo has been publicly disclosed.
Royalty-collateral regulatory event: Axsome Therapeutics / AUVELITY® (dextromethorphan/bupropion) FDA Approval in Alzheimer's-Disease Agitation. Antecip Bioventures II 3.0% Net-Sales Royalty Crystallized on Second Indication (April 30)
On Thursday April 30 (New York), Axsome Therapeutics, Inc. (Nasdaq: AXSM) announced that the U.S. FDA had approved AUVELITY® (dextromethorphan HBr and bupropion HCl) extended-release tablets for the treatment of agitation associated with dementia due to Alzheimer's disease in adults. The approval, granted on the April 30 PDUFA target action date, is the first non-antipsychotic FDA approval for AD agitation and the second indication for AUVELITY following its original approval in major depressive disorder (MDD) in August 2022. Primary source: FDA press announcement, April 30, 2026.
Deal economics: the Antecip Bioventures II related-party royalty layer
| Term | Detail |
|---|---|
| Marketing authorization holder | Axsome Therapeutics, Inc. (Nasdaq: AXSM) |
| Asset | AUVELITY (AXS-05); dextromethorphan / bupropion fixed-dose ER combination; NMDA antagonist + sigma-1 agonist + CYP2D6 inhibitor |
| Approval date | April 30, 2026 (PDUFA target action date met) |
| Designations | FDA Breakthrough Therapy (June 2020) + Priority Review |
| Pivotal data package | ADVANCE-1, ADVANCE-2, ACCORD-1, ACCORD-2 |
| Upstream licensor | Antecip Bioventures II LLC (Delaware LLC; controlled by Axsome CEO Herriot Tabuteau, MD) |
| Original license date | April 17, 2012; First Amendment August 21, 2015 |
| Royalty rate | 3.0% of net sales of products containing the licensed AXS-05 technology |
| Royalty offset | Up to 50% reduction for required third-party payments |
| Royalty term | Country-by-country until later of (i) last-to-expire valid patent claim in that country or (ii) 10 years from first commercial sale in that country |
| Patent estate | Patent protection extending to at least 2043 (per most recent Axsome filings) |
| Termination provisions | Antecip may terminate for cause; Axsome may terminate for convenience |
| Related-party qualifier | Yes; Antecip is a related-party of Axsome under SEC related-party rules; royalty obligation disclosed in Axsome 10-K and quarterly filings |
| Loan-collateral status | The Antecip license is collateralized under Axsome's outstanding Loan and Security Agreement via the September 25, 2020 Direct Agreement; Antecip has consented to collateral assignment |
Context: AUVELITY commercial trajectory and royalty implications
AUVELITY recorded net product sales of US$96.2M in Q1 2025 (vs US$53.4M Q1 2024, +80% YoY) and US$136.1M in Q3 2025 (+69% YoY, +14% sequential vs Q2 2025). On a 3.0% royalty rate, that 9-month run-rate alone implies an annualized royalty payment of approximately US$10–14M to Antecip Bioventures II for the MDD indication only. The April 30 sNDA approval expands the addressable population by approximately 6–7 million U.S. patients with Alzheimer's-disease-associated agitation, with up to 76% of patients with Alzheimer's disease experiencing agitation symptoms across the disease course. The first disclosed comparator in the indication (Otsuka / Lundbeck Rexulti® brexpiprazole, approved May 2023 for AD agitation) generated approximately US$1.5B in 2025 worldwide sales across all indications; an antipsychotic-alternative AD agitation label is structurally well-positioned for substantial uptake.
Royalty-fund read-through
The AUVELITY approval is one of the cleanest W18 worked examples of a related-party 3% net-sales royalty layer on an internally-controlled commercial CNS franchise. The structural features that matter for royalty-finance diligence are: (1) the conflict-of-interest disclosure, given the licensor-licensee relationship runs through the Axsome CEO; (2) the asymmetric termination rights (Antecip "for cause" only, Axsome "for convenience"); (3) the 50% offset against required third-party payments, which is a soft-cap mechanism rarely seen in arms-length royalty agreements; and (4) the collateral assignment under Axsome's secured debt facility. No third-party royalty-fund position on AUVELITY has been publicly disclosed, and Antecip has not been reported to have monetized or pledged its royalty stream. The structure is a plausible candidate for a future synthetic royalty financing on the Antecip royalty stream if any liquidity event were to be considered, given the near-term commercial growth trajectory and the 2043 patent-estate visibility.
Disclosure gaps
- Specific patent-by-country expiration schedule and relative weight of formulation versus method-of-use claims not in the public domain
- Whether the AD agitation indication carries any incremental milestone payment trigger to Antecip beyond ongoing 3% royalty has not been separately disclosed by Axsome
- The 50% third-party-payment offset is referenced in Axsome filings without enumeration of the relevant third-party payments
M&A: LEO Pharma / Replay Holdings. US$50M Upfront for HSV Gene Therapy Platform; University of Pittsburgh synHSV Upstream License Inherited (April 30)
On Thursday April 30 (Ballerup, Denmark / San Diego), LEO Pharma A/S (privately held; majority-owned by the Lundbeck Foundation) announced a definitive agreement to acquire Replay Holdings, Inc. (private; San Diego / London) and its preclinical herpes simplex virus (HSV) gene therapy platform for US$50 million in cash upfront. Further consideration was not disclosed. The acquisition adds Replay's high-payload synHSV™ delivery vector and the lead preclinical program in dystrophic epidermolysis bullosa (DEB) to LEO's rare-dermatology portfolio, alongside LEO's existing Boehringer Ingelheim Spevigo® partnership and DEBRA Research collaboration in the EB space. Primary source: LEO Pharma corporate press release, April 30, 2026.
Deal structure
| Term | Detail |
|---|---|
| Acquirer | LEO Pharma A/S (private; Lundbeck Foundation majority-owned) |
| Target | Replay Holdings, Inc. (private; San Diego / London) |
| Upfront consideration | US$50M cash |
| Further consideration | Not disclosed |
| Lead program | Preclinical topical-gel HSV gene therapy for dystrophic epidermolysis bullosa (DEB); addresses COL7A1 / type VII collagen deficiency |
| Platform inherited | synHSV™ (engineered HSV-1 delivery vector capable of 8x to 30x AAV payload), uCell (hypoimmunogenic iPSC-derived cell therapy), DropSynth (genome-writing platform) |
| Replay product companies inherited | Telaria (rare skin diseases; lead DEB program), Eudora (retinal diseases), Kaleibe (genetic brain disorders), Syena (oncology) |
| Replay seed financing (July 2022) | US$55M led by KKR (KKR Health Care Strategic Growth Fund II) and OMX Ventures, with ARTIS Ventures, Lansdowne Partners, SALT, Axial, DeciBio Ventures |
| Replay management | CEO Lachlan MacKinnon (Co-Founder); Executive Chairman Adrian Woolfson MD PhD (Co-Founder) |
| Expected close | Not disclosed |
Upstream IP and royalty stack: University of Pittsburgh synHSV exclusive license
The synHSV technology was developed by Professor Joe Glorioso, PhD (Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine; secondary appointment in Department of Human Genetics, University of Pittsburgh Graduate School of Public Health) over a 35-year HSV biology research program. Replay holds an exclusive license from the University of Pittsburgh to the synHSV vector platform; specific terms (royalty rate, milestone schedule, field carve-outs, exclusivity scope) are not in the public domain. Glorioso serves as synHSV Senior Advisor at Replay and is a co-founder of multiple Replay product companies including Telaria (DEB program; the asset of primary interest to LEO) and Eudora (retinal disease program).
| Layer | Licensor | Licensee | Terms |
|---|---|---|---|
| Foundational HSV vector IP | University of Pittsburgh (Glorioso lab) | Replay (now LEO post-close) | Exclusive license; specific royalty/milestone terms not disclosed |
| Replay platform | Replay Holdings (post-close: LEO Pharma) | Telaria, Eudora, Kaleibe, Syena product companies (now wholly owned by LEO) | Sub-licenses within hub-and-spoke structure; specific terms not disclosed |
| Lead asset | Telaria (DEB program; preclinical) | LEO Pharma (post-close) | Wholly owned by LEO post-close |
Read-through
This is the third HSV-platform M&A or platform-validation event in the 2025–2026 cycle, after Krystal Biotech's continued Vyjuvek franchise expansion (the only commercial-stage HSV-vector gene therapy, approved May 2023 for DEB and now expanding into ophthalmology and oncology indications), and Eli Lilly's interest in oncolytic HSV programs through earlier acquisitions. For LEO Pharma, the acquisition is the company's first move into gene therapy and follows the established LEO play of building rare-dermatology depth alongside its prurigo nodularis (Spevigo / spesolimab partnership with Boehringer Ingelheim) and DEB-adjacent programs. The DEB market is increasingly competitive: Krystal Biotech's Vyjuvek (beremagene geperpavec) is on the market, Abeona's prademagene zamikeracel (Zevaskyn) received FDA approval in 2025 as an autologous gene-modified epidermal sheet for RDEB, and Chiesi USA's Filsuvez (birch triterpenes) is approved as a topical gel for partial-thickness wounds in EB.
Royalty-fund read-through
LEO Pharma is privately held and does not disclose royalty-stack pass-through economics in its public filings. No third-party royalty-fund position on the Replay assets has been publicly disclosed. The Pittsburgh upstream license is the only structurally-relevant residual layer for any downstream royalty-finance underwriting. KKR's exit through the LEO acquisition crystallizes a return on the July 2022 seed-stage investment but the magnitude of that return is not disclosed.
Disclosure gaps
- Total deal value (upfront + earn-outs / milestones / contingent consideration) not disclosed
- University of Pittsburgh synHSV license royalty rate, milestone schedule, and field exclusivity terms not in the public domain
- KKR / OMX / ARTIS / Lansdowne return on the original seed financing not disclosed
- Closing date and any associated regulatory clearance schedule not disclosed
- Allocation of the US$50M upfront across the four Replay product companies (Telaria, Eudora, Kaleibe, Syena) not disclosed
Asia in-license: Cue Biopharma / Ascendant Health Sciences. Ascendant-221 Anti-IgE Monoclonal Antibody. US$15M Upfront + Up to US$676.5M Milestones + Tiered Royalties; Concurrent US$30M PIPE (April 30)
On Thursday April 30 (Boston), Cue Biopharma, Inc. (Nasdaq: CUE) announced an exclusive license agreement with Ascendant Health Sciences Ltd. (private; Greater China-based, related to Genesis Life Sciences which is running the Phase 2 China study) to develop, manufacture and commercialize Ascendant-221, a Phase 2 clinical-stage humanized anti-IgE monoclonal antibody for allergic diseases. Cue announced a concurrent US$30M private placement the same day to fund the upfront and clinical advancement. Primary source: Cue Biopharma SEC Form 8-K Exhibit 99.1, April 30, 2026; Cue Biopharma GlobeNewswire release, April 30, 2026.
Deal economics
| Term | Detail |
|---|---|
| Licensor | Ascendant Health Sciences Ltd. (private; related-company Genesis Life Sciences runs the China Phase 2 study) |
| Licensee | Cue Biopharma, Inc. (Nasdaq: CUE) |
| Asset | Ascendant-221 (humanized anti-IgE monoclonal antibody; dual mechanism: neutralizes free IgE plus leverages CD23-mediated IgE downregulation pathway to suppress new IgE synthesis) |
| Territory | Global, excluding mainland China, Hong Kong, Macau, and Taiwan (Greater China retained by Ascendant / Genesis) |
| Upfront | US$15M |
| Development, regulatory and commercial milestones | Up to US$676.5M |
| Total non-royalty consideration | Up to ~US$691.5M aggregate before royalties |
| Royalties | Tiered royalties on net sales (specific rates not disclosed) |
| Concurrent equity financing | US$30M Cue Biopharma PIPE announced same day |
| Phase 1 readout | Suppression of free IgE for >12 weeks with a single dose; favorable safety and tolerability |
| Active Phase 2 trial | China dose-ranging study in chronic spontaneous urticaria (CSU), run by Genesis Life Sciences; placebo and active-comparator-controlled; readout expected 2H 2026 |
| Cue's planned trial | Global Phase 2b in food allergy post-China data |
| Cue corporate context | New CEO Shao-Lee Lin MD PhD (announced April 30); 1-for-30 reverse stock split April 22, 2026; $7.5M preclinical milestone from Boehringer Ingelheim collaboration April 8, 2026 |
Royalty-stack and structural read-through
Ascendant-221 enters a class with material upstream royalty-stack precedent. The current standard-of-care, Novartis Xolair® (omalizumab), originated at Tanox (acquired by Genentech) and carries a long-standing Novartis-to-Genentech royalty layer alongside the Roche / Genentech in-license. The next-generation anti-IgE class, including Genentech's UB-221 and Korean-territory programs from various Asian originators, has shown durable suppression of free IgE for substantially longer than omalizumab through the addition of CD23-mediated downregulation. Ascendant-221's dual mechanism of action (free IgE neutralization plus CD23 pathway downregulation) is the same structural premise that distinguishes the new class from omalizumab.
For Cue Biopharma, the in-license is a strategic transformation: the company was previously a preclinical T-cell-modulator platform (CUE-401 lead asset for autoimmune disease, advancing to IMMUNOLOGY 2026 preclinical disclosure) and is now a clinical-stage company with a Phase 2 anti-IgE asset on a near-term readout cadence (CSU readout 2H 2026; food allergy Phase 2b initiation post-readout).
Royalty-fund read-through
The Ascendant-221 license is a structurally-clean Asia-originated, ex-Greater China license with US$691.5M aggregate biobucks before royalties and tiered royalties on global net sales (rates undisclosed). The pattern of Greater China-only retention by an Asian originator with global ex-Greater China rights to a Western-listed clinical-stage biotech is consistent with the 2023–2026 Asia-out-licensing wave that has placed approximately twenty Phase 2-and-later assets into Western development under similar structures. No third-party royalty-fund position has been publicly disclosed on Ascendant-221; if Cue advances the food-allergy Phase 2b on the disclosed timeline, the asset is a candidate for a future synthetic-royalty financing alongside the parallel CSU readout.
Disclosure gaps
- Tiered royalty rates not disclosed
- Milestone schedule split between development, regulatory, and commercial categories not disclosed
- Cost-sharing and supply terms between Cue and Genesis Life Sciences for the China Phase 2 trial not disclosed
- The Cue Biopharma April 30 PIPE syndicate was not disclosed in the same press release
Sub-license: Kissei / Orient EuroPharma (OEP) for REZLIDHIA® (olutasidenib) in Taiwan. Three-Tier Royalty Cascade Through Rigel and Forma / Novo Nordisk (May 1)
On Friday May 1, Kissei Pharmaceutical Co., Ltd. (TSE: 4547) announced a sub-license to Orient EuroPharma Co., Ltd. (OEP; Taipei-headquartered specialty pharma group with US subsidiary OEP Pharma in San Diego) for the development and commercialization of REZLIDHIA® (olutasidenib) in Taiwan. The sub-license is executed under Kissei's existing September 2024 head license from Rigel Pharmaceuticals for the Japan, Republic of Korea, and Taiwan territory. Specific sub-license financial terms were not disclosed. Primary source: Kissei sub-license disclosure summarised at TipRanks; see also Kissei TSE 4547 IR pages (Japanese-language original to be cross-referenced).
Three-tier upstream royalty cascade
| Tier | Licensor → Licensee | Date / Agreement | Economics |
|---|---|---|---|
| 1 (foundational) | Forma Therapeutics → Rigel Pharmaceuticals (Nasdaq: RIGL) | August 2022; Forma acquired by Novo Nordisk October 14, 2022 for ~US$1.1B | Exclusive worldwide license for development, manufacture, commercialization of olutasidenib; Forma (now Novo Nordisk) entitled to a portion of Rigel's sublicensing revenue plus ongoing royalties on Rigel-derived sales |
| 2 (territory) | Rigel → Kissei | September 2024; collaboration and license agreement | US$10M upfront paid Q3 2024 + up to US$152.5M development, regulatory, and commercial milestones; Rigel receives mid-twenty to lower-thirty percent tiered transfer-price payments based on tiered net sales for exclusive supply of REZLIDHIA in Japan / Korea / Taiwan; Kissei pays Rigel 50% of CDx development costs in Japan up to US$3M creditable against future milestones |
| 3 (sub-territory) | Kissei → Orient EuroPharma (OEP) | May 1, 2026; Taiwan sub-license | Sub-license terms not disclosed; OEP responsible for Taiwan TFDA development, registration, and commercialization activities |
Royalty-stack reconstruction
The economic flow on Taiwan net sales of REZLIDHIA, post Kissei / OEP sub-license, will follow the cascade: OEP records Taiwan net sales → OEP pays Kissei sub-license royalties or transfer-price payments (terms not disclosed) → Kissei pays Rigel a transfer-price payment of mid-20s to low-30s percent of net sales for exclusive supply → Rigel pays Forma / Novo Nordisk a portion of sublicensing-revenue and ongoing royalties under the August 2022 worldwide in-license. The mechanism is a four-party royalty cascade in which the upstream Western originator (Novo Nordisk via the 2022 Forma acquisition) economic interest is preserved through multiple territory-level sub-licensing layers.
REZLIDHIA commercial and clinical context
| Metric | Value |
|---|---|
| FDA approval date | December 1, 2022 |
| Indication | Adult patients with relapsed or refractory acute myeloid leukemia (AML) with susceptible IDH1 mutation as detected by an FDA-approved test (Abbott RealTime IDH1 Assay) |
| Patent estate | Composition-of-matter and method-of-use coverage extending through 2032–2034 base estate |
| Pivotal trial | Study 2102-HEM-101 (NCT02719574); n=147 efficacy-evaluable; CR/CRh rate 35% (95% CI 27–43%); median DoR 25.9 months |
| Final 5-year data | Cortes et al., Journal of Hematology & Oncology, 2025; median CR/CRh duration 25.3 months; median OS 11.5 months |
| 2024 Rigel net product sales | US$23.0M (+118% YoY) |
| 2025 Q3 Rigel REZLIDHIA growth | Continued double-digit growth; specific quarterly figure aggregated within Rigel commercial reporting |
| Japan PMDA filing strategy | Kissei to seek initial approval for R/R mIDH1 AML; PMDA registration trial design under planning |
| Competitor in IDH1 AML | Servier ivosidenib (Tibsovo®): first-in-class IDH1 inhibitor; Servier holds the underlying Agios upstream royalty agreement |
Royalty-fund read-through
This is a clean worked example of an Asia-territory sub-license cascade preserving Western originator royalty economics through multiple sub-licensing tiers. No third-party royalty-fund position has been publicly disclosed on the Rigel REZLIDHIA royalty stream. The structural template is relevant for diligence on (1) territory carve-out integrity through multi-party cascades and (2) the survival of upstream royalty obligations through licensor M&A events (Novo Nordisk's 2022 acquisition of Forma did not disrupt the Rigel-to-Forma royalty obligation but did transfer the licensor identity). Orient EuroPharma is the same Taiwan / Asia distribution partner of choice for several Japanese specialty pharma royalty cascades and is a recurring sub-licensee in this category.
Disclosure gaps
- OEP-to-Kissei sub-license financial terms not disclosed
- Specific Forma / Novo Nordisk royalty rate and sublicensing-revenue split with Rigel not in the public domain
- Taiwan TFDA registration timeline and trial requirements not disclosed
- Whether OEP has rights to other indications beyond R/R mIDH1 AML in Taiwan not specified
Clinical readout: Restore Vision Inc. RV-001 First-in-Human Optogenetic Gene Therapy Interim. All Low-Dose Patients Reached Light Perception in Advanced Retinitis Pigmentosa; High-Dose Patient Reached Berkeley-Measurable Visual Acuity (April 30 / May 1)
On Friday May 1 (Tokyo / Denver), Restore Vision Inc. (private; Tokyo / San Diego; Keio University spin-out; CEO Yusaku Katada, MD, PhD) announced first-in-human Phase 1/2 interim clinical results for RV-001, a novel adeno-associated virus (AAV) gene therapy delivering a "chimeric rhodopsin" optogenetic actuator for advanced retinitis pigmentosa (RP). The interim data were presented at Eyecelerator @ ARVO 2026 and the Retinal Therapeutics Innovation Summit organized by the Foundation Fighting Blindness and the Casey Eye Institute at Oregon Health & Science University, both held in Denver, Colorado on May 1, 2026. Primary source: Restore Vision PR Newswire release, May 1, 2026.
Trial design and headline results
| Metric | Value |
|---|---|
| Trial | Phase 1/2 first-in-human (Japan); conducted at Keio University Hospital |
| Asset | RV-001: AAV-vector-delivered chimeric rhodopsin (GHCR / coGHCR construct; G-protein-coupled mammalian-rhodopsin-derived photopigment) |
| Mechanism | Restoration of light sensitivity in surviving retinal interneurons via intravitreal AAV injection; delivers physiological-grade light amplification through G-protein activation rather than direct ion-channel gating (microbial-opsin class) |
| Patient population | Advanced retinitis pigmentosa, gene-agnostic (any RP genotype), severe vision loss with no- to limited vision at baseline |
| Cohort design | Two ascending dose cohorts (low dose, high dose); n=3 per cohort |
| First patient dosed | February 13, 2025 |
| Interim analysis duration | Out to 168 days post single intravitreal injection |
| Primary endpoint (safety) | No dose-limiting toxicities (DLTs) or drug-related serious adverse events (SAEs) reported in either cohort to date (n=3/cohort) |
| Exploratory efficacy | Low-dose cohort: 100% (3/3) progressed from no light perception (NLP) to light perception (LP) or better within one month post single intravitreal injection; one additional low-dose patient progressed to LP at approximately three months. High-dose cohort: 33.3% (1/3) progressed within one month, with one patient reporting chart-based visual acuity measurable by the Berkeley Rudimentary Vision Test (BRVT), a more advanced functional measurement than LP alone |
| Dose-response | Consistent dose-dependent trends across visual acuity, full-field stimulus testing (FST), and functional vision assessments including mobility and object recognition tasks |
Royalty stack
| Layer | Counterparty | Term |
|---|---|---|
| Asset originator | Keio University (chimeric rhodopsin construct GHCR / coGHCR; published Hayashi et al. 2023, iScience) | Spin-out company Restore Vision holds the rights |
| Lead developer | Restore Vision Inc. (private; Tokyo / San Diego) | Wholly owned at the program level |
| AAV capsid | Standard rAAV serotype (specific serotype / engineered variant not separately disclosed) | No public third-party capsid royalty layer disclosed |
| Royalty fund position | None disclosed | No third-party royalty-fund position publicly disclosed on RV-001 |
No public third-party royalty layer has been disclosed on RV-001. The chimeric rhodopsin IP originated at Keio University and is held by the Restore Vision spin-out; specific Keio-to-Restore Vision license terms (royalty rate, milestone schedule, field exclusivity) are not in the public domain.
Read-through to ophthalmology gene therapy royalty stacks
The chimeric-rhodopsin class is mechanistically differentiated from the established microbial-opsin optogenetic class that includes Bionic Sight's GS-030 (ChrimsonR; Allergan partnership) and RST-001 (channelrhodopsin-2; ClinicalTrials.gov NCT01648452). Microbial opsins require outdoor-light-intensity stimulation and historically have not restored vision in indoor or dim-light settings. The mammalian-rhodopsin-derived chimera in RV-001 leverages G-protein-coupled signal amplification, enabling light sensitivity at lower intensity. Validation of the class supports a broader royalty-stack thesis for the wider ophthalmology gene therapy royalty universe, where the validated commercial template is Roche / Spark Luxturna (RPE65 gene therapy; tiered royalties to upstream collaborators including the University of Pennsylvania), and the late-stage clinical comparators include Adverum Biotechnologies (AAV.7m8 capsid plus aflibercept transgene; Spark and 4DMT-related upstream royalty stacks), 4D Molecular Therapeutics (engineered AAV capsids; multiple ophthalmology programs), and MeiraGTx / Janssen (RPGR-XLRP, achromatopsia, and other RP / IRD gene therapies).
Disclosure gaps
- Specific AAV capsid / serotype not separately disclosed
- Keio University-to-Restore Vision license terms not disclosed
- Restore Vision capital structure and financing history not disclosed
- Phase 1/2 trial primary endpoint, formal statistical analysis plan, and full enrollment target not disclosed in the May 1 update
- Regulatory pathway (Japan PMDA-led vs FDA-led) and registration trial design not disclosed
Clinical readout: Contineum Therapeutics PIPE-791 Phase 1b LPA1 Antagonist Topline Positive in Chronic OA / Low Back Pain. PIPE-791 Wholly Owned; Separate PIPE-307 J&J License Layer (April 30)
On Thursday April 30 (San Diego), Contineum Therapeutics, Inc. (Nasdaq: CTNM) reported positive topline data from its exploratory Phase 1b trial of PIPE-791, a brain-penetrant, oral, once-daily small-molecule selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor, in chronic osteoarthritis pain (COAP) or chronic low back pain (CLBP) at the 10mg dose. Primary source: Contineum IR press release, April 30, 2026.
Trial design and result framing
| Metric | Value |
|---|---|
| Trial design | Exploratory Phase 1b, randomized, double-blind, placebo-controlled, 4-week crossover, multi-center (NCT06810245) |
| Lead indication framing | Chronic OA pain or chronic low back pain (COAP / CLBP), with washout prior to TP1 followed by immediate crossover into TP2 (no washout between treatment periods) |
| Dose | 10mg once-daily oral PIPE-791 |
| Treatment duration | 4 weeks per treatment period (TP1 + TP2 crossover) |
| Enrollment | n=43 enrolled (23 COAP + 20 CLBP) |
| Primary endpoint (safety / tolerability) | Met: AE profile consistent with prior PIPE-791 trials; most TEAEs mild-to-moderate; no SAEs; most common TEAEs headache (n=3) and fatigue (n=2); no clinically meaningful BP changes or orthostatic events |
| Exploratory PI-NRS efficacy (TP1 weekly average daily PI-NRS, change from baseline, 95% CI) | COAP arm: PIPE-791 -1.60 (-2.49, -0.72) vs placebo -1.27 (-2.15, -0.39). CLBP arm: PIPE-791 -1.33 (-1.83, -0.84) vs placebo -0.55 (-1.33, 0.22). Cleaner drug-vs-placebo separation in CLBP than in COAP at TP1 |
| Additional exploratory endpoints | 30%+ PI-NRS responder rate; Modified KOOS; functional patient-reported outcomes; reported as supportive of PI-NRS findings |
| First patient dosed | Q1 2025 |
| Topline announcement | April 30, 2026 |
Asset construction and royalty stack
| Asset | Mechanism | Status | IP / royalty layer |
|---|---|---|---|
| PIPE-791 | Brain-penetrant LPA1 receptor antagonist | Phase 1b chronic pain readout (Apr 30); Phase 2 PROPEL-IPF trial in IPF (lead indication) ongoing | Wholly owned by Contineum; no upstream third-party royalty obligation publicly disclosed |
| PIPE-307 (separate program) | M1 muscarinic receptor selective antagonist | Phase 2 VISTA trial in RRMS failed primary endpoint November 2025; J&J retains discretion to advance for MDD | Licensed worldwide to Janssen Pharmaceutica NV (Johnson & Johnson): US$50M upfront + US$25M equity (June 2023) + >US$1B in milestones + low-to-high teens royalty on net sales |
| CTX-343 | Peripherally-restricted LPA1 antagonist | Discovery / preclinical | Wholly owned; deferred until further funding |
Read-through to the 2026 non-opioid pain royalty stack
The PIPE-791 readout sits inside the broader 2026 non-opioid pain royalty-stack rebuild that has been catalyzed by Vertex Pharmaceuticals' Journavx (suzetrigine; NaV1.8 inhibitor) FDA approval in January 2025. Adjacent active programs in the same broad analgesia bucket include Eli Lilly's CCR1 / EP4 collaboration history, Pfizer's SI-449 EP4 antagonist, and inside W18 the Keythera Pharmaceuticals KF-0210 oral EP4 antagonist Phase 2a osteoarthritis readout with 86.7% reduction in WOMAC pain scores (April 27).
PIPE-791's lead indication is idiopathic pulmonary fibrosis (IPF), where the validated comparator is Bristol Myers Squibb's zimilparant (Phase 3 readout expected Q4 2026; itself originated at Roche / Genentech with a separate upstream royalty stack inherited through the historical Roivant / Galapagos / Genentech licensing structure on the LPA1 class). Contineum management has emphasized that PIPE-791 achieves ~90% receptor occupancy at doses as low as 1mg daily and is once-daily versus the BMS dose-titration strategy in Phase 3.
Royalty-fund read-through
PIPE-791 is wholly owned by Contineum with no upstream royalty obligation. If Contineum advances PIPE-791 into a registrational Phase 3 in IPF or further develops the chronic pain program toward Phase 3, the wholly-owned ownership construct positions PIPE-791 as a candidate for synthetic royalty financing on the future net product sales rather than for upstream royalty monetization. No third-party royalty-fund position has been publicly disclosed on PIPE-791.
The separate PIPE-307 J&J license is the more structurally relevant downstream royalty layer at Contineum and remains in motion despite the November 2025 RRMS Phase 2 failure: Janssen retains discretion to advance PIPE-307 in MDD, and the underlying low-to-high teens royalty on net sales structure remains intact.
Disclosure gaps
- TP2 efficacy data showed wash-out / carryover artifact for COAP (PIPE-791 -1.42 vs placebo -0.74) but inconclusive for CLBP (PIPE-791 +0.13 vs placebo -0.55); Contineum did not provide pooled-period statistics in the April 30 release
- Specific 30% PI-NRS responder-rate breakdown by arm and indication not disclosed in numeric form
- IPF Phase 2 PROPEL trial topline timing not disclosed in the April 30 release
- Regulatory path for a chronic-pain registration program not specified
- Whether J&J intends to formally exercise the MDD development option on PIPE-307 has not been publicly confirmed post the November 2025 RRMS data
PRV monetization: Rocket Pharmaceuticals. US$180M Cash Sale of KRESLADI Rare Pediatric Disease Priority Review Voucher (April 26 / 28)
On Sunday April 26 (Cranbury NJ), Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) signed an asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to an undisclosed buyer for US$180 million in cash at closing, subject to HSR clearance. The transaction was publicly announced via 8-K filing on Tuesday April 28. The PRV was awarded to Rocket on the December 2024 FDA approval of KRESLADI® (marnetegragene autotemcel), an autologous lentiviral haematopoietic stem cell gene therapy for severe leukocyte adhesion deficiency type I (LAD-I) in paediatric patients. Primary source: Rocket Pharmaceuticals SEC Form 8-K Exhibit 99.1, April 28, 2026.
| Term | Detail |
|---|---|
| Seller | Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) |
| Buyer | Undisclosed |
| Asset | Rare Pediatric Disease Priority Review Voucher |
| Origin of voucher | Awarded with KRESLADI FDA approval (Dec 2024); pediatric severe LAD-I |
| Cash consideration | US$180 million at closing |
| Closing condition | HSR clearance |
| Use of proceeds | Cash runway extension; non-dilutive funding for cardiovascular gene therapy programs (Danon disease RP-A501; PKP2-ACM RP-A601; BAG3-DCM RP-A701) |
| Cash runway impact | Extended into 2028 per Rocket guidance |
| Royalty obligations on PRV | None disclosed |
The Rocket transaction is the only standalone PRV monetization inside the W18 window and one of the cleaner non-dilutive funding mechanisms available to clinical-stage gene-therapy companies. PRV market clearing prices have ranged in the US$100M to US$200M+ band over recent quarters; the Rocket US$180M consideration sits in the upper-middle of that distribution and reflects (a) the durable scarcity of rare-paediatric-disease vouchers post the December 2024 sunset of new voucher awards, and (b) Rocket's status as a credible counterparty inside the rare-paediatric-disease category.
IPOs priced: Hemab Therapeutics US$301.5M + Seaport Therapeutics US$254.9M. Combined US$556.4M; Both Priced at $18.00; May 1 Trading Debut (April 30)
On Thursday April 30 evening, both Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG) and Seaport Therapeutics, Inc. (Nasdaq, ticker not disclosed at the announcement) priced their initial public offerings simultaneously at US$18.00 per share, surpassing their original price ranges. Combined gross proceeds: approximately US$556.4 million. Both stocks began trading on the Nasdaq Global Select Market on Friday May 1, 2026. Primary sources: Hemab IR pricing release, April 30, 2026; Seaport BusinessWire pricing release, April 30, 2026.
| Issuer | Pricing date | Shares | Price | Gross proceeds | Underwriters' option | Lead bookrunners | Trading start | Asset focus |
|---|---|---|---|---|---|---|---|---|
| Hemab Therapeutics (COAG) | Apr 30 evening | 16,750,000 (upsized 27% from original 11.76M) | US$18.00 | ~US$301.5M | +2,512,500 share option (30 days) | Goldman Sachs, Jefferies, Evercore ISI; Wedbush PacGrow lead manager | Fri May 1 | Sutacimig (HMB-001) bispecific antibody for Glanzmann thrombasthenia + Factor VII deficiency (Phase 3 Glanzmann initiating 2026); HMB-002 monovalent antibody for von Willebrand Disease |
| Seaport Therapeutics | Apr 30 evening | ~14.16M | US$18.00 | ~US$254.9M | n/a | n/a (PureTech-spinout positioning as Karuna successor) | Fri May 1 | Two assets in clinical testing for major depressive disorder + generalized anxiety disorder; built on the Glyph first-pass-protection oral-bioavailability platform; first neuro-focused biotech IPO of 2026 |
Hemab's pre-IPO venture syndicate included Sofinnova, RA Capital Management, and Novo Holdings, alongside the Novo Nordisk Foundation as a strategic anchor. Seaport is a PureTech Health spinout structurally positioned as the successor to Karuna Therapeutics (the BMS-acquired KarXT manufacturer); founder Steve Paul previously served as Sage Therapeutics CEO.
The combined US$556.4M from Hemab + Seaport, on top of Avalyn Pharma's US$345M (closed May 1), takes the W18 IPO total to approximately US$901M across three issuers, all pricing at exactly US$18.00 per share, the cleanest 2026 IPO-window data point on biotech-issuer pricing convergence at the upper end of disclosed price ranges. Year-to-date 2026 biotech IPO activity now stands at approximately ten issuers raising ~US$3.2B; six of those have secured at least US$300M, an uncommon density of US$300M+ IPOs since the pandemic-era peak.
Neither Hemab nor Seaport has disclosed a third-party royalty-fund position on its lead asset. The Glyph platform underlying Seaport's pipeline carries internal IP estate originating at Sage Therapeutics (Paul founder lineage) with Third Rock Ventures as founding investor.
M&A close: Gilead / Arcellx Tender Offer Expired April 27; Merger Closes April 28 (originally announced February 23, 2026)
The Gilead Sciences, Inc. (Nasdaq: GILD) tender offer for Arcellx, Inc. (Nasdaq: ACLX) expired on Monday April 27 at 5:00 pm ET, with the merger closing on Tuesday April 28. The transaction was originally announced February 23, 2026 at approximately US$7.8B implied equity value (all-cash). The closing collapses the prior anito-cel co-development / co-commercialization economics into full Gilead ownership; the asset's US PDUFA action date is expected in December 2026. Primary source: Gilead Sciences IR press release, April 28, 2026.
This is a closing event rather than a new W18 announcement, but is flagged here for completeness because the closing falls inside the W18 window and meaningfully alters the listed-issuer set: ACLX delists, and the iMMagine-1 / iMMagine-3 anito-cel BCMA CAR-T data set rolls into Gilead's Kite Pharma franchise (alongside the prior Yescarta and Tecartus assets).
Royalty trigger: Immutep FDA Orphan Drug Designation. Eftilagimod Alfa in Soft Tissue Sarcoma (April 27)
On Monday April 27, Immutep Limited (ASX: IMM; Nasdaq: IMMP) announced that the U.S. FDA had granted Orphan Drug Designation to eftilagimod alfa (efti) in soft tissue sarcoma. Efti is in Phase 2 EFTISARC-NEO development as part of a triplet combination with pembrolizumab and radiotherapy. Primary source: Immutep ASX announcement / corporate press release, April 27, 2026.
This is a designation event on a Phase 2 asset under collaboration with Merck (pembrolizumab supply); no new royalty-fund position has been disclosed at the announcement. Inclusion in W18 reflects the structural pattern of layered Orphan Drug Designations on existing collaboration-stage assets across the five-day window (alongside OSE / Veloxis pegrizeprument, covered above).
Smaller-ticket structural events in window
A short consolidation of three additional W18 transactions and disclosures that have meaningful structural reads but do not warrant standalone sections:
Avalo Therapeutics / AlmataBio milestone restructuring (April 28)
Avalo Therapeutics, Inc. (Nasdaq: AVTX) entered into a milestone restructuring agreement with the former AlmataBio shareholders. Avalo paid US$2.25M for a 90-day option to settle a previously-contracted US$15M Phase 3 first-patient-dosing milestone for an additional US$5.125M (cash, AVTX stock, or mix), capping potential consideration at US$7.375M versus the US$15M baseline. The lead asset, abdakibart (AVTX-009), is in Phase 2 LOTUS in hidradenitis suppurativa and carries an upstream Lilly license (up to US$70M development, up to US$650M sales milestones, 5–15% royalties), plus a Leap Therapeutics agreement (up to US$70M sales milestones). The April 28 restructuring is a refinement of contingent consideration on a prior 2024 acquisition and is reportable for completeness. Primary source: Avalo SEC Form 8-K Exhibit 99.1, April 28, 2026.
EvolveImmune Therapeutics achieves US$18M preclinical milestone from AbbVie (April 28)
EvolveImmune Therapeutics, Inc. (private) announced a US$18M preclinical milestone payment from AbbVie under the October 2024 EVOLVE platform option-to-license collaboration. The milestone was triggered on nomination of a development candidate (multi-specific T-cell engager, solid tumor). Execution under a prior deal, not a new transaction, but a clean datapoint for milestone-flow analysis; EVOLVE-style platform collaborations are increasingly common in 2025–2026 dealmaking and the per-milestone disclosure is unusually clean. Primary source: EvolveImmune GlobeNewswire release, April 28, 2026.
Arcera Life Sciences / Fosun Pharma non-binding strategic collaboration MoU (April 28)
Arcera Life Sciences (Abu Dhabi; established by sovereign investor ADQ) and Shanghai Fosun Pharmaceutical Group Co., Ltd. (SSE: 600196; HKEX: 02196) signed a non-binding memorandum of understanding (MoU) contemplating three future workstreams: (i) regional and global out-licensing of Fosun assets to Arcera with UAE / Middle East focus; (ii) incubation of frontier modalities (small molecules, biologics, radiopharmaceuticals, siRNA, cell and gene therapy); (iii) a strategic neuroscience collaboration including Alzheimer's disease.
No financial terms are disclosed. No upfront, no milestone schedule, no royalty rate, no equity component, and no specific compound named. Therapeutic-area scope covers oncology, neuroscience, rare diseases, and cardiometabolic disease, drawing from Fosun assets in advanced clinical development or commercial stages in China. No upstream third-party royalty obligations are mentioned, consistent with the non-binding nature. No SEC 8-K (neither party is SEC-registered); no separate HKEX filing identified, consistent with non-binding status. Inclusion in W18 reflects the framework character of the announcement, not a definitive transaction; a future conversion to a binding transaction would be reportable as a new W-numbered event.
Additional in-window licensing collaborations and transactions (brief items)
The following additional W18 disclosures complete the in-window transaction inventory but do not warrant standalone deep-dive sections at this stage given the absence of disclosed economics or the early-stage nature of the underlying assets:
- Sanofi CEO transition (April 29, effective May 1, 2026): Following the proposal of the Appointments Committee, Belén Garijo was formally appointed as Director and Chief Executive Officer of Sanofi (Euronext: SAN; Nasdaq: SNY) at the Group's Annual General Meeting held in Paris on April 29, 2026, under the chairmanship of Frédéric Oudéa. Shareholders approved all resolutions including the articles amendment raising the CEO appointment age limit. Garijo formally assumes the role on May 1, 2026, succeeding Paul Hudson (who left February 17, 2026 after a six-year tenure) and interim CEO Olivier Charmeil (EVP General Medicines). Garijo joins from Merck KGaA, where she served as Chair and CEO for five years leading a profound transformation of the Healthcare business including portfolio repositioning, R&D reorganisation, and commercial-model realignment. She previously served as Senior Vice President of Global Operations Europe at Sanofi-Aventis, where she led the integration of Genzyme following its acquisition; she is a physician by training, specialising in clinical pharmacology. Royalty-fund significance: Sanofi is a top-five royalty-counterparty for the listed-royalty-vehicle universe through (i) the Beyfortus / AstraZeneca alliance (US$91M Q1 2026 AZ Alliance Revenue; covered above), (ii) the Sarclisa anti-CD38 myeloma franchise (legacy ImmunoGen / AbbVie ADC dynamics on the maytansinoid linker), (iii) the Pompe / Genzyme franchise (Nexviazyme / Lumizyme), (iv) the Regeneron Dupixent profit-share (Sanofi's largest single revenue contributor), and (v) Sanofi's vaccine alliance and licensee portfolio across Sarepta, Daiichi Sankyo, Innate Pharma, and others. Garijo's prior Merck KGaA tenure also intersects the Pfizer Bavencio collaboration, the GSK / Hengrui Chinese-asset wave, and the Monte Rosa molecular glue partnership, making her a particularly well-positioned counterparty across the European pharma BD ecosystem. The transition is structurally significant for medium-term royalty-fund modelling of Sanofi licensee income streams and strategic-portfolio cadence.
- Remepy / Merck KGaA strategic R&D collaboration (April 28): collaboration to develop hybrid drug candidates combining Merck KGaA pharmacological assets with Remepy's digital intervention platform. Financial terms not disclosed. Structurally novel in that the collaboration explicitly combines a small-molecule/biologic asset with a digital therapeutic intervention as a single integrated treatment package; for a royalty-finance audience, the precedent matters because future monetisation of "hybrid drug" royalty streams may require specialised contractual architecture distinguishing pharmacological-component royalty bases from digital-component license fees.
- Teikoku Seiyaku / Curedisc license agreement (April 27): license for KTP-001, a recombinant human matrix metalloproteinase-7 therapeutic protein in development for lumbar disc herniation. Financial terms not disclosed. Strategic R&D collaboration alongside the license. Niche musculoskeletal indication; no disclosed third-party royalty-fund position.
- HK inno.N / Atomatrix R&D collaboration (April 27): collaboration to develop small-molecule non-incretin obesity treatments. Financial terms not disclosed. Structurally relevant as a Korean-Taiwan collaboration on a non-GLP-1 obesity mechanism in a category dominated by GLP-1 / GIP / glucagon agonists; the non-incretin angle is differentiated against the Lilly / Novo Nordisk / Zealand / Boehringer / Hengrui / Innovent incretin-class crowding.
- Ascendo Biotechnology Series A (April 30): financing for ASD141, a monoclonal antibody for advanced solid tumors (Phase 1; "innate immune checkpoint" mechanism). Financing size and syndicate composition not fully disclosed in publicly available materials.
Additional in-window regulatory designations
The following W18 regulatory-designation events round out the regulatory side of the W18 inventory; each touches an asset with potential downstream royalty-fund relevance:
- PRX004 / coramitug FDA Fast Track designation (April 27): Fast Track for the anti-misfolded-transthyretin amyloid-depleter monoclonal antibody coramitug (formerly PRX004; Novo Nordisk asset code NNC6019) in ATTR amyloidosis with cardiomyopathy (Phase 3 CLEOPATTRA, NCT07207811, initiated 2025). Structurally relevant for the broader W18 ATTR theme alongside the Pfizer Vyndamax ANDA settlements (April 28) and the BridgeBio Attruby franchise context. The asset originated at Prothena Corporation plc (Nasdaq: PRTA); Novo Nordisk acquired Prothena's wholly-owned ATTR amyloidosis subsidiary in July 2021 including full worldwide IP rights. Under the acquisition agreement, Prothena is eligible to receive up to US$1.2 billion in development, regulatory, and sales milestones, of which US$150 million has been earned to date (US$100M upfront/near-term clinical including the November 2022 US$40M Phase 2 advancement milestone, plus the Phase 3 advancement milestone earned in 2025). The Fast Track designation may trigger a further contractual milestone payment under the acquisition agreement, although the specific milestone schedule is not in the public domain. Coramitug targets an orthogonal amyloid-depletion mechanism rather than the stabilisation mechanism of tafamidis and acoramidis. Approval would create a meaningful new ATTR-CM franchise tail and a corresponding meaningful incremental milestone stream to Prothena.
- TERN-701 FDA Breakthrough Therapy designation (April 27): Breakthrough Therapy for the oral allosteric BCR::ABL1 inhibitor TERN-701 (Hansoh asset code HS-10382) in Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) (Phase 1/2 CARDINAL). The Breakthrough designation lands inside the W18 window while the Merck (NYSE: MRK) tender offer to acquire Terns Pharmaceuticals (Nasdaq: TERN) at US$53.00 per share / approximately US$6.7B equity value (definitive agreement March 25, 2026; tender offer commenced April 7, 2026; expires May 4, 2026, two business days after W18 close) is in flight. Merck will account for the transaction as an asset acquisition with an approximate US$5.8 billion charge (~US$2.35 per share) in Q2 and FY2026 GAAP and non-GAAP results. For royalty-finance purposes, the most relevant structural feature is the July 2020 Hansoh / Terns Greater China sublicense agreement: Terns out-licensed development and commercialisation rights for TERN-701 in mainland China, Taiwan, Hong Kong, and Macau to Hansoh Pharmaceutical Group (HKEX: 3692) for upfront payment + up to US$68 million development, regulatory, and commercial milestones + royalties on future product sales. Merck inherits the Greater China sublicense royalty stream from Hansoh as part of the asset acquisition; CARDINAL global Phase 1/2 dose-expansion data have shown 75% MMR (18/24) by 24 weeks at >320mg QD and 36% DMR (10/28). The structural read-through: Merck pays US$5.8B for the global asset on top of which Hansoh retains exclusive Greater China commercialisation with milestones-and-royalties flowing back to Merck.
- SGT-003 EC Orphan Drug Designation (April 28): EC ODD for the AAV-based microdystrophin gene therapy SGT-003 for Duchenne muscular dystrophy (DMD) (Phase 1/2 INSPIRE DUCHENNE, NCT06138639, n=43 target, dosed 33 of n=43 as of January 2026). Asset is in development at Solid Biosciences (Nasdaq: SLDB); the program uses Solid's proprietary AAV-SLB101 (now also called POLARIS-101) next-generation capsid (rationally designed to target integrin receptors with enhanced cardiac and skeletal muscle transduction and decreased liver targeting), and a microdystrophin construct that includes the R16/17 nNOS-binding domain that distinguishes it from earlier-generation microdystrophin gene therapies. Existing regulatory designations: FDA Fast Track + Orphan Drug + Rare Pediatric Disease + UK ILAP. Initial 90-day biopsy data showed 110% microdystrophin expression by Western blot (108% by mass spectrometry; 78% dystrophin-positive fibres by IF) in the first three patients, with no serious adverse events. Solid Biosciences is the worldwide proprietor of the AAV-SLB101 capsid and the microdystrophin construct; no third-party upstream royalty obligation has been publicly disclosed. Structural read-through to the broader DMD landscape that includes the W18-coverage Santhera vamorolone CHMP positive opinion (April 27) and the existing Sarepta Elevidys (delandistrogene moxeparvovec) franchise.
- Orca Bio Orca-Q FDA RMAT designation (April 28): Regenerative Medicine Advanced Therapy designation for the second-generation allogeneic T-cell immunotherapy Orca-Q (Phase 1) in high-risk haematologic malignancies including patients receiving haploidentical donors. Orca Bio's lead asset Orca-T has previously received RMAT + Orphan Drug Designation; the Orca-T BLA is currently under FDA Priority Review with the PDUFA target action date extended from April 6, 2026 to July 6, 2026. Both assets are Orca Bio internal programs; no third-party upstream royalty obligation has been publicly disclosed on either Orca-T or Orca-Q. The RMAT designation supports accelerated development discussions with FDA and is the cleanest regulatory de-risking event for cell-therapy assets short of approval; for a royalty-finance audience, the Orca-T BLA July 6, 2026 PDUFA is the next gating regulatory event and could drive a future synthetic-royalty financing on the Orca-T launch trajectory.
- ALK201 FDA Orphan Drug Designation (April 30): ODD for the FGFR2b-targeted antibody-drug conjugate ALK201 for gastric cancer (Phase 1/2). Asset is in development at Shanghai Allink Biotherapeutics Co., Ltd. (AllinkBio), a privately-held Chinese biotech; the program uses AllinkBio's proprietary hydrophilic linker and rationally selected payload. No third-party upstream royalty obligation has been publicly disclosed. FGFR2b is a validated GC target with ~20-30% prevalence in advanced G/GEJ; the validated comparator is Amgen's bemarituzumab (Phase 3 FORTITUDE programme); ALK201 is the second meaningfully-advanced FGFR2b-targeted asset in late-stage clinical development.
- Keythera KF-0210 Phase 2a osteoarthritis readout (April 27): Korean / regional company Keythera Pharmaceuticals reported that the oral EP4 receptor antagonist KF-0210 reduced WOMAC pain scores by 86.7% in a Phase 2a knee osteoarthritis study. The EP4 mechanism is positioned as a non-opioid analgesic alternative; for a royalty-finance audience, the W18 KF-0210 readout sits adjacent to the broader Eli Lilly EP4 / Pain royalty stack following Lilly's CCR1 / EP4 collaboration history and the ongoing Pfizer / SI-449 EP4 antagonist clinical programme. Disclosure thin on trial design, n, and statistical analysis at the W18 announcement.
Royalty trigger: OSE Immunotherapeutics FDA Orphan Drug Designation. Pegrizeprument under Veloxis Worldwide License (April 27)
On Monday April 27, OSE Immunotherapeutics SA (Euronext Paris: OSE) announced that the U.S. FDA had granted Orphan Drug Designation to pegrizeprument (VEL-101) for the prevention of organ rejection in heart transplantation. Pegrizeprument is an Fc-silent humanized monoclonal antibody antagonist of the CD28 costimulation pathway, in late-stage clinical development for kidney, heart, and other solid-organ transplantation. Primary source: OSE Immunotherapeutics corporate press release, April 27, 2026.
The structural significance for a royalty-finance audience is that pegrizeprument is licensed worldwide to Veloxis Pharmaceuticals A/S (a wholly-owned subsidiary of Asahi Kasei Pharma) under an April 2021 exclusive worldwide development and commercialization agreement covering all transplant indications. OSE retains a milestone-and-royalty-bearing inbound stream from Veloxis. Whether the Orphan Drug Designation itself triggers a contractual milestone payment under the OSE / Veloxis agreement, and the corresponding milestone amount, has not been publicly disclosed.
In structural terms, this is an existing royalty-bearing license on a late-stage clinical asset receiving an FDA designation that may, depending on the specific terms of the 2021 OSE / Veloxis agreement, trigger contractual milestone economics to OSE. The detailed milestone schedule and royalty-rate band have not been re-disclosed at the OSE / Veloxis layer.
Royalty-license dispute crystallization: GSK / TESARO vs AnaptysBio Jemperli. Delaware Chancery dismisses TESARO's anticipatory breach claim. Reversion trial set July 14–17, 2026. Sagard US$300M monetization exposed (April 24 / 27)
On Friday April 24, the Delaware Chancery Court granted AnaptysBio's motion to dismiss TESARO's anticipatory breach of contract claim (court order, CourtListener). GSK confirmed the ruling via a TESARO press release on Monday April 27, placing the procedural update inside the W18 window. The court ruled that AnaptysBio's October 2025 letter did not constitute repudiation of the March 2014 Collaboration and Exclusive License Agreement governing dostarlimab (Jemperli). The dismissal does not address the merits of the principal contractual dispute. TESARO's separate declaratory judgment claim and AnaptysBio's countersuit (alleging material breach by TESARO and tortious interference by GSK) both remain pending. Trial is scheduled for July 14–17, 2026 in Delaware Chancery Court.
For a royalty-finance audience this is the second listed-royalty-vehicle dispute of W18 alongside the Ligand / XOMA TREMFYA litigation CVR, and the more consequential of the two on a present-value basis. Sagard Healthcare Royalty Partners carries US$300M of deployed capital across two tranches against AnaptysBio's GSK royalty entitlement. Jemperli crossed the US$1B annual net-sales threshold in 2025 (£861M / ~US$1.128B; +89% YoY); GSK most recently guided to >£2B in monotherapy peak sales.
Royalty stack reconstruction: Jemperli upstream layer
| Date | Event | Royalty / consideration impact |
|---|---|---|
| March 2014 | AnaptysBio licenses dostarlimab plus cobolimab (TIM-3, GSK4069889) and GSK4074386 (LAG-3) to TESARO | Tiered low-to-high single-digit (4–8%) royalty; up to US$1.1B aggregate cash milestone potential across the three programs |
| 2019 | TESARO acquired by GSK (US$5.1B) | License obligations assumed by GSK group |
| August 2020 | AnaptysBio sues TESARO for breach (Zejula / competitor-PD-1 trial designs) | Initiates the predecessor dispute |
| October 23, 2020 | Confidential Settlement and Modification Agreement (8-K, Oct 2020) (agreement text) | US$60M one-time cash + 1% royalty on global Zejula net sales (effective Jan 1, 2021) + Jemperli royalty step-up to 8% (<US$1B) / 12% (US$1B–1.5B) / 20% (US$1.5B–2B) / 25% (>US$2.5B) + additional US$165M sales milestones |
| Q4 2025 | Jemperli annual net sales cross US$1B | First sale-tier crossover; AnaptysBio retains a US$75M one-time milestone outside the Sagard agreement |
| November 20, 2025 | TESARO initiates litigation alleging AnaptysBio repudiation; AnaptysBio simultaneously files Verified Complaint (8-K Nov 26, public version; redacted complaint text) | Predecessor dispute reopened in Delaware Chancery |
| April 24, 2026 | TESARO anticipatory breach claim dismissed; declaratory judgment claim survives | Royalty rates preserved; trial set July 14–17, 2026 |
| Royalty term | Through composition-of-matter expiration | 2035 (US) / 2036 (EU), country-by-country |
Sagard monetization stack
| Tranche | Date | Sagard upfront | Royalty interest | Cap |
|---|---|---|---|---|
| Original | October 25, 2021 | US$250M | 8% royalty on global net sales below US$1B + US$15M regulatory milestones + up to US$90M commercial milestones below US$1B | US$312.5M (125%) by YE 2026 / US$337.5M (135%) during 2027 / US$412.5M (165%) thereafter |
| Amendment No. 1 | May 9, 2024 | US$50M | All Jemperli sales above US$1B added (12% / 20% / 25% tiers); 8% below-US$1B tier unchanged | US$600M by March 31, 2031 / US$675M thereafter |
| Total deployed | 2021 + 2024 | US$300M | Combined royalty interest spans all sales tiers | US$600M / US$675M cap |
Per AnaptysBio disclosure, approximately US$250M had accrued to Sagard through year-end 2025, with full paydown of the US$600M cap anticipated Q2 2027 to Q2 2028 assuming ~10% QoQ Jemperli growth and modest dMMR rectal regulatory milestones in the EU.
The dispute: claims, counterclaims, and remedies
| Party | Claim | Underlying allegation | Remedy sought |
|---|---|---|---|
| AnaptysBio (countersuit, Verified Complaint Nov 26, 2025) | Material breach of exclusivity duty | GSK's multi-billion-dollar ADC programs paired clinically with Keytruda and other competitor PD-1s rather than with dostarlimab; I-SPY trial ongoing at 2020 settlement undisclosed by TESARO | Full reversion of dostarlimab rights to AnaptysBio within 60 days of notice of breach |
| AnaptysBio | Material breach of diligence duty | GSK has not sought Jemperli's contractually required "optimum commercial return" relative to its ADC + Keytruda effort | Reversion (any one breach upheld triggers reversion) |
| AnaptysBio | Material breach of notice duties | TESARO failed to disclose clinical trial plans involving competitive therapeutics paired with dostarlimab | Reversion |
| AnaptysBio (against GSK directly) | Tortious interference with the Collaboration Agreement | GSK induced TESARO breaches | Damages |
| TESARO / GSK (initial complaint Nov 20, 2025; anticipatory breach dismissed Apr 24, 2026; declaratory judgment claim pending) | Anticipatory breach + declaratory judgment | AnaptysBio repudiated the Collaboration Agreement | Termination of agreement, perpetual license to TESARO, ~50% reduction in royalty and milestone payments to AnaptysBio |
Milestone and royalty payments to AnaptysBio continue during the proceedings.
Royalty-fund and structural read-throughs
| Scenario | Sagard | ANAB | GSK |
|---|---|---|---|
| Base case (status quo) | Cap recovery on schedule; US$600M / US$300M = 2.0x MOIC over ~6.5 years deployed | Full upper-tier accrual post-cap; >US$390M peak annual royalty at ~US$2.7B Jemperli peak | Full retention; oncology growth narrative intact |
| TESARO prevails on royalty reduction | Per-period accrual reduced ~50%; cap timeline materially extended | Loss of upper-tier exposure | Margin expansion of US$300M+ annually post-2027 |
| AnaptysBio prevails on reversion | Subject matter reverts; recoverability of receivable subject to restatement; legal questions on date-of-reversion accruals | Regains 100% of Jemperli economics globally | Complete loss of Jemperli: ~£861M annualized 2025 revenue plus contingent peak guidance |
The Sagard US$300M deployment is the single most exposed listed royalty-fund position to a near-term binary trial event in the current public market, and the cleanest worked example in W18 of how an upstream-licensor reversion clause can re-frame the recoverability of an already-monetized royalty stream.
Disclosure gaps
- The 2014 Collaboration Agreement, 2020 Settlement and Modification Agreement, and 2024 Sagard Amendment No. 1 remain redacted in their as-filed SEC versions.
- Contractual treatment of accrued-but-unpaid royalties to Sagard in a reversion scenario has not been disclosed.
- Specific identity of the GSK ADC programs alleged to be the exclusivity breach is partially redacted in the public Verified Complaint.
- GSK Q1 2026 earnings release on April 29, 2026 is the next disclosed catalyst with potential litigation-position commentary; AnaptysBio Q1 2026 earnings timing is the second.
Royalty-collateral regulatory event: Jazz Pharmaceuticals / Ziihera (zanidatamab) FDA sBLA Priority Review. PDUFA August 25, 2026. Royalty Pharma March 2026 Royalty-Backed Note Materially De-Risked (April 27)
On Monday April 27 (Dublin), Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced that the U.S. FDA has accepted for filing with Priority Review the supplemental Biologics License Application (sBLA) for Ziihera® (zanidatamab-hrii) in combination regimens for the first-line treatment of adult patients with HER2-positive (HER2+) unresectable locally advanced or metastatic gastric, gastroesophageal junction (GEJ), or gastroesophageal adenocarcinoma (GEA). The FDA has set a PDUFA target action date of August 25, 2026. Primary source: Jazz Pharmaceuticals investor relations release, April 27, 2026.
The sBLA is supported by data from the pivotal HERIZON-GEA-01 Phase 3 trial (NCT05152147, n=914 across approximately 300 sites in more than 30 countries), conducted jointly with BeOne Medicines (formerly BeiGene). HERIZON-GEA-01 is an international randomized, multicenter, open-label Phase 3 trial with three arms:
| Arm | Regimen | n |
|---|---|---|
| Arm A (control) | Trastuzumab + chemotherapy (physician's choice: CAPOX or 5-FU/cisplatin) | 308 |
| Arm B | Ziihera (zanidatamab) + chemotherapy | 304 |
| Arm C | Ziihera (zanidatamab) + chemotherapy + Tevimbra (tislelizumab, PD-1 inhibitor) | 302 |
At median follow-up of approximately 26 months (data cutoff October 2025), with co-primary endpoints PFS by blinded independent central review (BICR) and OS:
- PFS (median): Arm A 8.1 months; Arm B 12.4 months (HR 0.65, 95% CI 0.52–0.81, p<0.0001, ~35% risk reduction); Arm C 12.4 months (HR 0.63, 95% CI 0.51–0.78, p<0.0001, ~37% risk reduction).
- OS (median, first interim analysis): Arm A 19.2 months; Arm C 26.4 months (HR 0.72, 95% CI 0.57–0.90, p=0.0043, statistically significant, >7-month improvement); Arm B 24.4 months (HR 0.80, p=0.0564, strong positive trend, OS data not yet mature). An additional planned OS interim analysis for Arm B (Ziihera plus chemotherapy without tislelizumab) is currently expected mid-2026 and would feed into the FDA review window before the August 25, 2026 PDUFA action date.
- PFS and OS benefits were generally consistent across major prespecified subgroups including geographic region and PD-L1 status. PD-L1 subgroup analyses are scheduled for rapid oral presentation at ASCO 2026 (May 29 – June 2, Chicago).
- Safety: consistent with HER2-directed therapy and immunotherapy class profiles. Grade ≥3 TRAE rates were 71.8% (Arm C), 59.0% (Arm B), and 59.6% (Arm A); duration of treatment was longest on Arm C; no new safety signals.
Lead presenting author at the January 2026 ASCO Gastrointestinal Cancers Symposium (LBA285): Elena Elimova, MD (Princess Margaret Cancer Centre, Toronto). The HERIZON-GEA-01 sBLA is being reviewed by the FDA under Real-Time Oncology Review (RTOR).
Ziihera is currently approved in the U.S. (accelerated approval, November 2024) for previously treated HER2-positive (IHC 3+) biliary tract cancer (BTC); the GEA indication, if approved, would be the first 1L solid-tumor label and the principal commercial-scale indication driving the asset's revenue trajectory.
Royalty stack reconstruction
The Jazz / Ziihera FDA filing acceptance is a regulatory event whose principal interest to a royalty-finance audience lies in its position as the first major catalyst inside the Royalty Pharma / Zymeworks royalty-backed note signed on March 2, 2026 (covered in WTS 2026-W09). The full upstream and downstream layers:
| Layer | Counterparty | Term | Source |
|---|---|---|---|
| Asset origin | Zymeworks Inc. (Nasdaq: ZYME) | Engineered using proprietary Azymetric™ bispecific platform (biparatopic HER2-binding antibody) | Zymeworks corporate disclosure |
| Major-markets license to Jazz | Jazz Pharmaceuticals → Zymeworks (Oct 19, 2022 agreement; Dec 21, 2022 opt-in) | Exclusive worldwide rights ex-named Asia/Pacific territories (US, Europe, Japan, RoW) | Jazz / Zymeworks Oct 2022 and Dec 2022 press releases |
| Asia/Pacific license | BeOne Medicines (formerly BeiGene) → Zymeworks (pre-existing) | Exclusive Asia/Pacific rights including China, Australia, New Zealand | Zymeworks corporate disclosure |
| Upfront paid by Jazz to Zymeworks | Zymeworks (received) | US$50M upfront + US$325M opt-in (total US$375M paid in 2022) | Jazz / Zymeworks Dec 2022 |
| Regulatory milestone tail | Zymeworks (eligible) | Up to US$525M in regulatory milestones | Jazz / Zymeworks Oct 2022 |
| Commercial milestone tail | Zymeworks (eligible) | Up to US$862.5M in commercial milestones | Jazz / Zymeworks Oct 2022 |
| Total potential payments cap (ex-royalty) | n/a | Up to US$1.76B | Jazz / Zymeworks Oct 2022 |
| Tiered royalty on Jazz worldwide net sales | Jazz → Zymeworks | 10% to 20% tiered on annual net sales | Jazz / Zymeworks Oct / Dec 2022 |
| Tiered royalty on BeOne Asia/Pacific net sales | BeOne → Zymeworks | Tiered (rate band not separately re-disclosed at Ziihera program level) | Zymeworks corporate disclosure |
| March 2, 2026 Royalty Pharma / Zymeworks note | Royalty Pharma plc (Nasdaq: RPRX) → Zymeworks | US$250M non-recourse royalty-backed note; repaid from 30% of worldwide tiered royalties on Ziihera owed to Zymeworks from Jazz and BeOne | Royalty Pharma / Zymeworks March 2, 2026 announcement |
Net pass-through structure post-approval (model, not disclosed): Jazz reports worldwide ex-Asia/Pacific net sales → 10–20% tiered royalty flows to Zymeworks → 30% of that royalty flow (i.e. roughly 3–6% of Jazz worldwide ex-Asia/Pacific net sales, before any minimum / cap mechanics) is contractually applied to repayment of the Royalty Pharma note until the note's repayment threshold is reached. BeOne Asia/Pacific net sales contribute on the same 30% pass-through basis through the Zymeworks-BeOne royalty layer.
Royalty Pharma's standard non-recourse royalty-backed note architecture in the 2023 to 2026 vintage (ImmunoGen, Cytokinetics, Biohaven, MorphoSys-related notes) consistently caps repayment in the rough range of 1.85x to 2.10x deployed capital with an internal rate of return floor in the 12% to 15% range, whichever results in earlier note retirement. Applied to the US$250M Zymeworks note, this comparable-precedent band implies a repayment ceiling in the rough range of US$465M to US$525M, with the 30% Ziihera royalty pass-through (estimated at 3–6% of Jazz worldwide ex-Asia/Pacific net sales, plus the Zymeworks-BeOne Asia/Pacific layer) as the dedicated source of repayment. Under a base-case Ziihera revenue trajectory ramping to peak global net sales of roughly US$2.0B to US$2.5B by the early 2030s, the implied note-retirement window is approximately 2031 to 2033; the specific cap and IRR mechanics inside the March 2, 2026 Zymeworks note have not been re-disclosed and may step up or down from this band.
Royalty-fund read-through
The April 27 sBLA filing acceptance materially de-risks the Royalty Pharma note collateral in three respects: (1) the regulatory pathway is now under Priority Review with a defined PDUFA action date of August 25, 2026, narrowing the timing variance of the 1L GEA cash-flow onset; (2) the HERIZON-GEA-01 efficacy and safety profile (median OS >2 years in the lead Phase 3 arm) is consistent with a base-case standard-of-care displacement of trastuzumab in the 1L HER2+ GEA segment, supporting Royalty Pharma's underwriting assumptions for the asset's commercial trajectory; (3) the BeOne layer (covered by the same 30% royalty pass-through under the March 2, 2026 note) is operating on the same HERIZON-GEA-01 dataset for the relevant Asia/Pacific filings.
This is a clean illustration of why post-approval, royalty-rate, and territory data on bispecific oncology assets are precisely the disclosure layer that royalty-fund underwriting relies on at deal time, and why the Jazz / Zymeworks / RPRX three-way structure is one of the more cleanly traceable upstream-IP-to-listed-royalty-vehicle examples in the current market. Healthcare Royalty (HCRx) has not disclosed a Ziihera position; Sagard Healthcare Royalty has not disclosed a Ziihera position; OrbiMed Royalty & Credit Opportunities has not disclosed a Ziihera position. The note is held by Royalty Pharma at the listed-vehicle level.
Disclosure gaps
- The specific 30% pass-through cap structure inside the Royalty Pharma / Zymeworks note (whether there is a maximum repayment amount, an internal rate of return target, or both) has not been re-disclosed at filing-acceptance.
- The BeOne Asia/Pacific royalty rate band on Ziihera has not been separately re-disclosed at the Ziihera program level (BeOne pays Zymeworks under its own pre-existing license agreement, separate from the Jazz license).
- The OS interim analysis date for the Ziihera plus chemotherapy (without tislelizumab) arm is currently expected mid-2026 and would be the principal additional clinical data feeding into the FDA review window.
- Approval scope (whether the 1L GEA label is inclusive of the tislelizumab combination, the chemotherapy-only combination, or both) is not pre-determined by the filing acceptance; FDA may approve one or both arms at the August 25, 2026 PDUFA date.
Clinical readout: Intellia / Lonvo-z (NTLA-2002). HAELO Phase 3 Met Primary and All Key Secondary Endpoints. Rolling BLA Initiated (April 27)
On Monday April 27, Intellia Therapeutics (Nasdaq: NTLA) reported positive topline results from the global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002**)** in hereditary angioedema (HAE). This is the first-ever Phase 3 readout for an in vivo CRISPR gene-editing therapy. A single 50 mg IV dose reduced HAE attacks by 87% versus placebo (p<0.0001) over the six-month efficacy evaluation period; all key secondary endpoints met with statistical significance (p<0.0001), including 62% of lonvo-z patients attack-free and free of long-term prophylaxis versus 11% on placebo. No serious adverse events in the lonvo-z arm. Intellia simultaneously initiated a rolling BLA submission to the FDA; expected completion 2H 2026, potential US launch 1H 2027. Primary source: Intellia SEC Form 8-K Exhibit 99.1, April 27, 2026.
Royalty stack
Lonvo-z is wholly owned by Intellia at the program level. Regeneron's 25% co-development / co-promotion right applies to nex-z (ATTR) only, not to lonvo-z. The relevant upstream IP layer is the foundational CRISPR/Cas9 patent estate held jointly by UC Berkeley, the University of Vienna, and Emmanuelle Charpentier, sublicensed to Intellia via Caribou Biosciences. The specific royalty rate band and milestone schedule under the Caribou / UC sublicense have not been re-disclosed at the lonvo-z program level. No third-party royalty-fund position on lonvo-z has been publicly disclosed. The HAELO readout puts lonvo-z on a credible synthetic-royalty target trajectory through the BLA / approval / launch sequence in 2H 2026 to 1H 2027.
Intellia priced an underwritten US$180M public offering on April 29 (CIK 0001652130; Form 8-K Acc# 0001193125-26-197489), monetising the readout into the rolling-BLA window: 16,744,187 firm shares at US$10.75 per share (gross ~US$180M), plus a 30-day over-allotment option for 2,511,628 additional shares that was fully exercised by the underwriters on April 29, taking total shares to 19,255,815 and estimated net proceeds to ~US$194.6M. Joint book-running managers: Jefferies, Goldman Sachs, and Citigroup. Automatic shelf S-3 No. 333-275740. Closing April 30, 2026.
Clinical readout: Oruka / ORKA-001. EVERLAST-A Phase 2a Met PASI 100 Primary Endpoint at Week 16 in Plaque Psoriasis. Paragon Upstream Royalty Stack (April 27)
On Monday April 27, Oruka Therapeutics (Nasdaq: ORKA) reported positive Week 16 data from the EVERLAST-A Phase 2a trial of ORKA-001 (half-life-extended IL-23p19 monoclonal antibody) in moderate-to-severe plaque psoriasis. 63.5% of ORKA-001 patients achieved PASI 100 at Week 16 versus 4.8% on placebo; PASI 90 of 83% and IGA 0/1 of 84% on key secondaries. Phase 1 PK supports a once-yearly dosing thesis. ORKA shares moved approximately +33% intraday on the readout. Primary source: Oruka Therapeutics GlobeNewswire release, April 27, 2026.
Royalty stack
ORKA-001 is in-licensed from Paragon Therapeutics under a December 17, 2024 agreement, with terms substantially similar to those on Oruka's IL-17A/F program ORKA-002. Paragon is the Fairmount-founded antibody-discovery engine whose previous spin-outs include Apogee Therapeutics, Spyre Therapeutics, Jade Biosciences, and Crescent Biopharma.
| Layer | Disclosed terms |
|---|---|
| Paragon worldwide royalty-bearing exclusive license to ORKA-001 (ex-IBD) | Up to ~US$22M in development and regulatory milestones per program |
| Royalty rate to Paragon on net sales | Low single-digit percentage; step-down conditional on patent coverage |
| Royalty term | Later of last-to-expire licensed patent or 12 years from first commercial sale |
| Manufacturing | WuXi Biologics cell-line technology |
The structural read for a royalty-finance audience is that the Fairmount / Paragon spin-out factory model (Apogee, Spyre, Oruka, Jade, Crescent) carries a recurring upstream royalty layer that could be aggregated and synthetically monetised at the Paragon corporate level. No third-party royalty-fund position on ORKA-001 has been publicly disclosed. EVERLAST-A Week 28 / 52-week subset readout in 2H 2026; EVERLAST-B Phase 2b dose-ranging topline expected 2027.
Oruka monetised the readout immediately, pricing an upsized US$700.4M follow-on at US$72.50 per share on April 28 (Leerink, TD Cowen, Goldman Sachs, Stifel, Guggenheim; LifeSci passive). Largest biopharma equity financing of W18.
Clinical readout: Veradermics / VDPHL01 (extended-release oral minoxidil). Phase 2/3 '302' Met All Primary and Key Secondary Endpoints in Male Pattern Hair Loss (April 27)
On Monday April 27, Veradermics, Incorporated (NYSE: MANE) reported positive topline results from Part A of Study '302', a Phase 2/3 trial of VDPHL01 (extended-release oral minoxidil) in 519 men with mild-to-moderate pattern hair loss, dosed at 8.5 mg QD or BID over 52 weeks. All primary and key secondary endpoints met (p<0.0001) in both active arms. Mean increase in non-vellus target area hair count at Month 6: 30.3 (QD) and 33.0 (BID) hairs/cm² versus 7.3 placebo. MANE shares moved approximately +17% intraday.
Royalty stack and pipeline
VDPHL01 is internally discovered and developed by Veradermics; the proprietary extended-release gel-matrix formulation is Veradermics-originated and no third-party upstream license / royalty obligation has been publicly disclosed. Earliest expiring patent term 2043. Veradermics intends to pursue approval via the 505(b)(2) regulatory pathway. The second pivotal Phase 3 male trial '304' (n=536) completed enrolment February 2026, topline expected 2H 2026; female Phase 2/3 program enrolling.
For royalty-finance underwriting, the Veradermics readout is the least structurally complex of the four April 27 clinical readouts because VDPHL01 carries no disclosed upstream royalty obligation. Inclusion in W18 reflects the high-prevalence aesthetic-dermatology category (50M U.S. men, 30M U.S. women) and the long IP tail to 2043 supporting meaningful tail-NPV under royalty-fund underwriting models. No royalty-fund position on VDPHL01 has been publicly disclosed.
Veradermics priced an upsized US$384.4M public offering at US$100.00 per share on April 29 (Jefferies, Leerink, Citigroup, Cantor; LifeSci passive; Needham lead manager) plus a concurrent private placement, monetising the readout into the '304' confirmatory Phase 3 readout window.
Clinical readout: Mirum / Brelovitug. AZURE-1 Phase 2b Primary Endpoint Met in Chronic Hepatitis Delta Virus (April 27)
On Monday April 27, Mirum Pharmaceuticals (Nasdaq: MIRM) announced that brelovitug met the primary endpoint in the Phase 2b portion of the AZURE-1 study in chronic hepatitis delta virus (HDV). The Phase 2b portion evaluated the first 50 treatment-naïve HDV patients at the Week 24 timepoint on the composite endpoint of virologic response and ALT normalization, the endpoint aligned with FDA guidance for accelerated approval. Brelovitug carries FDA Breakthrough Therapy designation and EMA PRIME and Orphan designations. AZURE-1 (n~200) and AZURE-4 (n~80) Phase 3 topline 24-week data expected 2H 2026, supporting US BLA submission and potential 2027 launch. Primary source: Mirum Pharmaceuticals BusinessWire release, April 27, 2026.
Royalty stack
Mirum acquired worldwide rights to brelovitug via the completed January 26, 2026 acquisition of Bluejay Therapeutics (US$250M cash + US$370M Mirum stock at close, plus up to US$200M tiered sales-based milestones to former Bluejay shareholders, plus a concurrent US$268.5M PIPE; verified Mirum 8-K filed December 8, 2025, Acc# 0001193125-25-310611, with Merger Agreement Exhibit 2.1; Schedule 1.18 milestone-tier table omitted pursuant to Item 601(a)(5) and not in the public domain). No third-party academic, NIH, or partner-licensor royalty obligation on brelovitug has been publicly disclosed; Mirum's worldwide-rights statement is unqualified. The principal contingent economic structure is the US$200M tiered Bluejay-shareholder milestone tranche; specific tier breakpoints are not in the public domain. Bluejay-Novartis legacy royalty stack (per the Mirum supplemental 8-K/A): Bluejay paid Novartis US$4M for two 2025 development milestones, and the merger triggered an additional US$4M payment to Novartis under the pre-existing license agreement.
| Layer | Direction | Counterparty | Disclosed terms |
|---|---|---|---|
| Brelovitug worldwide net sales | Inflow to Mirum | Mirum (consolidated) | 100% post-close |
| Tiered sales-based milestones | Outflow | Former Bluejay shareholders | Up to US$200M cash; tier breakpoints undisclosed |
| Upstream third-party royalty | None publicly identified | n/a | 0% |
No royalty-fund position on brelovitug has been publicly disclosed. Phase 3 AZURE-1 / AZURE-4 topline (2H 2026) is the next disclosed catalyst.
Clinical readout: Relay / Zovegalisib + Pfizer's Atirmociclib Triplet. Phase 3 Frontline PIK3CA-Mutated HR+/HER2- Metastatic Breast Cancer Plan. DESRES Upstream Royalty Layer (April 27)
On Monday April 27, Relay Therapeutics, Inc. (Nasdaq: RLAY) announced plans to advance zovegalisib + atirmociclib + AI as a frontline triplet regimen into Phase 3 development for PIK3CA-mutated, HR+/HER2- metastatic breast cancer, with initiation expected early 2027. Zovegalisib (RLY-2608) is Relay's oral allosteric pan-mutant isoform-selective PI3Kα inhibitor; atirmociclib is Pfizer's investigational selective CDK4 inhibitor. The supporting ReDiscover Phase 1/2 triplet topline (data cutoff April 13, 2026) showed 44% ORR in 34 measurable patients in a CDK4/6-experienced population (median 2 prior therapies), with no Grade 3 hyperglycaemia and 3% zovegalisib discontinuation. Relay's standalone Phase 3 ReDiscover-2 trial of zovegalisib + fulvestrant in 2L runs in parallel.
Royalty stack
| Asset | Rights holder | Upstream layer |
|---|---|---|
| Zovegalisib (RLY-2608) | Relay (worldwide; internally discovered via Dynamo® platform) | D. E. Shaw Research (DESRES): low single-digit royalty on worldwide net sales under the DESRES Amended and Restated Collaboration and License Agreement (June 15, 2020). PI3Kα is a Category 1 Target. Royalty term: later of 12 years from first commercial sale (country-by-country) or regulatory exclusivity exhaustion. Research term expired August 16, 2025; royalty obligations on already-discovered compounds (zovegalisib included) survive |
| Atirmociclib (PF-07220060) | Pfizer (worldwide; internally discovered) | None disclosed |
| Relay ↔ Pfizer collaboration | n/a (clinical supply only) | June 5, 2024 clinical trial supply agreement extended to the planned Phase 3: No upfront, no milestones, no royalty either direction; each party retains 100% of its own asset's economics |
Zovegalisib joins AJ1-11095 (Lilly / Ajax → Schrödinger) and ORKA-001 (Oruka → Paragon) as the third W18 asset carrying a computational-platform-coupled upstream royalty layer. The DESRES royalty tail on zovegalisib alone runs to approximately 2040 or later (assuming a 2027 to 2028 FDA approval). Future synthetic royalties on zovegalisib would price against Relay's standalone economics minus the DESRES single-digit layer, with no Pfizer claim. No third-party royalty-fund position on zovegalisib has been publicly disclosed. Initial zovegalisib vascular-anomalies data scheduled for ISSVA 2026 (Philadelphia, May 20, 2026).
Clinical readout: Zealand / Boehringer Ingelheim. Survodutide SYNCHRONIZE-1 Phase 3 Positive in Obesity. EUR 315M Outstanding Milestones + High Single-Digit to Low Double-Digit Royalty (April 28)
On Tuesday April 28, Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) announced positive topline results from the SYNCHRONIZE-1 Phase 3 trial of survodutide in adults with obesity or overweight, conducted by Boehringer Ingelheim. 16.6% mean weight loss versus 3.2% placebo at 76 weeks (efficacy estimand, p<0.0001). Survodutide is a GLP-1 / glucagon dual agonist licensed by Zealand to Boehringer Ingelheim under a 2011 collaboration; Boehringer funds all R&D and commercialization globally. Primary source: Zealand Pharma GlobeNewswire release, April 28, 2026.
Royalty stack
| Term | Detail |
|---|---|
| Outstanding milestone potential to Zealand | Up to EUR 315 million (stepped down sequentially from EUR 365M at Phase 2 initiation in September 2019, reflecting EUR 50M of milestones earned across the development cycle) |
| Royalty rate to Zealand | High single-digit to low double-digit percentage royalties on global net sales |
| Zealand Nordic co-promotion right | Retained |
| Other related Phase 3 programs | SYNCHRONIZE-2 (T2D), SYNCHRONIZE-CVOT, SYNCHRONIZE-JP, SYNCHRONIZE-CN |
| Full data presentation | American Diabetes Association (ADA), June 2026 |
The SYNCHRONIZE-1 readout converts an existing Zealand royalty position from a clinical-stage milestone-bearing license into a near-term commercial royalty stream under Boehringer's worldwide commercialization. No third-party royalty-fund position on survodutide has been publicly disclosed.
Clinical readout: PTC / Novartis. Votoplam (PTC518) PIVOT-HD 24-Month Interim Positive in Huntington's Disease. PTC 40/60 US Profit Share + Tiered Double-Digit Ex-US Royalties (April 28)
On Tuesday April 28, PTC Therapeutics, Inc. (Nasdaq: PTCT) announced positive topline results from the 24-month interim analysis of the PIVOT-HD Phase 2 trial of votoplam (PTC518), an HTT mRNA splice modulator, in Huntington's disease. Stage 2 patients on the 10mg dose showed 52% slowing on cUHDRS versus a propensity-weighted natural-history comparator; 5mg arm showed 28% slowing. Neurofilament light chain stayed below baseline at 24 months. Novartis Phase 3 INVEST-HD trial is now underway (~770 patients, 3:2 randomization vs placebo at 10mg). Primary source: PTC Therapeutics IR press release, April 28, 2026.
Royalty stack
Votoplam is licensed to Novartis under the December 2, 2024 PTC–Novartis global license and collaboration agreement (~US$2.9B aggregate):
| Term | Detail |
|---|---|
| Upfront paid | US$1.0B in cash at closing |
| Aggregate milestones | Up to US$1.9B development, regulatory, and sales |
| US profit/loss split | 40% PTC / 60% Novartis |
| Ex-US royalty rate | Tiered double-digit royalties on ex-US net sales |
| Upstream third-party royalty | None publicly identified (PTC518 internally discovered via PTC's splicing platform) |
For royalty-fund underwriters, the votoplam economics are structurally distinct from PTC's separate 22% Evrysdi (risdiplam) royalty interest from Roche on worldwide net sales. The Evrysdi position remains the principal listed-royalty-vehicle-relevant asset on PTC's balance sheet; votoplam is a structurally credible second royalty stream activating into the late decade. No third-party royalty-fund position on votoplam has been publicly disclosed at PTC.
Clinical readout: Compass / ABL Bio (CTX-009). Tovecimig + Paclitaxel COMPANION-002 Phase 2/3 Secondary Endpoint Update. PFS Met; OS Missed in ITT Due to Crossover (April 27)
On Monday April 27, Compass Therapeutics, Inc. (Nasdaq: CMPX) announced topline secondary-endpoint data from the Phase 2/3 COMPANION-002 trial of tovecimig (CTX-009) in combination with paclitaxel in second-line biliary tract cancer. The primary endpoint (ORR) had been met previously in March 2025 (17.1% vs 5.3%, p=0.031). The April 27 readout: PFS hit (4.7 vs 2.6 months, HR=0.44, p<0.0001); OS missed in ITT (HR=1.05, p=0.78) structurally driven by the 54% crossover rate from control to tovecimig. Post-hoc crossover-vs-non-crossover OS in the control arm: 12.8 vs 6.1 months (HR=0.54, p=0.04). CMPX shares fell approximately 50% on the OS miss; class-action investigation announced. Primary source: Compass Therapeutics SEC Form 8-K Exhibit 99.1, April 27, 2026.
Royalty stack
Tovecimig is a bispecific antibody (DLL4 / VEGF-A) originated at ABL Bio Inc. (KOSDAQ: 298380; Korean Grabody platform). 2018 ex-Asia license to TRIGR Therapeutics, then assigned to Compass via TRIGR-Compass merger (May 2021). ABL Bio retained Korea (Handok partnership) and Greater China (Elpiscience). ABL Bio receives milestone payments and tiered single-digit royalties on net sales of tovecimig in both oncology and ophthalmology indications, plus up to US$96M development and regulatory milestones + up to US$303M commercial milestones (oncology) and up to US$75M development and regulatory milestones + up to US$110M commercial milestones (ophthalmology) per the Compass Therapeutics 10-K FY2025; specific tier breakpoints are redacted under confidential treatment in the underlying license exhibit. FDA Fast Track (April 2024); FDA Orphan Drug Designation (April 8, 2026, in BTC).
The COMPANION-002 readout illustrates the increasingly common 2026 pattern of Korean / China-originated bispecific antibodies licensed ex-Asia to US-listed clinical-stage operators, with the upstream royalty-layer concentration in the Asian originator. Compass is expected to pursue regulatory discussions and a possible BLA submission. No third-party royalty-fund position on tovecimig has been publicly disclosed.
Clinical readout: Mundipharma / REZZAYO (rezafungin) Phase 3 ReSPECT Positive in HSCT Antifungal Prophylaxis (April 27)
On Monday April 27, Mundipharma International Limited (private) announced positive topline results from the Phase 3 ReSPECT trial of REZZAYO® (rezafungin) for prophylaxis of invasive fungal diseases in allogeneic HSCT. Trial met non-inferiority on fungal-free survival at Day 90. Primary source: Mundipharma BusinessWire release, April 27, 2026.
Royalty stack
The royalty stack was consolidated inside Mundipharma via the April 24, 2024 Cidara asset purchase agreement, under which Cidara sold all rezafungin assets to Mundipharma. All future royalties from Melinta (US commercialization partner under July 26, 2022 license) now flow upstream to Mundipharma, with no Cidara residual. Cidara consideration was non-cash: Mundipharma waived an US$11.145M development-milestone advance, with Cidara estimating ~US$128M in cost savings through the patent life. There is no listed royalty-fund counterparty currently positioned upstream or downstream.
If Mundipharma elects to monetise the consolidated rezafungin royalty stream (synthetic royalty against Melinta US sales or portfolio-level financing), this would be a structurally credible 2026 to 2027 transaction. The HSCT-prophylaxis indication broadens the addressable population materially beyond the existing invasive-candidiasis label. sNDA filing target 2H 2026; EMA submission Q3 2026.
Regulatory event: Santhera Pharmaceuticals Positive CHMP Opinion for AGAMREE (vamorolone) in DMD Ages 2 and Older (EU). Royalty Cascade to ReveraGen, Catalyst, Sperogenix (April 27)
On Monday April 27 (Pratteln Switzerland), Santhera Pharmaceuticals Holding AG (SIX: SANN) received a positive Committee for Medicinal Products for Human Use (CHMP) opinion to expand AGAMREE® (vamorolone) use in paediatric Duchenne muscular dystrophy (DMD) patients aged two and older in the EU. The opinion was adopted at the April 20–23 CHMP meeting and announced April 27. Primary source: EMA CHMP variation page for AGAMREE; Santhera corporate press release, April 27, 2026.
The royalty cascade on AGAMREE spans three counterparties:
| Layer | Direction | Counterparty | Disclosed terms |
|---|---|---|---|
| Net product sales (worldwide) | n/a | Santhera (with regional partners) | 100% recorded |
| Worldwide license to Santhera | Inflow to Santhera | ReveraGen BioPharma, Inc. (private) | Worldwide royalty-bearing exclusive license |
| US partnership | Outflow from Santhera | Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) | Catalyst paid Santhera US$12.5M milestone on US$117M of 2025 US net sales |
| China partnership | Outflow from Santhera | Sperogenix Therapeutics (private) | Royalty-and-milestone bearing |
Each market expansion drives milestones through the chain. The April 27 CHMP opinion specifically expands the EU label to younger paediatric patients, which materially enlarges the addressable population in the EU territory. No listed royalty-fund position on AGAMREE has been publicly disclosed.
Q1 2026 royalty-relevant disclosures from the in-window earnings cluster
Seven Q1 2026 earnings releases inside or immediately bordering W18 carried disclosure directly relevant to royalty-fund modelling. The remainder of the in-window earnings cluster is omitted here as not material to a readout, new study, or financing.
GSK plc Q1 2026 (April 29). GSK reaffirmed FY2026 royalty income guidance of £800M to £850M. The principal royalty income drivers remain Kesimpta (Novartis ofatumumab; legacy Genmab / GSK out-license layer), Abrysvo (Pfizer RSV), and Comirnaty (Pfizer / BioNTech COVID adjuvant-related upstream). The £800M to £850M FY2026 royalty income guidance is the cleanest large-cap pharma royalty-stream disclosure inside the W18 window. The Q1 release included no further commentary on the TESARO / AnaptysBio Jemperli litigation beyond the previously-disclosed April 24 Delaware Chancery dismissal of the anticipatory breach claim and the July 14 to 17, 2026 reversion trial (covered above). Primary source: GSK Q1 2026 results press release, April 29, 2026.
AstraZeneca plc Q1 2026 (April 29). AstraZeneca reported Q1 2026 Alliance Revenue of US$825M (+26% CER), the single largest quarterly externally-sourced revenue disclosure in the W18 window:
| Q1 2026 alliance line | Amount (US$m) | Counterparty | Structure |
|---|---|---|---|
| Enhertu | 508 | Daiichi Sankyo | 50% profit-share on AZN-recorded net sales (2019 collaboration: US$1.35B upfront + up to US$5.55B contingent) |
| Tezspire | 154 | Amgen | Co-promote (mirrored against Amgen disclosure) |
| Beyfortus | 91 | Sanofi | Pediatric RSV alliance |
| Datroway | 42 | Daiichi Sankyo | Profit-share (>10x YoY; early-launch ramp) |
| Other royalty revenue | 29 | Various | n/a |
| Alliance Revenue total | 825 | n/a | +26% CER |
Collaboration Revenue of US$77M (Farxiga US$44M, Crestor US$32M) sits alongside as the milestone-driven line. Enhertu at US$508M in Q1 alone (+23% CER) is the largest disclosed quarterly profit-share line in the W18 cluster. Primary source: AstraZeneca Q1 2026 results announcement, April 29, 2026 (PDF).
Teva Pharmaceutical Industries Q1 2026 (April 29). Beyond the Emalex acquisition agreement (covered in dedicated section above), Teva confirmed two pre-existing external development financings: (i) the March 3, 2026 Blackstone Life Sciences US$400M four-year duvakitug financing agreement, under which Teva recognised US$30M of R&D-expense reimbursement in Q1 2026, and (ii) the January 11, 2026 Royalty Pharma up to US$500M funding agreement for the anti-IL-15 antibody TEV-'408. Combined external development funding plus the Emalex acquisition put up to US$1.6B of external acquisition and development capital across Teva's late-stage assets, with the broader 2027 financial targets maintained. Primary source: Teva IR Q1 2026 release, April 29, 2026.
Novartis AG Q1 2026 (April 28). One royalty-fund-relevant item: the April 24 CHMP positive opinion for Itvisma (intrathecal onasemnogene abeparvovec) in SMA. Itvisma carries upstream Regenxbio AAV9 capsid royalty obligations under the legacy AveXis acquisition and Regenxbio license; the CHMP opinion is the second commercial expansion of the AAV9 royalty stream after the original Zolgensma label. The remainder of the Novartis Q1 release is omitted here as not royalty-material. Primary source: Novartis Q1 2026 results, April 28, 2026.
Sanofi Q1 2026 (April 23 release; W18 follow-on commentary). Sanofi released Q1 2026 results on April 23 (W17 by date), but the investor calls and follow-on commentary extended into the early days of W18. The single royalty-fund-relevant disclosure: €40M financial income from unwinding of the Beyfortus US royalty liability under the Sobi / Sanofi structure. This is a discrete worked example of how a previously-recognised royalty liability matures and is reversed through the income statement of a Big Pharma licensee, mirroring the BMS legacy AstraZeneca diabetes royalty cessation (covered above) at the opposite end of the same cycle. CEO commentary on the call signaled BD/M&A activity will increase financial expenses through 2026 and may slip later than budgeted; this is read-through-relevant for the broader Big Pharma BD-spending cadence into the May 12 Citi Healthcare conference, the June 15 HLTH Europe Amsterdam window, and BIO San Diego June 22 to 25. Primary source: Sanofi SEC Form 6-K Q1 2026 press release, April 23, 2026.
AbbVie Q1 2026 (April 29). AbbVie reported US$744M IPR&D + milestones expense for Q1 2026, materially above the company's prior cadence and Street expectations, driven by the RemeGen RC148 PD-1 × VEGF bispecific close, the Capstan Therapeutics close, and the Kestrel Therapeutics warrant + acquisition option (covered in dedicated section above). FY2026 EPS guidance was updated to US$13.96 to US$14.16 to incorporate these BD-driven expense step-ups. AbbVie is the most BD-active Big Pharma counterparty inside the W18 window; the IPR&D expense disclosure provides a quantitative anchor for the cumulative cost of AbbVie's 2026 BD push and is the cleanest in-window data point for any analyst tracking Big Pharma BD-expense ramp into a year that includes the AUTM Annual Meeting cycle, the HLTH Europe Amsterdam window, and BIO San Diego. Primary source: AbbVie Q1 2026 results press release, April 29, 2026.
Genmab Q1 2026 royalty-stream disclosure (April 30 / J&J synchronised release). J&J reported, alongside Genmab's mirrored disclosure, DARZALEX worldwide net trade sales of US$3,964M for Q1 2026 (US US$2,208M + ROW US$1,756M). Genmab earns up to a ~20% royalty under the exclusive 2012 J&J license, with stepped reductions at higher US and ex-US sales tiers. DARZALEX remains the largest single-antibody royalty stream tracked anywhere in the W18 window and the highest-revenue royalty-bearing biologic asset in the listed pharma universe. The continued double-digit revenue growth supports a multi-year royalty-cliff modelling approach for the SC-formulation patent estate and for the post-2030 biosimilar entry assumption set; it is the natural benchmark comparator for any out-licensed-antibody royalty modelling exercise on a new licensed asset (Cue / Ascendant-221, Pinetree / AZ PTX-299, Huahui / BeOne HH160). Primary source: Genmab SEC Form 6-K Q1 2026 disclosure, April 30, 2026.
Nxera Pharma Co., Ltd. (TSE: 4565) Q1 2026 (May 1). Nxera released Q1 FY2026 results on May 1, capturing three royalty / milestone-relevant items inside the window:
| Item | Counterparty | Asset / event | Q1 2026 revenue treatment |
|---|---|---|---|
| US$22.5M milestone | Neurocrine Biosciences | NBI-1117570 (oral dual M1/M4 muscarinic agonist) Phase 2 first-patient-dosed in adult schizophrenia (originally announced April 13) | Recognised in full as Q1 FY2026 revenue |
| Undisclosed milestone | Eli Lilly | Multi-target metabolic disease collaboration; development milestone trigger | Recognised in full as Q1 2026 revenue; Nxera retains downstream milestone plus royalty stream and Centessa equity following Lilly's March 31 Centessa close |
| APAC sublicensing milestone | Holling Bio-Pharma Corp. (Taiwan) | Taiwan TFDA approval of QUVIVIQ (daridorexant) under Nxera's commercial licensing partnership | Triggers contractual sublicensing milestone within Nxera's APAC commercial network |
The Nxera disclosure is the cleanest in-window worked example of an Asia-headquartered drug-discovery platform earning multi-counterparty royalty income across both a partnered CNS franchise (Neurocrine; muscarinic-agonist portfolio including direclidine / NBI-1117568 in Phase 3 schizophrenia, NBI-1117567 M1-preferring agonist in Phase 2 Alzheimer's cognition, NBI-1117569 dual M1/M4 in Phase 1 Alzheimer's psychosis) and a metabolic platform (Lilly). For a royalty-fund audience Nxera is a transferable comparator for cross-border platform-licensing royalty stack design, and is the only Japanese-listed milestones-and-royalties story to fully clear inside the W18 window. Primary source: Nxera Pharma Q1 2026 release, May 1, 2026.
Structural legal event: SCOTUS Oral Argument in Hikma v. Amarin (No. 24-889). Skinny-Label Induced-Infringement Pleading Standard (April 29)
On Wednesday April 29, the Supreme Court of the United States heard oral argument in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (No. 24-889), the Court's first patent inducement case since Commil v. Cisco (2015) and first skinny-label case since Caraco v. Novo Nordisk (2012). The question presented is whether allegations that a generic drugmaker called its product a "generic version" of the brand and cited public sales data are enough to plead induced infringement of a carved-out patented use under 35 U.S.C. § 271(b), where the complaint does not allege any instruction or statement encouraging the patented use. The Solicitor General supports Hikma; the Court granted divided argument time. Ruling expected before the July 2026 recess. Primary source: SCOTUS oral argument transcript, No. 24-889, April 29, 2026.
The eventual decision will reshape royalty enforceability for method-of-use patents underpinning later-developed indications across pharma royalty stacks, with the most exposed listed-royalty-vehicle positions concentrated at Royalty Pharma (Imbruvica, Trodelvy, Trelegy, Evrysdi method-of-use layers), Ligand post-XOMA close (Vabysmo, Filspari, Ohtuvayre, Capvaxive), and dispersed exposure across HCRx, Sagard, NovaQuest, DRI, and OrbiMed portfolios. The temporal coincidence of the SCOTUS argument and the Pfizer Vyndamax ANDA settlements within a 24-hour window inside W18 is structurally significant: a narrower inducement standard from SCOTUS would reinforce the carveout pathway and may support earlier generic entry post-exclusivity for next-generation TTR-stabilizer indications and across the broader royalty-fund underwriting universe.
For full coverage of the case background (Vascepa SH/CV split, Hatch-Waxman skinny-label pathway, Hikma's allegedly inducement-tipping marketing conduct, the Cox v. Sony shadow, Amarin's "improvidently granted" defensive posture, and the three questions to watch), see the dedicated p05.org analysis: The Skinny Label Question Comes to One First Street: What Hikma v. Amarin Means for Pharmaceutical Royalty Financing.
Late-stage clinical and regulatory readouts (April 26 to 30)
| Asset | Sponsor | Trial / readout | Upstream royalty layer | Next disclosed catalyst |
|---|---|---|---|---|
| Lonvo-z (NTLA-2002) | Intellia (NTLA), Apr 27 | HAELO Phase 3 met primary + all key secondary endpoints in HAE; first-ever Phase 3 readout for in vivo CRISPR; rolling BLA initiated | Caribou / UC Berkeley / Univ. Vienna / Charpentier sublicense (rate undisclosed at lonvo-z program level) | Full HAELO dataset at 2026 EAACI Congress; potential US launch 1H 2027 |
| ORKA-001 | Oruka (ORKA), Apr 27 | EVERLAST-A Phase 2a: 63.5% PASI 100 at Week 16 in plaque psoriasis | Paragon Therapeutics low single-digit royalty (per 2024 license) | Week 28 efficacy + 52-week durability subset, 2H 2026 |
| VDPHL01 | Veradermics, Apr 27 | Phase 2/3 '302' met all primary + key secondary endpoints in male pattern hair loss (oral extended-release minoxidil) | None disclosed (internally developed; earliest patent term 2043) | Confirmatory '304' Phase 3 male topline, 2H 2026 |
| Brelovitug | Mirum (MIRM), Apr 27 | AZURE-1 Phase 2b primary endpoint met (composite virologic + ALT response) in HDV | None disclosed; up to US$200M tiered sales-based milestones to former Bluejay shareholders (downstream earnout, not upstream royalty) | AZURE-1 / AZURE-4 Phase 3 24-week topline, 2H 2026 |
| Zovegalisib (RLY-2608) + atirmociclib + AI | Relay (RLAY) + Pfizer (PFE, supply only), Apr 27 | ReDiscover Phase 1/2 triplet supportive of frontline Phase 3 in PIK3CA-mutated HR+/HER2- mBC; 44% ORR in median 3L | DESRES low single-digit on zovegalisib (PI3Kα Category 1 Target); none on atirmociclib | Phase 3 initiation early 2027; ISSVA 2026 vascular-anomalies data May 20, 2026 |
| Tovecimig (CTX-009) | Compass Therapeutics (CMPX), Apr 27 | COMPANION-002 Phase 2/3: primary ORR met (17.1% vs 5.3%, p=0.031, prior March 2025); secondary PFS hit (4.7 vs 2.6 mo, HR=0.44, p<0.0001, 56% reduction); secondary OS missed in ITT (HR=1.05, p=0.78) due to 54% crossover; post-hoc crossover OS 12.8 vs 6.1 mo (HR=0.54, p=0.04). CMPX -50% | ABL Bio (KOSDAQ: 298380; Korean originator; 2018 ex-Asia license to TRIGR / Compass; tiered single-digit royalties on net sales (both oncology and ophthalmology) per Compass 10-K FY2025; tier breakpoints redacted). FDA Fast Track + Orphan Drug Designation | Regulatory pathway discussions; possible BLA submission post-OS confounding |
| REZZAYO (rezafungin) | Mundipharma (private), Apr 27 | Phase 3 ReSPECT positive on fungal-free survival at Day 90 in HSCT antifungal prophylaxis | Royalty stack consolidated post-April 24, 2024 Cidara asset purchase agreement; Melinta US royalties to Mundipharma; ReSTORE Phase 3 China trial active | sNDA 2H 2026 (US, with Melinta); EMA submission Q3 2026 |
| Survodutide | Zealand Pharma (ZEAL) → Boehringer Ingelheim, Apr 28 | SYNCHRONIZE-1 Phase 3 positive in obesity: 16.6% mean weight loss vs 3.2% placebo at 76 weeks (p<0.0001) | Zealand high single-digit to low double-digit royalty + EUR 315M outstanding milestones; Nordic co-promotion retained | Full data at ADA June 2026; MASH program separately Breakthrough designated |
| Votoplam (PTC518) | PTC Therapeutics (PTCT) → Novartis, Apr 28 | PIVOT-HD Phase 2 24-month interim: 52% slowing on cUHDRS at 10mg vs natural history; 28% at 5mg; NfL stayed below baseline | Dec 2024 PTC–Novartis collaboration: $1.0B upfront paid + up to $1.9B milestones + 40/60 US profit share (PTC/Novartis) + tiered double-digit ex-US royalties (separate from PTC's 22% Evrysdi royalty from Roche) | Novartis Phase 3 INVEST-HD initiated (~770 patients, 3:2 vs placebo) |
| AGAMREE (vamorolone) EU label expansion | Santhera (SANN), Apr 27 | CHMP positive opinion to expand DMD use to ages 2 and older | ReveraGen worldwide license; Catalyst US partner ($12.5M milestone on $117M 2025 US sales); Sperogenix China partner | EC decision Q3 2026 |
| ELREXFIO® (elranatamab) | Pfizer (PFE), Apr 29 | Phase 3 MagnetisMM-5 met PFS primary endpoint at interim analysis vs DPd in 2L+ RRMM (n=497); OS immature; safety consistent | Internally discovered at Pfizer (PF-06863135); no third-party upstream royalty | MagnetisMM-32 (1L post-daratumumab) data; planned regulatory submissions for 2L+ label expansion |
| AUVELITY® (AXS-05; dextromethorphan/bupropion) | Axsome (AXSM), Apr 30 | FDA approval (sNDA, label expansion) for agitation associated with dementia due to Alzheimer's disease; first non-antipsychotic in indication; pivotal data ADVANCE-1 / ADVANCE-2 / ACCORD-1 / ACCORD-2 | Antecip Bioventures II LLC (Tabuteau-controlled related party): 3.0% royalty on net sales subject to up to 50% reduction for required third-party payments; royalty term to later of last-to-expire patent or 10 years from first sale per country; patent estate to ≥2043 | Commercial launch in AD agitation; Phase 2/3 smoking cessation pivotal initiation Q2 2026 |
| PIPE-791 | Contineum Therapeutics (CTNM), Apr 30 | Phase 1b oral once-daily 10mg LPA1 antagonist (NCT06810245); n=43 (23 COAP + 20 CLBP); primary endpoint (safety/tolerability) met, no SAEs; TP1 efficacy: COAP -1.60 PI-NRS vs placebo -1.27; CLBP -1.33 vs placebo -0.55 | PIPE-791 wholly owned (no upstream royalty); separately, Contineum's PIPE-307 M1 program is licensed to Janssen Pharmaceutica NV for $50M upfront + $25M equity (Jun 2023) + >$1B in milestones + low-to-high teens royalty | Phase 2 PROPEL-IPF readout; possible synthetic-royalty financing candidate on PIPE-791 net sales if Phase 3 advances |
| RV-001 | Restore Vision (private; Keio U. spin-out), Apr 30 / May 1 | Phase 1/2 first-in-human optogenetic gene therapy interim (jRCT2033240611, n=6); low-dose cohort 100% (3/3) progressed to light perception within one month from NLP baseline; high-dose cohort 33.3% (1/3) within one month, one patient with chart-based visual acuity on Berkeley Rudimentary Vision Test (BRVT); no DLTs / drug-related SAEs in either cohort | Keio University foundational chimeric rhodopsin IP licensed to Restore Vision; specific Keio license terms not disclosed; no third-party royalty layer disclosed | Continued Phase 1/2 enrollment expansion; Eyecelerator @ ARVO 2026 + Retinal Therapeutics Innovation Summit data May 1, 2026 |
| KF-0210 | Keythera Pharmaceuticals (private), Apr 27 | Phase 2a oral EP4 receptor antagonist; 86.7% reduction in WOMAC pain scores in knee osteoarthritis study; positions as non-opioid analgesic | Korean / regional originator; specific royalty stack and IP license terms not disclosed; sits adjacent to Lilly EP4 / Pain royalty stack and Pfizer SI-449 EP4 program | Trial design, n, and statistical analysis disclosure expected at follow-up; further Phase 2 / 3 development pathway TBD |
The Weekly Term Sheet is published by Capital for Cures AG. Nothing in this publication constitutes investment advice or a recommendation to buy or sell any security. Royalty-rate ranges, milestone schedules, and specific deal terms are reconstructed from public filings, press releases, and investor materials; specific contractual terms not in the public domain are noted as such. Errors and omissions are the author's own. For corrections, queries, or republication requests, contact the editorial team via p05.org.